Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,24916770,MTD,"The MTD of navitoclax was 325 mg co-administered with gemcitabine 1,000 mg/m(2) for the 21-day schedule.","A phase I clinical trial of navitoclax, a targeted high-affinity Bcl-2 family inhibitor, in combination with gemcitabine in patients with solid tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24916770/),mg,325,107,DB00441,Gemcitabine
,15131031,area under the curve (AUC),"Pharmacokinetic (PK) studies showed a median area under the curve (AUC) i.p. of 3041 h. micro M (range, 676-5702 h. micro M) and AUC in plasma of 4.0 h. micro M (range, 0.92-8.2 h. micro M) reached between 120 and 240 min; the pharmacological advantage was 759-fold (range, 217-1415-fold) for i.p. versus plasma drug levels.",Intraperitoneal cisplatin with intraperitoneal gemcitabine in patients with epithelial ovarian cancer: results of a phase I/II Trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15131031/),h·μM,3041,4233,DB00441,Gemcitabine
,15131031,AUC,"Pharmacokinetic (PK) studies showed a median area under the curve (AUC) i.p. of 3041 h. micro M (range, 676-5702 h. micro M) and AUC in plasma of 4.0 h. micro M (range, 0.92-8.2 h. micro M) reached between 120 and 240 min; the pharmacological advantage was 759-fold (range, 217-1415-fold) for i.p. versus plasma drug levels.",Intraperitoneal cisplatin with intraperitoneal gemcitabine in patients with epithelial ovarian cancer: results of a phase I/II Trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15131031/),h·μM,4.0,4234,DB00441,Gemcitabine
,15131031,mean residence time,The mean residence time of gemcitabine with i.p. administration was 4.7 h.,Intraperitoneal cisplatin with intraperitoneal gemcitabine in patients with epithelial ovarian cancer: results of a phase I/II Trial. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15131031/),h,4.7,4235,DB00441,Gemcitabine
,15131031,time to progression,"The median time to progression of the intent to treat population was 15.93 months (95% confidence interval, 9.13-25.9 months), with a median overall survival of 43.5 months [95% confidence interval, (34.66- infinity)].",Intraperitoneal cisplatin with intraperitoneal gemcitabine in patients with epithelial ovarian cancer: results of a phase I/II Trial. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15131031/),month,15.93,4236,DB00441,Gemcitabine
,15131031,overall survival,"The median time to progression of the intent to treat population was 15.93 months (95% confidence interval, 9.13-25.9 months), with a median overall survival of 43.5 months [95% confidence interval, (34.66- infinity)].",Intraperitoneal cisplatin with intraperitoneal gemcitabine in patients with epithelial ovarian cancer: results of a phase I/II Trial. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15131031/),month,43.5,4237,DB00441,Gemcitabine
,15131031,time to treatment failure,"With regard to time to treatment failure, a statistical difference favored patients with optimal versus nonoptimal primary debulking (25.2 versus 10.2 months, respectively; P = 0.03).",Intraperitoneal cisplatin with intraperitoneal gemcitabine in patients with epithelial ovarian cancer: results of a phase I/II Trial. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15131031/),month,25.2,4238,DB00441,Gemcitabine
,15131031,time to treatment failure,"With regard to time to treatment failure, a statistical difference favored patients with optimal versus nonoptimal primary debulking (25.2 versus 10.2 months, respectively; P = 0.03).",Intraperitoneal cisplatin with intraperitoneal gemcitabine in patients with epithelial ovarian cancer: results of a phase I/II Trial. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15131031/),month,10.2,4239,DB00441,Gemcitabine
,15131031,time to treatment failure,"The median time to treatment failure and overall survival of 15.9 months and 43.5 months, respectively, are consistent with our historical data in patients receiving i.p. platinum-based regimens for consolidation.",Intraperitoneal cisplatin with intraperitoneal gemcitabine in patients with epithelial ovarian cancer: results of a phase I/II Trial. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15131031/),month,15.9,4240,DB00441,Gemcitabine
,15131031,overall survival,"The median time to treatment failure and overall survival of 15.9 months and 43.5 months, respectively, are consistent with our historical data in patients receiving i.p. platinum-based regimens for consolidation.",Intraperitoneal cisplatin with intraperitoneal gemcitabine in patients with epithelial ovarian cancer: results of a phase I/II Trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15131031/),month,43.5,4241,DB00441,Gemcitabine
,12811513,area under the concentration-time curve (AUC),"The doses of each drug ranged from an area under the concentration-time curve (AUC) of 5 to 6 for carboplatin, 135 to 175 mg/m(2) for paclitaxel, and 300 to 1000 mg/m(2) for gemcitabine.","Phase I combination trial of gemcitabine, paclitaxel, and carboplatin in patients with advanced malignancy. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12811513/),[mg] / [m(2],5 to 6,4780,DB00441,Gemcitabine
,12811513,area under the concentration-time curve (AUC),"The doses of each drug ranged from an area under the concentration-time curve (AUC) of 5 to 6 for carboplatin, 135 to 175 mg/m(2) for paclitaxel, and 300 to 1000 mg/m(2) for gemcitabine.","Phase I combination trial of gemcitabine, paclitaxel, and carboplatin in patients with advanced malignancy. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12811513/),[mg] / [m(2],135 to 175,4781,DB00441,Gemcitabine
,12621462,MTD,Mucositis was the dose-limiting toxicity and the MTD was 60 mg/m(2).,High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12621462/),mg,60,5056,DB00441,Gemcitabine
,12621462,C(max),C(max) of Idarubicin and idarubicinol were 7.7+/-2.0 and 26.3+/-9.7 ng/ml at 40 mg/m(2) and increased to 14.8+3.0 and 47.4+12.6 ng/ml at 70 mg/m(2).,High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12621462/),[ng] / [ml],7.7,5057,DB00441,Gemcitabine
,12621462,C(max),C(max) of Idarubicin and idarubicinol were 7.7+/-2.0 and 26.3+/-9.7 ng/ml at 40 mg/m(2) and increased to 14.8+3.0 and 47.4+12.6 ng/ml at 70 mg/m(2).,High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12621462/),[ng] / [ml],26.3,5058,DB00441,Gemcitabine
,12621462,C(max),C(max) of Idarubicin and idarubicinol were 7.7+/-2.0 and 26.3+/-9.7 ng/ml at 40 mg/m(2) and increased to 14.8+3.0 and 47.4+12.6 ng/ml at 70 mg/m(2).,High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12621462/),[ng] / [ml],14.8,5059,DB00441,Gemcitabine
,12621462,C(max),C(max) of Idarubicin and idarubicinol were 7.7+/-2.0 and 26.3+/-9.7 ng/ml at 40 mg/m(2) and increased to 14.8+3.0 and 47.4+12.6 ng/ml at 70 mg/m(2).,High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12621462/),[ng] / [ml],47.4,5060,DB00441,Gemcitabine
,12621462,AUCt(0-264),AUCt(0-264) of idarubicin and idarubicinol increased from 423.2+/-111.6 and 2581+/-606 hng/ml at 40 mg/m(2) to 732.8+/-140.2 and 4590+/-1258 hng/ml at 70 mg/m(2).,High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12621462/),[hng] / [ml],423.2,5061,DB00441,Gemcitabine
,12621462,AUCt(0-264),AUCt(0-264) of idarubicin and idarubicinol increased from 423.2+/-111.6 and 2581+/-606 hng/ml at 40 mg/m(2) to 732.8+/-140.2 and 4590+/-1258 hng/ml at 70 mg/m(2).,High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12621462/),[hng] / [ml],2581,5062,DB00441,Gemcitabine
,12621462,AUCt(0-264),AUCt(0-264) of idarubicin and idarubicinol increased from 423.2+/-111.6 and 2581+/-606 hng/ml at 40 mg/m(2) to 732.8+/-140.2 and 4590+/-1258 hng/ml at 70 mg/m(2).,High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12621462/),[hng] / [ml],732.8,5063,DB00441,Gemcitabine
,12621462,AUCt(0-264),AUCt(0-264) of idarubicin and idarubicinol increased from 423.2+/-111.6 and 2581+/-606 hng/ml at 40 mg/m(2) to 732.8+/-140.2 and 4590+/-1258 hng/ml at 70 mg/m(2).,High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12621462/),[hng] / [ml],4590,5064,DB00441,Gemcitabine
,12621462,Conversion rates,"Conversion rates after HD-Ida and HD-TM were 28.6 and 38.5%, respectively.",High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12621462/),%,28.6,5065,DB00441,Gemcitabine
,12621462,Conversion rates,"Conversion rates after HD-Ida and HD-TM were 28.6 and 38.5%, respectively.",High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12621462/),%,38.5,5066,DB00441,Gemcitabine
,18971935,objective response rate,"The objective response rate was 4% (1 of 26), and 27% (7 of 26) of patients achieved stable disease.",Safety and pharmacokinetics of motesanib in combination with gemcitabine for the treatment of patients with solid tumours. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18971935/),%,4,5112,DB00441,Gemcitabine
,30298303,overall survival,"Median overall survival and progression-free survival was 9.73 [95%CI:9.73-13.5] and 7.53 (95%CI:6.05-12.8) months, respectively.",Phase 1 trial of enzalutamide in combination with gemcitabine and nab-paclitaxel for the treatment of advanced pancreatic cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30298303/),month,9.73,5702,DB00441,Gemcitabine
,30298303,progression-free survival,"Median overall survival and progression-free survival was 9.73 [95%CI:9.73-13.5] and 7.53 (95%CI:6.05-12.8) months, respectively.",Phase 1 trial of enzalutamide in combination with gemcitabine and nab-paclitaxel for the treatment of advanced pancreatic cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30298303/),month,7.53,5703,DB00441,Gemcitabine
,30298303,half-life,Enzalutamide reached steady-state levels between day 22 and 29 and the mean half-life of nab-paclitaxel was 19.6 ± 4.7 h.,Phase 1 trial of enzalutamide in combination with gemcitabine and nab-paclitaxel for the treatment of advanced pancreatic cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30298303/),h,19.6,5704,DB00441,Gemcitabine
,17909804,terminal half-life,Gemcitabine was rapidly eliminated from the CSF with a terminal half-life of 61 +/- 50 min.,Phase I clinical trial of intrathecal gemcitabine in patients with neoplastic meningitis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17909804/),min,61,5828,DB00441,Gemcitabine
,29019099,encapsulation efficiency,The optimized CSNPs had a particle size of 241 ± 36.2 nm and an encapsulation efficiency of 41.52%.,Formulation and Pharmacokinetics of HSA-core and PLGA-shell Nanoparticles for Delivering Gemcitabine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29019099/),%,41.52,8072,DB00441,Gemcitabine
,12481889,MTD,The MTD of gemcitabine in these patients was 3600 mg/m2/week for three consecutive weeks (10 mg/m2/min for 360 min).,Phase I study of gemcitabine (difluorodeoxycytidine) in children with relapsed or refractory leukemia (CCG-0955): a report from the Children's Cancer Group. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12481889/),[mg] / [m2·week],3600,8372,DB00441,Gemcitabine
,12481889,terminal half-life,"Pharmacokinetics of gemcitabine fit a two-compartment open model with terminal half-life and plasma clearance value of 62 min and 2.2 l/min/m2, respectively.",Phase I study of gemcitabine (difluorodeoxycytidine) in children with relapsed or refractory leukemia (CCG-0955): a report from the Children's Cancer Group. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12481889/),min,62,8373,DB00441,Gemcitabine
,12481889,plasma clearance,"Pharmacokinetics of gemcitabine fit a two-compartment open model with terminal half-life and plasma clearance value of 62 min and 2.2 l/min/m2, respectively.",Phase I study of gemcitabine (difluorodeoxycytidine) in children with relapsed or refractory leukemia (CCG-0955): a report from the Children's Cancer Group. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12481889/),[l] / [m2·min],2.2,8374,DB00441,Gemcitabine
,12481889,MTD,"In conclusion, the MTD of gemcitabine was 10 mg/m2/min for 360 min every week for 3 weeks.",Phase I study of gemcitabine (difluorodeoxycytidine) in children with relapsed or refractory leukemia (CCG-0955): a report from the Children's Cancer Group. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12481889/),[mg] / [m2·min],10,8375,DB00441,Gemcitabine
,15814642,area under the concentration-time curve,The area under the concentration-time curve value of gemcitabine in this patient (54.54 microg hour/mL) was five times higher than the average value for five other patients (10.88 microg hour/mL) treated with gemcitabine plus cisplatin.,Severe drug toxicity associated with a single-nucleotide polymorphism of the cytidine deaminase gene in a Japanese cancer patient treated with gemcitabine plus cisplatin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15814642/),[h·μg] / [ml],54.54,10451,DB00441,Gemcitabine
,15814642,area under the concentration-time curve,The area under the concentration-time curve value of gemcitabine in this patient (54.54 microg hour/mL) was five times higher than the average value for five other patients (10.88 microg hour/mL) treated with gemcitabine plus cisplatin.,Severe drug toxicity associated with a single-nucleotide polymorphism of the cytidine deaminase gene in a Japanese cancer patient treated with gemcitabine plus cisplatin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15814642/),[h·μg] / [ml],10.88,10452,DB00441,Gemcitabine
,15814642,area under the concentration-time curve,"The area under the concentration-time curve of 2',2'-difluorodeoxyuridine in this patient (41.58 microg hour/mL) was less than the half of the average value of the five patients (106.13 microg hour/mL).",Severe drug toxicity associated with a single-nucleotide polymorphism of the cytidine deaminase gene in a Japanese cancer patient treated with gemcitabine plus cisplatin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15814642/),[h·μg] / [ml],41.58,10453,DB00441,Gemcitabine
,15814642,area under the concentration-time curve,"The area under the concentration-time curve of 2',2'-difluorodeoxyuridine in this patient (41.58 microg hour/mL) was less than the half of the average value of the five patients (106.13 microg hour/mL).",Severe drug toxicity associated with a single-nucleotide polymorphism of the cytidine deaminase gene in a Japanese cancer patient treated with gemcitabine plus cisplatin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15814642/),[h·μg] / [ml],106.13,10454,DB00441,Gemcitabine
,30105668,Objective response rate,"Objective response rate was 28% (all partial responses), and 13 (52%) patients had a best response of stable disease.","Phase 1 dose-escalation study of momelotinib, a Janus kinase 1/2 inhibitor, combined with gemcitabine and nab-paclitaxel in patients with previously untreated metastatic pancreatic ductal adenocarcinoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30105668/),%,28,11177,DB00441,Gemcitabine
,28934281,Area under the plasma concentration time curve (AUC),"Area under the plasma concentration time curve (AUC) of Gem-TSLnps (35.17± 0.04 μghr/mL) was significantly higher than that of free Gem (2.09 ± 0.01 μghr/mL) whereas, AUC of Gd-TSLnps was higher than free Gd by 3.9 fold high.",Smart thermosensitive liposomes for effective solid tumor therapy and in vivo imaging. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28934281/),[μghr] / [ml],35.17,12054,DB00441,Gemcitabine
,28934281,Area under the plasma concentration time curve (AUC),"Area under the plasma concentration time curve (AUC) of Gem-TSLnps (35.17± 0.04 μghr/mL) was significantly higher than that of free Gem (2.09 ± 0.01 μghr/mL) whereas, AUC of Gd-TSLnps was higher than free Gd by 3.9 fold high.",Smart thermosensitive liposomes for effective solid tumor therapy and in vivo imaging. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28934281/),[μghr] / [ml],2.09,12055,DB00441,Gemcitabine
,1362937,plasma half-life,"The mouse exhibited the shortest plasma half-life, approximately 0.28 hr, contrasted with 2.14 and 1.38 hr half-lives in rat and dog, respectively.","Metabolism and disposition of gemcitabine, and oncolytic deoxycytidine analog, in mice, rats, and dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1362937/),h,0.28,15920,DB00441,Gemcitabine
,1362937,plasma half-life,"The mouse exhibited the shortest plasma half-life, approximately 0.28 hr, contrasted with 2.14 and 1.38 hr half-lives in rat and dog, respectively.","Metabolism and disposition of gemcitabine, and oncolytic deoxycytidine analog, in mice, rats, and dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1362937/),h,2.14,15921,DB00441,Gemcitabine
,1362937,plasma half-life,"The mouse exhibited the shortest plasma half-life, approximately 0.28 hr, contrasted with 2.14 and 1.38 hr half-lives in rat and dog, respectively.","Metabolism and disposition of gemcitabine, and oncolytic deoxycytidine analog, in mice, rats, and dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1362937/),h,1.38,15922,DB00441,Gemcitabine
,1362937,half-lives,"The mouse exhibited the shortest plasma half-life, approximately 0.28 hr, contrasted with 2.14 and 1.38 hr half-lives in rat and dog, respectively.","Metabolism and disposition of gemcitabine, and oncolytic deoxycytidine analog, in mice, rats, and dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1362937/),h,2.14,15923,DB00441,Gemcitabine
,1362937,half-lives,"The mouse exhibited the shortest plasma half-life, approximately 0.28 hr, contrasted with 2.14 and 1.38 hr half-lives in rat and dog, respectively.","Metabolism and disposition of gemcitabine, and oncolytic deoxycytidine analog, in mice, rats, and dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1362937/),h,1.38,15924,DB00441,Gemcitabine
,1362937,tissue half-lives,"Half-lives of radioactivity in tissues of both the rat and mouse were relatively short, with the longest tissue half-lives of 5.7 and 3.0 hr, respectively.","Metabolism and disposition of gemcitabine, and oncolytic deoxycytidine analog, in mice, rats, and dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1362937/),h,5.7,15925,DB00441,Gemcitabine
,1362937,tissue half-lives,"Half-lives of radioactivity in tissues of both the rat and mouse were relatively short, with the longest tissue half-lives of 5.7 and 3.0 hr, respectively.","Metabolism and disposition of gemcitabine, and oncolytic deoxycytidine analog, in mice, rats, and dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1362937/),h,3.0,15926,DB00441,Gemcitabine
,27765756,progression-free survival,"Three, three, six, and one patient achieved partial response while median progression-free survival was 6.28, 9.63 months, not reached, and 3.15 months in arms A, B, C, and D, respectively.",Safety and efficacy of nivolumab and standard chemotherapy drug combination in patients with advanced non-small-cell lung cancer: a four arms phase Ib study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27765756/),month,6.28,17149,DB00441,Gemcitabine
,27765756,progression-free survival,"Three, three, six, and one patient achieved partial response while median progression-free survival was 6.28, 9.63 months, not reached, and 3.15 months in arms A, B, C, and D, respectively.",Safety and efficacy of nivolumab and standard chemotherapy drug combination in patients with advanced non-small-cell lung cancer: a four arms phase Ib study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27765756/),month,9.63,17150,DB00441,Gemcitabine
,27765756,progression-free survival,"Three, three, six, and one patient achieved partial response while median progression-free survival was 6.28, 9.63 months, not reached, and 3.15 months in arms A, B, C, and D, respectively.",Safety and efficacy of nivolumab and standard chemotherapy drug combination in patients with advanced non-small-cell lung cancer: a four arms phase Ib study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27765756/),month,3.15,17151,DB00441,Gemcitabine
,19520688,survival time,"Among 12 evaluable patients, 7 patients had stable diseases and 5 patients had progressive diseases, and the median survival time was 3.8 months.",A phase I study of gemcitabine and carboplatin in patients with advanced non-small cell lung cancer and a performance status of 2. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19520688/),month,3.8,18435,DB00441,Gemcitabine
,19520688,AUC,The MTD and the recommended dose for Phase II studies of this regimen were determined to be GEM 1000 mg/m(2) and CBDCA AUC of 4.,A phase I study of gemcitabine and carboplatin in patients with advanced non-small cell lung cancer and a performance status of 2. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19520688/),,4,18436,DB00441,Gemcitabine
,30512187,AUC1,"The mean AUC1 was 7.20 ± 1.48 mg • h/L, which ranged from 4.70 to 9.46 mg • h/L.",Accurate Prediction of Initial Busulfan Exposure Using a Test Dose With 2- and 6-Hour Blood Sampling in Adult Patients Receiving a Twice-Daily Intravenous Busulfan-Based Conditioning Regimen. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30512187/),[h·mg] / [l],7.20,20380,DB00441,Gemcitabine
below,30512187,AUC1,The AUC1 was below the therapeutic concentration of 7.38 mg • h/L in 45% (9 of 20) of the patients.,Accurate Prediction of Initial Busulfan Exposure Using a Test Dose With 2- and 6-Hour Blood Sampling in Adult Patients Receiving a Twice-Daily Intravenous Busulfan-Based Conditioning Regimen. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30512187/),[h·mg] / [l],7.38,20381,DB00441,Gemcitabine
,30512187,CLT,The CLT of 3.05 ± 0.56 mL/min/kg was not significantly different with the CL1 of 3.03 ± 0.69 mL/min/kg (P = .901).,Accurate Prediction of Initial Busulfan Exposure Using a Test Dose With 2- and 6-Hour Blood Sampling in Adult Patients Receiving a Twice-Daily Intravenous Busulfan-Based Conditioning Regimen. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30512187/),[ml] / [kg·min],3.05,20382,DB00441,Gemcitabine
,30512187,CL1,The CLT of 3.05 ± 0.56 mL/min/kg was not significantly different with the CL1 of 3.03 ± 0.69 mL/min/kg (P = .901).,Accurate Prediction of Initial Busulfan Exposure Using a Test Dose With 2- and 6-Hour Blood Sampling in Adult Patients Receiving a Twice-Daily Intravenous Busulfan-Based Conditioning Regimen. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30512187/),[ml] / [kg·min],3.03,20383,DB00441,Gemcitabine
,23880820,progression-free survival,"The study met its primary end point with an OS(3-month) of 75%, with median progression-free survival and overall survival of 2.4 and 5.2 months, respectively.","A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23880820/),month,2.,21657,DB00441,Gemcitabine
,23880820,overall survival,"The study met its primary end point with an OS(3-month) of 75%, with median progression-free survival and overall survival of 2.4 and 5.2 months, respectively.","A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23880820/),month,5,21658,DB00441,Gemcitabine
,8674156,peak concentration,"The peak concentration of gemcitabine was 225 microM and that of the deaminated catabolite 2',2'-difluorodeoxyuridine (dFdU) was 79 microM.","Antitumor activity of prolonged as compared with bolus administration of 2',2'-difluorodeoxycytidine in vivo against murine colon tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8674156/),μM,225,23410,DB00441,Gemcitabine
,8674156,peak concentration,"The peak concentration of gemcitabine was 225 microM and that of the deaminated catabolite 2',2'-difluorodeoxyuridine (dFdU) was 79 microM.","Antitumor activity of prolonged as compared with bolus administration of 2',2'-difluorodeoxycytidine in vivo against murine colon tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8674156/),μM,79,23411,DB00441,Gemcitabine
,8674156,t1/2 beta,"The elimination of gemcitabine was much faster than that of dFdU, with the t1/2 beta values being 15 min and 8 h, respectively.","Antitumor activity of prolonged as compared with bolus administration of 2',2'-difluorodeoxycytidine in vivo against murine colon tumors. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8674156/),min,15,23412,DB00441,Gemcitabine
,8674156,t1/2 beta,"The elimination of gemcitabine was much faster than that of dFdU, with the t1/2 beta values being 15 min and 8 h, respectively.","Antitumor activity of prolonged as compared with bolus administration of 2',2'-difluorodeoxycytidine in vivo against murine colon tumors. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8674156/),h,8,23413,DB00441,Gemcitabine
,18519786,oral bioavailability,"3,4,5,6-Tetrahydrouridine (THU) is a potent CD inhibitor with a 20% oral bioavailability.","Modulation of gemcitabine (2',2'-difluoro-2'-deoxycytidine) pharmacokinetics, metabolism, and bioavailability in mice by 3,4,5,6-tetrahydrouridine. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18519786/),%,20,23922,DB00441,Gemcitabine
,18519786,Absorption,"Absorption of dFdC orally was 59%, but only 10% passed liver and gut CD and eventually reached the systemic circulation.","Modulation of gemcitabine (2',2'-difluoro-2'-deoxycytidine) pharmacokinetics, metabolism, and bioavailability in mice by 3,4,5,6-tetrahydrouridine. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18519786/),%,59,23923,DB00441,Gemcitabine
,18519786,Absorption,"Absorption of dFdC orally was 59%, but only 10% passed liver and gut CD and eventually reached the systemic circulation.","Modulation of gemcitabine (2',2'-difluoro-2'-deoxycytidine) pharmacokinetics, metabolism, and bioavailability in mice by 3,4,5,6-tetrahydrouridine. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18519786/),%,10,23924,DB00441,Gemcitabine
,18519786,oral bioavailability,Coadministration of THU orally increased dFdC oral bioavailability from 10% to 40%.,"Modulation of gemcitabine (2',2'-difluoro-2'-deoxycytidine) pharmacokinetics, metabolism, and bioavailability in mice by 3,4,5,6-tetrahydrouridine. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18519786/),%,10,23925,DB00441,Gemcitabine
,18519786,oral bioavailability,Coadministration of THU orally increased dFdC oral bioavailability from 10% to 40%.,"Modulation of gemcitabine (2',2'-difluoro-2'-deoxycytidine) pharmacokinetics, metabolism, and bioavailability in mice by 3,4,5,6-tetrahydrouridine. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18519786/),%,40,23926,DB00441,Gemcitabine
,7839703,half-lives,2. Radioactivity was eliminated from the blood in a biphasic manner with half-lives of approximately 2 and 15 h in both the male and female rat.,Disposition of gemcitabine in rat and dog after single and multiple dosings. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7839703/),h,2,23961,DB00441,Gemcitabine
,7839703,half-lives,2. Radioactivity was eliminated from the blood in a biphasic manner with half-lives of approximately 2 and 15 h in both the male and female rat.,Disposition of gemcitabine in rat and dog after single and multiple dosings. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7839703/),h,15,23962,DB00441,Gemcitabine
,11822754,peak plasma levels (Cmax,"A nonproportional increase in gemcitabine peak plasma levels (Cmax, from 18.56 +/- 4.94 to 40.85 +/- 14.85 microg/ml) and area under the plasma concentration-time curve (AUC, from 9.99 +/- 2.75 to 25.01 +/- 9.87 h x microg/ml) at 1,500 and 2,000 mg/m, respectively, was observed, suggesting the occurrence of saturation kinetics at higher doses.",Drug distribution and pharmacokinetic/pharmacodynamic relationship of paclitaxel and gemcitabine in patients with non-small-cell lung cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11822754/),[μg] / [ml],18.56,25768,DB00441,Gemcitabine
,11822754,peak plasma levels (Cmax,"A nonproportional increase in gemcitabine peak plasma levels (Cmax, from 18.56 +/- 4.94 to 40.85 +/- 14.85 microg/ml) and area under the plasma concentration-time curve (AUC, from 9.99 +/- 2.75 to 25.01 +/- 9.87 h x microg/ml) at 1,500 and 2,000 mg/m, respectively, was observed, suggesting the occurrence of saturation kinetics at higher doses.",Drug distribution and pharmacokinetic/pharmacodynamic relationship of paclitaxel and gemcitabine in patients with non-small-cell lung cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11822754/),[μg] / [ml],40.85,25769,DB00441,Gemcitabine
,11822754,area under the plasma concentration-time curve (AUC,"A nonproportional increase in gemcitabine peak plasma levels (Cmax, from 18.56 +/- 4.94 to 40.85 +/- 14.85 microg/ml) and area under the plasma concentration-time curve (AUC, from 9.99 +/- 2.75 to 25.01 +/- 9.87 h x microg/ml) at 1,500 and 2,000 mg/m, respectively, was observed, suggesting the occurrence of saturation kinetics at higher doses.",Drug distribution and pharmacokinetic/pharmacodynamic relationship of paclitaxel and gemcitabine in patients with non-small-cell lung cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11822754/),[h·μg] / [ml],9.99,25770,DB00441,Gemcitabine
,11822754,area under the plasma concentration-time curve (AUC,"A nonproportional increase in gemcitabine peak plasma levels (Cmax, from 18.56 +/- 4.94 to 40.85 +/- 14.85 microg/ml) and area under the plasma concentration-time curve (AUC, from 9.99 +/- 2.75 to 25.01 +/- 9.87 h x microg/ml) at 1,500 and 2,000 mg/m, respectively, was observed, suggesting the occurrence of saturation kinetics at higher doses.",Drug distribution and pharmacokinetic/pharmacodynamic relationship of paclitaxel and gemcitabine in patients with non-small-cell lung cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11822754/),[h·μg] / [ml],25.01,25771,DB00441,Gemcitabine
,11822754,time,"A significant relationship between neutropenia and time of paclitaxel plasma levels > or = 0.05 micromol/l was observed, with a predicted time of 10.4 h to decrease cell count by 50%.",Drug distribution and pharmacokinetic/pharmacodynamic relationship of paclitaxel and gemcitabine in patients with non-small-cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11822754/),,10.4,25772,DB00441,Gemcitabine
,11822754,effective concentration,"A correlation was also observed between percentage reduction of platelet count and gemcitabine Cmax, with a predicted effective concentration to induce a 50% decrease of 14.3 microg/ml.",Drug distribution and pharmacokinetic/pharmacodynamic relationship of paclitaxel and gemcitabine in patients with non-small-cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11822754/),[μg] / [ml],14.3,25773,DB00441,Gemcitabine
,24040280,half-life,The compound was well tolerated and rapidly absorbed into the bloodstream with a half-life of approximately 30 min.,In vivo activity and pharmacokinetics of nemorosone on pancreatic cancer xenografts. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24040280/),min,30,26237,DB00441,Gemcitabine
,29548985,zeta potential,"The CSK-TMC conjugates were prepared by ionic gelation to achieve particles sized at 173.6 ± 6.8 nm, zeta potential of +18.5 ± 0.2 mV and entrapment efficiency of 66.4 ± 0.1%, capable of sustained drug release.",N-trimethyl chitosan nanoparticles and CSKSSDYQC peptide: N-trimethyl chitosan conjugates enhance the oral bioavailability of gemcitabine to treat breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29548985/),m,18.5,28651,DB00441,Gemcitabine
,29548985,entrapment efficiency,"The CSK-TMC conjugates were prepared by ionic gelation to achieve particles sized at 173.6 ± 6.8 nm, zeta potential of +18.5 ± 0.2 mV and entrapment efficiency of 66.4 ± 0.1%, capable of sustained drug release.",N-trimethyl chitosan nanoparticles and CSKSSDYQC peptide: N-trimethyl chitosan conjugates enhance the oral bioavailability of gemcitabine to treat breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29548985/),%,66.4,28652,DB00441,Gemcitabine
,29548985,oral bioavailability,"Importantly, during the pharmacokinetic studies, the orally administrated drug loaded into TMC NPs showed an improved oral bioavailability of 54.0%, compared with gemcitabine solution of 9.9%.",N-trimethyl chitosan nanoparticles and CSKSSDYQC peptide: N-trimethyl chitosan conjugates enhance the oral bioavailability of gemcitabine to treat breast cancer. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29548985/),%,54.0,28653,DB00441,Gemcitabine
,29548985,oral bioavailability,"Importantly, during the pharmacokinetic studies, the orally administrated drug loaded into TMC NPs showed an improved oral bioavailability of 54.0%, compared with gemcitabine solution of 9.9%.",N-trimethyl chitosan nanoparticles and CSKSSDYQC peptide: N-trimethyl chitosan conjugates enhance the oral bioavailability of gemcitabine to treat breast cancer. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29548985/),%,9.9,28654,DB00441,Gemcitabine
,29548985,oral bioavailability,"Notable, the CSK-TMC conjugates further improved oral bioavailability to 60.1% and reduced the tumour growth rate in a BALB/c nude mouse model, with a 5.1-fold and 3.3-fold reduction compare with the non-treated group and gemcitabine solution group.",N-trimethyl chitosan nanoparticles and CSKSSDYQC peptide: N-trimethyl chitosan conjugates enhance the oral bioavailability of gemcitabine to treat breast cancer. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29548985/),%,60.1,28655,DB00441,Gemcitabine
,18305939,population clearance,The median population clearance estimate for dFdCTP formation with the full dataset was 70.2 L/h/70 kg/1.7 m.,Does saturable formation of gemcitabine triphosphate occur in patients? ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18305939/),[l] / [1.7·70·h·kg·m],70.2,29084,DB00441,Gemcitabine
,18305939,maximum gemcitabine concentration,Modeling Michaelis-Menten formation of dFdCTP on a reduced dataset estimated K(m) to be 3.6 times higher than the maximum gemcitabine concentration (72.2 microM) measured in this study.,Does saturable formation of gemcitabine triphosphate occur in patients? ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18305939/),μM,72.2,29085,DB00441,Gemcitabine
,2208147,steady-state plasma dFdC levels,"The average steady-state plasma dFdC levels, achieved within 15 min after the infusion began, were 43.8 microM during infusion of 800 mg/m2/h, 9.4 microM during infusion of 400 mg/m2/h, and 5.6 microM at 267 mg/m2/h.","Pharmacologically directed design of the dose rate and schedule of 2',2'-difluorodeoxycytidine (Gemcitabine) administration in leukemia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2208147/),μM,43.8,29140,DB00441,Gemcitabine
,2208147,steady-state plasma dFdC levels,"The average steady-state plasma dFdC levels, achieved within 15 min after the infusion began, were 43.8 microM during infusion of 800 mg/m2/h, 9.4 microM during infusion of 400 mg/m2/h, and 5.6 microM at 267 mg/m2/h.","Pharmacologically directed design of the dose rate and schedule of 2',2'-difluorodeoxycytidine (Gemcitabine) administration in leukemia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2208147/),μM,9.4,29141,DB00441,Gemcitabine
,2208147,steady-state plasma dFdC levels,"The average steady-state plasma dFdC levels, achieved within 15 min after the infusion began, were 43.8 microM during infusion of 800 mg/m2/h, 9.4 microM during infusion of 400 mg/m2/h, and 5.6 microM at 267 mg/m2/h.","Pharmacologically directed design of the dose rate and schedule of 2',2'-difluorodeoxycytidine (Gemcitabine) administration in leukemia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2208147/),μM,5.6,29142,DB00441,Gemcitabine
,25344453,maximal tolerable dose,The maximal tolerable dose was 300 and 450 mg/m(2) of NAMI-A (21 day schedule).,Phase I/II study with ruthenium compound NAMI-A and gemcitabine in patients with non-small cell lung cancer after first line therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25344453/),[mg] / [m(2],300,30771,DB00441,Gemcitabine
,25344453,maximal tolerable dose,The maximal tolerable dose was 300 and 450 mg/m(2) of NAMI-A (21 day schedule).,Phase I/II study with ruthenium compound NAMI-A and gemcitabine in patients with non-small cell lung cancer after first line therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25344453/),[mg] / [m(2],450,30772,DB00441,Gemcitabine
,30082474,disease control rate,"The disease control rate was 57% for patients treated with abemaciclib-pemetrexed, 25% for abemaciclib-gemcitabine, and 54% for abemaciclib-ramucirumab.",Abemaciclib in Combination with Single-Agent Options in Patients with Stage IV Non-Small Cell Lung Cancer: A Phase Ib Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30082474/),%,57,31844,DB00441,Gemcitabine
,30082474,disease control rate,"The disease control rate was 57% for patients treated with abemaciclib-pemetrexed, 25% for abemaciclib-gemcitabine, and 54% for abemaciclib-ramucirumab.",Abemaciclib in Combination with Single-Agent Options in Patients with Stage IV Non-Small Cell Lung Cancer: A Phase Ib Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30082474/),%,25,31845,DB00441,Gemcitabine
,30082474,disease control rate,"The disease control rate was 57% for patients treated with abemaciclib-pemetrexed, 25% for abemaciclib-gemcitabine, and 54% for abemaciclib-ramucirumab.",Abemaciclib in Combination with Single-Agent Options in Patients with Stage IV Non-Small Cell Lung Cancer: A Phase Ib Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30082474/),%,54,31846,DB00441,Gemcitabine
,30082474,progression-free survival,"Median progression-free survival was 5.55, 1.58, and 4.83 months, respectively.",Abemaciclib in Combination with Single-Agent Options in Patients with Stage IV Non-Small Cell Lung Cancer: A Phase Ib Study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30082474/),month,5.55,31847,DB00441,Gemcitabine
,30082474,progression-free survival,"Median progression-free survival was 5.55, 1.58, and 4.83 months, respectively.",Abemaciclib in Combination with Single-Agent Options in Patients with Stage IV Non-Small Cell Lung Cancer: A Phase Ib Study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30082474/),month,1.58,31848,DB00441,Gemcitabine
,30082474,progression-free survival,"Median progression-free survival was 5.55, 1.58, and 4.83 months, respectively.",Abemaciclib in Combination with Single-Agent Options in Patients with Stage IV Non-Small Cell Lung Cancer: A Phase Ib Study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30082474/),month,4.83,31849,DB00441,Gemcitabine
,33210382,area under the plasma concentration-time curve from time 0 to last measurable time,"The median estimates of area under the plasma concentration-time curve from time 0 to last measurable time and maximum concentration were highest for NUC-1031 (218-324 μg•h/mL and 309-889 μg/mL, respectively) and lowest for di-fluoro-deoxycytidine (0.47-1.56 μg•h/mL and 0.284-0.522 μg/mL, respectively).",A Phase Ib Study of NUC-1031 in Combination with Cisplatin for the First-Line Treatment of Patients with Advanced Biliary Tract Cancer (ABC-08). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33210382/),[h·μg] / [ml],218-324,32594,DB00441,Gemcitabine
,33210382,area under the plasma concentration-time curve from time 0 to last measurable time,"The median estimates of area under the plasma concentration-time curve from time 0 to last measurable time and maximum concentration were highest for NUC-1031 (218-324 μg•h/mL and 309-889 μg/mL, respectively) and lowest for di-fluoro-deoxycytidine (0.47-1.56 μg•h/mL and 0.284-0.522 μg/mL, respectively).",A Phase Ib Study of NUC-1031 in Combination with Cisplatin for the First-Line Treatment of Patients with Advanced Biliary Tract Cancer (ABC-08). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33210382/),[h·μg] / [ml],0.47-1.56,32595,DB00441,Gemcitabine
,33210382,area under the plasma concentration-time curve from time 0 to last measurable time,"The median estimates of area under the plasma concentration-time curve from time 0 to last measurable time and maximum concentration were highest for NUC-1031 (218-324 μg•h/mL and 309-889 μg/mL, respectively) and lowest for di-fluoro-deoxycytidine (0.47-1.56 μg•h/mL and 0.284-0.522 μg/mL, respectively).",A Phase Ib Study of NUC-1031 in Combination with Cisplatin for the First-Line Treatment of Patients with Advanced Biliary Tract Cancer (ABC-08). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33210382/),[μg] / [ml],0.284-0.522,32596,DB00441,Gemcitabine
,33210382,maximum concentration,"The median estimates of area under the plasma concentration-time curve from time 0 to last measurable time and maximum concentration were highest for NUC-1031 (218-324 μg•h/mL and 309-889 μg/mL, respectively) and lowest for di-fluoro-deoxycytidine (0.47-1.56 μg•h/mL and 0.284-0.522 μg/mL, respectively).",A Phase Ib Study of NUC-1031 in Combination with Cisplatin for the First-Line Treatment of Patients with Advanced Biliary Tract Cancer (ABC-08). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33210382/),[μg] / [ml],309-889,32597,DB00441,Gemcitabine
,33210382,maximum concentration,"The median estimates of area under the plasma concentration-time curve from time 0 to last measurable time and maximum concentration were highest for NUC-1031 (218-324 μg•h/mL and 309-889 μg/mL, respectively) and lowest for di-fluoro-deoxycytidine (0.47-1.56 μg•h/mL and 0.284-0.522 μg/mL, respectively).",A Phase Ib Study of NUC-1031 in Combination with Cisplatin for the First-Line Treatment of Patients with Advanced Biliary Tract Cancer (ABC-08). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33210382/),[h·μg] / [ml],0.47-1.56,32598,DB00441,Gemcitabine
,33210382,maximum concentration,"The median estimates of area under the plasma concentration-time curve from time 0 to last measurable time and maximum concentration were highest for NUC-1031 (218-324 μg•h/mL and 309-889 μg/mL, respectively) and lowest for di-fluoro-deoxycytidine (0.47-1.56 μg•h/mL and 0.284-0.522 μg/mL, respectively).",A Phase Ib Study of NUC-1031 in Combination with Cisplatin for the First-Line Treatment of Patients with Advanced Biliary Tract Cancer (ABC-08). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33210382/),[μg] / [ml],0.284-0.522,32599,DB00441,Gemcitabine
,18040687,area under the concentration versus time curve (AUC),"The mean area under the concentration versus time curve (AUC) for dFdC in peritoneal fluid was 182 microg/ml x h, which was approximately 70x the AUC of dFdC reported in the ascites of a patient undergoing systemic dFdC therapy.",Intraperitoneal gemcitabine pharmacokinetics: a pilot and pharmacokinetic study in patients with advanced adenocarcinoma of the pancreas. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18040687/),[μg] / [h·ml],182,33341,DB00441,Gemcitabine
,28314923,plasma concentrations,"Gemcitabine plasma concentrations peaked at about 105,000 ± 30,000, 252 ± 101, 22 ± 29, and 0 ± 0 ppb for the IV, fast-release, slow-release, and bland treatments, respectively.",New Interventional Treatment Model for Pancreatic Neoplasms Using Gemcitabine-Eluting Hydrogel Devices: In Vitro and In Vivo Results. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28314923/),ppb,"105,000",34061,DB00441,Gemcitabine
,28314923,plasma concentrations,"Gemcitabine plasma concentrations peaked at about 105,000 ± 30,000, 252 ± 101, 22 ± 29, and 0 ± 0 ppb for the IV, fast-release, slow-release, and bland treatments, respectively.",New Interventional Treatment Model for Pancreatic Neoplasms Using Gemcitabine-Eluting Hydrogel Devices: In Vitro and In Vivo Results. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28314923/),ppb,252,34062,DB00441,Gemcitabine
,28314923,plasma concentrations,"Gemcitabine plasma concentrations peaked at about 105,000 ± 30,000, 252 ± 101, 22 ± 29, and 0 ± 0 ppb for the IV, fast-release, slow-release, and bland treatments, respectively.",New Interventional Treatment Model for Pancreatic Neoplasms Using Gemcitabine-Eluting Hydrogel Devices: In Vitro and In Vivo Results. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28314923/),ppb,22,34063,DB00441,Gemcitabine
,28314923,plasma concentrations,"Gemcitabine plasma concentrations peaked at about 105,000 ± 30,000, 252 ± 101, 22 ± 29, and 0 ± 0 ppb for the IV, fast-release, slow-release, and bland treatments, respectively.",New Interventional Treatment Model for Pancreatic Neoplasms Using Gemcitabine-Eluting Hydrogel Devices: In Vitro and In Vivo Results. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28314923/),ppb,0,34064,DB00441,Gemcitabine
,15767790,time to progression (TTP),"Median time to progression (TTP) and overall survival were 7.1 months and 13.0 months, respectively.",Short communication: the efficacy of fixed dose rate infusion of gemcitabine combined with IFN-alpha2a in patients with advanced refractory renal cell carcinoma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15767790/),month,7.1,37685,DB00441,Gemcitabine
,15767790,overall survival,"Median time to progression (TTP) and overall survival were 7.1 months and 13.0 months, respectively.",Short communication: the efficacy of fixed dose rate infusion of gemcitabine combined with IFN-alpha2a in patients with advanced refractory renal cell carcinoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15767790/),month,13.0,37686,DB00441,Gemcitabine
,32397338,Cmax,"After intragastric Cbz-dFdC administration, the Cmax of Cbz-dFdC and dFdC was 451.1 ± 106.7 and 1656.3 ± 431.5 ng/mL, respectively.",A Pharmacokinetic and Pharmacodynamic Evaluation of the Anti-Hepatocellular Carcinoma Compound 4-N-Carbobenzoxy-gemcitabine (Cbz-dFdC). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32397338/),[ng] / [ml],451.1,38074,DB00441,Gemcitabine
,32397338,Cmax,"After intragastric Cbz-dFdC administration, the Cmax of Cbz-dFdC and dFdC was 451.1 ± 106.7 and 1656.3 ± 431.5 ng/mL, respectively.",A Pharmacokinetic and Pharmacodynamic Evaluation of the Anti-Hepatocellular Carcinoma Compound 4-N-Carbobenzoxy-gemcitabine (Cbz-dFdC). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32397338/),[ng] / [ml],1656.3,38075,DB00441,Gemcitabine
,32397338,Tmax,"The Tmax of Cbz-dFdC and dFdC was 2 and 4 h, respectively.",A Pharmacokinetic and Pharmacodynamic Evaluation of the Anti-Hepatocellular Carcinoma Compound 4-N-Carbobenzoxy-gemcitabine (Cbz-dFdC). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32397338/),h,2,38076,DB00441,Gemcitabine
,32397338,Tmax,"The Tmax of Cbz-dFdC and dFdC was 2 and 4 h, respectively.",A Pharmacokinetic and Pharmacodynamic Evaluation of the Anti-Hepatocellular Carcinoma Compound 4-N-Carbobenzoxy-gemcitabine (Cbz-dFdC). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32397338/),h,4,38077,DB00441,Gemcitabine
,31514844,m/,"PEGylated gemcitabine underwent dissociation in collision cell to generate a series of PEG related ions at m/z 89.0604, 133.0868, 177.1129 of 2, 3, 4 repeating ethylene oxide subunits and PEGylated gemcitabine related ions at m/z 112.0514.",Comparative pharmacokinetic study of PEGylated gemcitabine and gemcitabine in rats by LC-MS/MS coupled with pre-column derivatization and MSALL technique. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31514844/),,112.0514,38564,DB00441,Gemcitabine
,15245614,area under the curve (AUC),"From February 2002 to May 2003, 30 previously treated patients with adenocarcinoma of the breast received gemcitabine 1000 mg/m2 on days 1 and 8 plus carboplatin to an area under the curve (AUC) of 5 on day 1.",Gemcitabine plus carboplatin combination therapy as second-line treatment in patients with relapsed breast cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15245614/),,5,40018,DB00441,Gemcitabine
,15245614,AUC,"The carboplatin dose was changed to an AUC of 4.5 because of toxicity, with cycles repeated every 3 weeks.",Gemcitabine plus carboplatin combination therapy as second-line treatment in patients with relapsed breast cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15245614/),,4.5,40019,DB00441,Gemcitabine
,15245614,time to progression,"The median time to progression for the study group was 20.47 weeks (range, 8-46 weeks).",Gemcitabine plus carboplatin combination therapy as second-line treatment in patients with relapsed breast cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15245614/),weeks,20.47,40020,DB00441,Gemcitabine
,11688520,overall response rate,"The overall response rate to GET was 92% (95% CI, 77.53%-98.25%); CR 31% and PR 61%.",Gemcitabine plus epirubicin plus taxol (GET) in advanced breast cancer: a phase II study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11688520/),%,92,40254,DB00441,Gemcitabine
,11688520,overall response rate,"After six courses of GET, 25 patients received HDCT, leading to an overall response rate of 96% with 58% CR.",Gemcitabine plus epirubicin plus taxol (GET) in advanced breast cancer: a phase II study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11688520/),%,96,40255,DB00441,Gemcitabine
,11688520,progression free survival,"Median progression free survival is 21 months, while median overall survival has not yet been reached.",Gemcitabine plus epirubicin plus taxol (GET) in advanced breast cancer: a phase II study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11688520/),month,21,40256,DB00441,Gemcitabine
,17009034,Objective response rate,Objective response rate was 34% and median survival time was 11.7 months.,"A triplet chemotherapy with cisplatin, docetaxel and gemcitabine in patients with advanced non-small-cell lung cancer: a phase I/II study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17009034/),%,34,40609,DB00441,Gemcitabine
,17009034,survival time,Objective response rate was 34% and median survival time was 11.7 months.,"A triplet chemotherapy with cisplatin, docetaxel and gemcitabine in patients with advanced non-small-cell lung cancer: a phase I/II study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17009034/),month,11.7,40610,DB00441,Gemcitabine
exceed,1740680,steady-state plasma dFdC levels,"Thus, we designed a phase I study to maximize the accumulation of dFdCTP by leukemia cells by administering dFdC at 10 mg/m2/min, a dose rate calculated to produce steady-state plasma dFdC levels that exceed 15 to 20 mumol/L.","Gemcitabine in leukemia: a phase I clinical, plasma, and cellular pharmacology study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1740680/),[μM] / [l],15 to 20,43144,DB00441,Gemcitabine
,1740680,steady-state dFdC level,The mean steady-state dFdC level in plasma of all infusions was 26.5 +/- 9 mumol/L (n = 19).,"Gemcitabine in leukemia: a phase I clinical, plasma, and cellular pharmacology study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1740680/),[μM] / [l],26.5,43145,DB00441,Gemcitabine
,33250343,Serum peak concentrations (cmax),"Serum peak concentrations (cmax) of gemcitabine were low at 5.5 µg/ml compared to the 10 to 30 µg/ml levels observed after a single intravenous dose of 1,000 mg/m2 gemcitabine.",A polymeric paste-drug formulation for local treatment of upper tract urothelial carcinoma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33250343/),[μg] / [ml],5.5,43146,DB00441,Gemcitabine
,33250343,Serum peak concentrations (cmax),"Serum peak concentrations (cmax) of gemcitabine were low at 5.5 µg/ml compared to the 10 to 30 µg/ml levels observed after a single intravenous dose of 1,000 mg/m2 gemcitabine.",A polymeric paste-drug formulation for local treatment of upper tract urothelial carcinoma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33250343/),[μg] / [ml],10 to 30,43147,DB00441,Gemcitabine
,32694153,progression-free survival,"Median progression-free survival was 5.9 m [95% confidence interval (CI), 3.4-18.4], median overall survival was 9.7 m (95% CI, 7.0-14).",Phase Ib Study of Wnt Inhibitor Ipafricept with Gemcitabine and nab-paclitaxel in Patients with Previously Untreated Stage IV Pancreatic Cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32694153/),m,5.9,43180,DB00441,Gemcitabine
,32694153,overall survival,"Median progression-free survival was 5.9 m [95% confidence interval (CI), 3.4-18.4], median overall survival was 9.7 m (95% CI, 7.0-14).",Phase Ib Study of Wnt Inhibitor Ipafricept with Gemcitabine and nab-paclitaxel in Patients with Previously Untreated Stage IV Pancreatic Cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32694153/),m,9.7,43181,DB00441,Gemcitabine
,17961191,clearance,"The population mean (and between-subject variability, CV%) for clearance and volume of distribution of the central compartment (V(C)) for gemcitabine were 2.7 l min(-1) (31%) and 15 l (39%), respectively, and 0.04 l min(-1) (35%) and 46 l (15%), respectively, for dFdU.",Population pharmacokinetics of gemcitabine and its metabolite in patients with cancer: effect of oxaliplatin and infusion rate. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17961191/),[l] / [min],2.7,47387,DB00441,Gemcitabine
,17961191,clearance,"The population mean (and between-subject variability, CV%) for clearance and volume of distribution of the central compartment (V(C)) for gemcitabine were 2.7 l min(-1) (31%) and 15 l (39%), respectively, and 0.04 l min(-1) (35%) and 46 l (15%), respectively, for dFdU.",Population pharmacokinetics of gemcitabine and its metabolite in patients with cancer: effect of oxaliplatin and infusion rate. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17961191/),[l] / [min],0.04,47388,DB00441,Gemcitabine
,17961191,volume of distribution of the central compartment (V(C)),"The population mean (and between-subject variability, CV%) for clearance and volume of distribution of the central compartment (V(C)) for gemcitabine were 2.7 l min(-1) (31%) and 15 l (39%), respectively, and 0.04 l min(-1) (35%) and 46 l (15%), respectively, for dFdU.",Population pharmacokinetics of gemcitabine and its metabolite in patients with cancer: effect of oxaliplatin and infusion rate. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17961191/),l,15,47389,DB00441,Gemcitabine
,17961191,volume of distribution of the central compartment (V(C)),"The population mean (and between-subject variability, CV%) for clearance and volume of distribution of the central compartment (V(C)) for gemcitabine were 2.7 l min(-1) (31%) and 15 l (39%), respectively, and 0.04 l min(-1) (35%) and 46 l (15%), respectively, for dFdU.",Population pharmacokinetics of gemcitabine and its metabolite in patients with cancer: effect of oxaliplatin and infusion rate. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17961191/),l,46,47390,DB00441,Gemcitabine
,31301340,circulation half-life,"Liposomal encapsulation resulted in a circulation half-life of ~2 h in vivo (compared to reported circulation of 16 min for free gemcitabine in mice), and free drug was not detected within the plasma.",Tumor-specific delivery of gemcitabine with activatable liposomes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31301340/),h,2,47544,DB00441,Gemcitabine
,31301340,circulation,"Liposomal encapsulation resulted in a circulation half-life of ~2 h in vivo (compared to reported circulation of 16 min for free gemcitabine in mice), and free drug was not detected within the plasma.",Tumor-specific delivery of gemcitabine with activatable liposomes. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31301340/),min,16,47545,DB00441,Gemcitabine
,23543271,Peak plasma curcumin levels,"Peak plasma curcumin levels (median) after Theracurmin administration were 324 ng/mL (range, 47-1,029 ng/mL) at Level 1 and 440 ng/mL (range, 179-1,380 ng/mL) at Level 2.",A phase I study investigating the safety and pharmacokinetics of highly bioavailable curcumin (Theracurmin) in cancer patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23543271/),[ng] / [ml],324,50672,DB00441,Gemcitabine
,23543271,Peak plasma curcumin levels,"Peak plasma curcumin levels (median) after Theracurmin administration were 324 ng/mL (range, 47-1,029 ng/mL) at Level 1 and 440 ng/mL (range, 179-1,380 ng/mL) at Level 2.",A phase I study investigating the safety and pharmacokinetics of highly bioavailable curcumin (Theracurmin) in cancer patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23543271/),[ng] / [ml],440,50673,DB00441,Gemcitabine
,30519478,-AUC,"The measured-AUC was 5.96 mg/mL min in the first cycle, after which the patient developed grade 3/4 hematologic toxicities.",Investigation of tolerability and quality of life for carboplatin-based chemotherapy in an elderly urothelial carcinoma patient undergoing hemodialysis: a case report. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30519478/),[mg] / [min·ml],5.96,50902,DB00441,Gemcitabine
,30519478,-AUC,"The measured-AUC in the second cycle was 4.97 mg/mL min, and hematologic toxic effects decreased to grade 2.",Investigation of tolerability and quality of life for carboplatin-based chemotherapy in an elderly urothelial carcinoma patient undergoing hemodialysis: a case report. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30519478/),[mg] / [min·ml],4.97,50903,DB00441,Gemcitabine
,12885837,survival,"Time to treatment failure was comparable in both treatment groups; however, the median survival for all patients was 5.0 months in the standard arm and 8.0 months in the FDR arm (P =.013).",Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12885837/),month,5.0,51082,DB00441,Gemcitabine
,12885837,survival,"Time to treatment failure was comparable in both treatment groups; however, the median survival for all patients was 5.0 months in the standard arm and 8.0 months in the FDR arm (P =.013).",Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12885837/),month,8.0,51083,DB00441,Gemcitabine
,12885837,survival,"For patients with metastases, the median survival was 4.9 months in the standard arm and 7.3 months in FDR arm (P =.094).",Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12885837/),month,4.9,51084,DB00441,Gemcitabine
,12885837,survival,"For patients with metastases, the median survival was 4.9 months in the standard arm and 7.3 months in FDR arm (P =.094).",Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12885837/),month,7.3,51085,DB00441,Gemcitabine
,17908977,Cmax,Pharmacokinetic studies showed Cmax ranging from 1.49 +/- 0.69 micromol/L (flavopiridol 20 mg/m2) to 4.54 +/- 0.08 micromol/L (flavopiridol 60 mg/m2) in cycle 1.,Phase I dose-finding study of weekly docetaxel followed by flavopiridol for patients with advanced solid tumors. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17908977/),[μM] / [l],1.49,52705,DB00441,Gemcitabine
,17908977,Cmax,Pharmacokinetic studies showed Cmax ranging from 1.49 +/- 0.69 micromol/L (flavopiridol 20 mg/m2) to 4.54 +/- 0.08 micromol/L (flavopiridol 60 mg/m2) in cycle 1.,Phase I dose-finding study of weekly docetaxel followed by flavopiridol for patients with advanced solid tumors. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17908977/),[μM] / [l],4.54,52706,DB00441,Gemcitabine
,26193987,AUCt,"Significant differences were noted between infusion duration (GFI = 30.0 ± 2.6 min, IP = 29.1 ± 1.2 min, PAR = 33.7 ± 3.5 min; p = 0.003) and AUCt (GFI = 23.5 ± 8.2 µM h, IP = 25.4 ± 9.1 µM h, PAR = 28.5 ± 6.3 µM h; p = 0.0009), which was significantly higher in the infusion group with post-administration rinsing than in the other groups.",Influence of infusion method on gemcitabine pharmacokinetics: a controlled randomized multicenter trial. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26193987/),h·μM,23.5,52828,DB00441,Gemcitabine
,26193987,AUCt,"Significant differences were noted between infusion duration (GFI = 30.0 ± 2.6 min, IP = 29.1 ± 1.2 min, PAR = 33.7 ± 3.5 min; p = 0.003) and AUCt (GFI = 23.5 ± 8.2 µM h, IP = 25.4 ± 9.1 µM h, PAR = 28.5 ± 6.3 µM h; p = 0.0009), which was significantly higher in the infusion group with post-administration rinsing than in the other groups.",Influence of infusion method on gemcitabine pharmacokinetics: a controlled randomized multicenter trial. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26193987/),h·μM,25.4,52829,DB00441,Gemcitabine
,26193987,AUCt,"Significant differences were noted between infusion duration (GFI = 30.0 ± 2.6 min, IP = 29.1 ± 1.2 min, PAR = 33.7 ± 3.5 min; p = 0.003) and AUCt (GFI = 23.5 ± 8.2 µM h, IP = 25.4 ± 9.1 µM h, PAR = 28.5 ± 6.3 µM h; p = 0.0009), which was significantly higher in the infusion group with post-administration rinsing than in the other groups.",Influence of infusion method on gemcitabine pharmacokinetics: a controlled randomized multicenter trial. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26193987/),h·μM,28.5,52830,DB00441,Gemcitabine
,29748012,disease control rate,Five patients had partial responses (31.3%) and eight had stable disease (50.0%); disease control rate was 81.3%.,A phase I study of nintedanib combined with cisplatin/gemcitabine as first-line therapy for advanced squamous non-small cell lung cancer (LUME-Lung 3). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29748012/),%,81.3,52933,DB00441,Gemcitabine
<,24300978,Infusion rate,Infusion rate <25 mg m(-2) min(-1) and carriers for SLC28A3 variant were each associated with about two-fold higher dFdCTP formation clearance.,SLC28A3 genotype and gemcitabine rate of infusion affect dFdCTP metabolite disposition in patients with solid tumours. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24300978/),[mg] / [(m)^2·min],25,56302,DB00441,Gemcitabine
,27044830,degradation half-life (t1/2),"However, the degradation half-life (t1/2) of CPDG was about 43h in the mouse plasma, longer than the t1/2 at pH 2.0.",Long-circulating and liver-targeted nanoassemblies of cyclic phosphoryl N-dodecanoyl gemcitabine for the treatment of hepatocellular carcinoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27044830/),h,43,56826,DB00441,Gemcitabine
,27044830,tumor inhibitory rates,"The tumor inhibitory rates of GEM, the long circulating CPDG nanoassemblies (37.5, 75 μmol/kg) were 49.54, 42.97, 65.10%, respectively.",Long-circulating and liver-targeted nanoassemblies of cyclic phosphoryl N-dodecanoyl gemcitabine for the treatment of hepatocellular carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27044830/),%,49.54,56827,DB00441,Gemcitabine
,27044830,tumor inhibitory rates,"The tumor inhibitory rates of GEM, the long circulating CPDG nanoassemblies (37.5, 75 μmol/kg) were 49.54, 42.97, 65.10%, respectively.",Long-circulating and liver-targeted nanoassemblies of cyclic phosphoryl N-dodecanoyl gemcitabine for the treatment of hepatocellular carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27044830/),%,42.97,56828,DB00441,Gemcitabine
,27044830,tumor inhibitory rates,"The tumor inhibitory rates of GEM, the long circulating CPDG nanoassemblies (37.5, 75 μmol/kg) were 49.54, 42.97, 65.10%, respectively.",Long-circulating and liver-targeted nanoassemblies of cyclic phosphoryl N-dodecanoyl gemcitabine for the treatment of hepatocellular carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27044830/),%,65.10,56829,DB00441,Gemcitabine
,23143189,oral bioavailability,In vivo pharmacokinetics showed the oral bioavailability of D07001-F4 to be 34%.,"In vitro and in vivo studies of pharmacokinetics and antitumor efficacy of D07001-F4, an oral gemcitabine formulation. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23143189/),%,34,57736,DB00441,Gemcitabine
,19855966,terminal half life,There was a dose proportional increase in imexon AUC across the doses tested with terminal half life 69 min at the MTD and no alteration of gemcitabine pharmacokinetics.,A phase I study of imexon plus gemcitabine as first-line therapy for advanced pancreatic cancer. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19855966/),min,69,58801,DB00441,Gemcitabine
,33114652,progression-free survival,"The median progression-free survival reached statistical significance in patients who had metastatic disease (1.6 vs. 2.9 months, p = 0.025).","Safety, Efficacy and Pharcacokinetics of Targeted Therapy with The Liposomal RNA Interference Therapeutic Atu027 Combined with Gemcitabine in Patients with Pancreatic Adenocarcinoma. A Randomized Phase Ib/IIa Study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33114652/),month,1.6,61846,DB00441,Gemcitabine
,33114652,progression-free survival,"The median progression-free survival reached statistical significance in patients who had metastatic disease (1.6 vs. 2.9 months, p = 0.025).","Safety, Efficacy and Pharcacokinetics of Targeted Therapy with The Liposomal RNA Interference Therapeutic Atu027 Combined with Gemcitabine in Patients with Pancreatic Adenocarcinoma. A Randomized Phase Ib/IIa Study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33114652/),month,2.9,61847,DB00441,Gemcitabine
,23616084,progression-free survival,Two patients (30 mg/day) achieved stable disease with progression-free survival lasting 135 and 155 days.,Phase I study of oral gemcitabine prodrug (LY2334737) in Japanese patients with advanced solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23616084/),d,135,63093,DB00441,Gemcitabine
,23616084,progression-free survival,Two patients (30 mg/day) achieved stable disease with progression-free survival lasting 135 and 155 days.,Phase I study of oral gemcitabine prodrug (LY2334737) in Japanese patients with advanced solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23616084/),d,155,63094,DB00441,Gemcitabine
,20528225,progression-free survival,The salirasib recommended dose was 600 mg twice daily and the progression-free survival was 4.7 months.,Salirasib in the treatment of pancreatic cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20528225/),month,4.7,64123,DB00441,Gemcitabine
,17465260,maximum gemcitabine concentrations,Mean maximum gemcitabine concentrations were 1.47 microg/ml in small TURB and 2.8 microg/ml in large TURB.,Pharmacokinetics and toxicity of an early single intravesical instillation of gemcitabine after endoscopic resection of superficial bladder cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17465260/),[μg] / [ml],1.47,64416,DB00441,Gemcitabine
,17465260,maximum gemcitabine concentrations,Mean maximum gemcitabine concentrations were 1.47 microg/ml in small TURB and 2.8 microg/ml in large TURB.,Pharmacokinetics and toxicity of an early single intravesical instillation of gemcitabine after endoscopic resection of superficial bladder cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17465260/),[μg] / [ml],2.8,64417,DB00441,Gemcitabine
,17465260,peak concentration,The highest peak concentration of 4.26 microg/ml was found after extended bladder resection.,Pharmacokinetics and toxicity of an early single intravesical instillation of gemcitabine after endoscopic resection of superficial bladder cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17465260/),[μg] / [ml],4.26,64418,DB00441,Gemcitabine
,16344320,time to progression,"Median time to progression was 3.9 months and median survival was 7.1 months, with an estimated 1-year survival rate of 29%.",Phase II study of fixed dose rate gemcitabine with cisplatin for metastatic adenocarcinoma of the pancreas. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16344320/),month,3.9,64880,DB00441,Gemcitabine
,16344320,survival,"Median time to progression was 3.9 months and median survival was 7.1 months, with an estimated 1-year survival rate of 29%.",Phase II study of fixed dose rate gemcitabine with cisplatin for metastatic adenocarcinoma of the pancreas. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16344320/),month,7.1,64881,DB00441,Gemcitabine
,15325290,Maximum plasma concentrations (C(max)),"Maximum plasma concentrations (C(max)) and area under the plasma concentration-time curve for dFdC and dFdU were 24.5 microg/ml and 11200 microg/Lh, 49.1 microg/ml and 272,800 microg/Lh, respectively.","Investigation of the pharmacokinetics of gemcitabine and 2',2'-difluorodeoxyuridine in human plasma by liquid chromatography. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15325290/),[μg] / [ml],24.5,64993,DB00441,Gemcitabine
,15325290,Maximum plasma concentrations (C(max)),"Maximum plasma concentrations (C(max)) and area under the plasma concentration-time curve for dFdC and dFdU were 24.5 microg/ml and 11200 microg/Lh, 49.1 microg/ml and 272,800 microg/Lh, respectively.","Investigation of the pharmacokinetics of gemcitabine and 2',2'-difluorodeoxyuridine in human plasma by liquid chromatography. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15325290/),[μg] / [lh],11200,64994,DB00441,Gemcitabine
,15325290,Maximum plasma concentrations (C(max)),"Maximum plasma concentrations (C(max)) and area under the plasma concentration-time curve for dFdC and dFdU were 24.5 microg/ml and 11200 microg/Lh, 49.1 microg/ml and 272,800 microg/Lh, respectively.","Investigation of the pharmacokinetics of gemcitabine and 2',2'-difluorodeoxyuridine in human plasma by liquid chromatography. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15325290/),[μg] / [ml],49.1,64995,DB00441,Gemcitabine
,15325290,area under the plasma concentration-time curve,"Maximum plasma concentrations (C(max)) and area under the plasma concentration-time curve for dFdC and dFdU were 24.5 microg/ml and 11200 microg/Lh, 49.1 microg/ml and 272,800 microg/Lh, respectively.","Investigation of the pharmacokinetics of gemcitabine and 2',2'-difluorodeoxyuridine in human plasma by liquid chromatography. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15325290/),[μg] / [lh],11200,64996,DB00441,Gemcitabine
,15325290,area under the plasma concentration-time curve,"Maximum plasma concentrations (C(max)) and area under the plasma concentration-time curve for dFdC and dFdU were 24.5 microg/ml and 11200 microg/Lh, 49.1 microg/ml and 272,800 microg/Lh, respectively.","Investigation of the pharmacokinetics of gemcitabine and 2',2'-difluorodeoxyuridine in human plasma by liquid chromatography. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15325290/),[μg] / [lh],"272,800",64997,DB00441,Gemcitabine
,27798825,Area under the curve (AUC),"Area under the curve (AUC), elimination half-life (t1/2), and mean residence time (MRT) of P-GEM treated group were significantly higher compared to those of F-GEM treated group: 246,425 ± 1605 vs 83,591 ± 1844 ng/mL × h as AUC, 5.77 ± 2.02 vs 1.99 ± 0.09 h as t1/2, and 4.45 ± 0.15 vs 1.12 ± 0.13 h as MRT.",Biodistribution of Self-Assembling Polymer-Gemcitabine Conjugate after Systemic Administration into Orthotopic Pancreatic Tumor Bearing Mice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27798825/),[ng] / [h·ml],"246,425",66134,DB00441,Gemcitabine
,27798825,elimination half-life (t1/2),"Area under the curve (AUC), elimination half-life (t1/2), and mean residence time (MRT) of P-GEM treated group were significantly higher compared to those of F-GEM treated group: 246,425 ± 1605 vs 83,591 ± 1844 ng/mL × h as AUC, 5.77 ± 2.02 vs 1.99 ± 0.09 h as t1/2, and 4.45 ± 0.15 vs 1.12 ± 0.13 h as MRT.",Biodistribution of Self-Assembling Polymer-Gemcitabine Conjugate after Systemic Administration into Orthotopic Pancreatic Tumor Bearing Mice. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27798825/),[ng] / [h·ml],"83,591",66135,DB00441,Gemcitabine
,27798825,AUC,"Area under the curve (AUC), elimination half-life (t1/2), and mean residence time (MRT) of P-GEM treated group were significantly higher compared to those of F-GEM treated group: 246,425 ± 1605 vs 83,591 ± 1844 ng/mL × h as AUC, 5.77 ± 2.02 vs 1.99 ± 0.09 h as t1/2, and 4.45 ± 0.15 vs 1.12 ± 0.13 h as MRT.",Biodistribution of Self-Assembling Polymer-Gemcitabine Conjugate after Systemic Administration into Orthotopic Pancreatic Tumor Bearing Mice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27798825/),[ng] / [h·ml],"83,591",66136,DB00441,Gemcitabine
,27798825,t1/2,"Area under the curve (AUC), elimination half-life (t1/2), and mean residence time (MRT) of P-GEM treated group were significantly higher compared to those of F-GEM treated group: 246,425 ± 1605 vs 83,591 ± 1844 ng/mL × h as AUC, 5.77 ± 2.02 vs 1.99 ± 0.09 h as t1/2, and 4.45 ± 0.15 vs 1.12 ± 0.13 h as MRT.",Biodistribution of Self-Assembling Polymer-Gemcitabine Conjugate after Systemic Administration into Orthotopic Pancreatic Tumor Bearing Mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27798825/),h,5.77,66137,DB00441,Gemcitabine
,27798825,t1/2,"Area under the curve (AUC), elimination half-life (t1/2), and mean residence time (MRT) of P-GEM treated group were significantly higher compared to those of F-GEM treated group: 246,425 ± 1605 vs 83,591 ± 1844 ng/mL × h as AUC, 5.77 ± 2.02 vs 1.99 ± 0.09 h as t1/2, and 4.45 ± 0.15 vs 1.12 ± 0.13 h as MRT.",Biodistribution of Self-Assembling Polymer-Gemcitabine Conjugate after Systemic Administration into Orthotopic Pancreatic Tumor Bearing Mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27798825/),h,1.99,66138,DB00441,Gemcitabine
,27798825,MRT,"Area under the curve (AUC), elimination half-life (t1/2), and mean residence time (MRT) of P-GEM treated group were significantly higher compared to those of F-GEM treated group: 246,425 ± 1605 vs 83,591 ± 1844 ng/mL × h as AUC, 5.77 ± 2.02 vs 1.99 ± 0.09 h as t1/2, and 4.45 ± 0.15 vs 1.12 ± 0.13 h as MRT.",Biodistribution of Self-Assembling Polymer-Gemcitabine Conjugate after Systemic Administration into Orthotopic Pancreatic Tumor Bearing Mice. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27798825/),h,4.45,66139,DB00441,Gemcitabine
,27798825,MRT,"Area under the curve (AUC), elimination half-life (t1/2), and mean residence time (MRT) of P-GEM treated group were significantly higher compared to those of F-GEM treated group: 246,425 ± 1605 vs 83,591 ± 1844 ng/mL × h as AUC, 5.77 ± 2.02 vs 1.99 ± 0.09 h as t1/2, and 4.45 ± 0.15 vs 1.12 ± 0.13 h as MRT.",Biodistribution of Self-Assembling Polymer-Gemcitabine Conjugate after Systemic Administration into Orthotopic Pancreatic Tumor Bearing Mice. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27798825/),h,1.12,66140,DB00441,Gemcitabine
,33536754,ζ-potential,"GMC LPs, GMC-Fo LPs, and GMC-SoS Fo LPs were successfully prepared, with sizes of <120.3±2.4 nm, 39.7 mV ζ-potential, and 86.3%±1.84% entrapped drug.",Externally Triggered Novel Rapid-Release Sonosensitive Folate-Modified Liposomes for Gemcitabine: Development and Characteristics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33536754/),mv,39.7,67152,DB00441,Gemcitabine
,16786333,AUC(0-8),"The AUC(0-8) of 5-FU at the 30 and 35 mg/m2 dose levels were 875 +/- 212 and 894 +/- 151 h ng/ml, respectively.",Phase I and pharmacokinetic study of S-1 administered for 14 days in a 21-day cycle in patients with advanced upper gastrointestinal cancer. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16786333/),[h·ng] / [ml],875,70220,DB00441,Gemcitabine
,16786333,AUC(0-8),"The AUC(0-8) of 5-FU at the 30 and 35 mg/m2 dose levels were 875 +/- 212 and 894 +/- 151 h ng/ml, respectively.",Phase I and pharmacokinetic study of S-1 administered for 14 days in a 21-day cycle in patients with advanced upper gastrointestinal cancer. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16786333/),[h·ng] / [ml],894,70221,DB00441,Gemcitabine
,16786333,MTD,"In a 14-day dosing schedule, the MTD of S-1 was 30 mg/m2 and preliminary evidence of antitumor activity was seen in a North American population with refractory upper gastrointestinal malignancies.",Phase I and pharmacokinetic study of S-1 administered for 14 days in a 21-day cycle in patients with advanced upper gastrointestinal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16786333/),[mg] / [m],30,70222,DB00441,Gemcitabine
,30314360,total clearance,"Moreover, the Gem-Thr showed the increased systemic exposure of formed gemcitabine by 1.83-fold, compared to free gemcitabine treatment, due to the significantly decreased total clearance (0.60 vs. 4.23 mL/min/kg), indicating that the amide prodrug approach improves the metabolic stability of gemcitabine in vivo.",Synthesis of Gemcitabine-Threonine Amide Prodrug Effective on Pancreatic Cancer Cells with Improved Pharmacokinetic Properties. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30314360/),[ml] / [kg·min],0.60,71078,DB00441,Gemcitabine
,30314360,total clearance,"Moreover, the Gem-Thr showed the increased systemic exposure of formed gemcitabine by 1.83-fold, compared to free gemcitabine treatment, due to the significantly decreased total clearance (0.60 vs. 4.23 mL/min/kg), indicating that the amide prodrug approach improves the metabolic stability of gemcitabine in vivo.",Synthesis of Gemcitabine-Threonine Amide Prodrug Effective on Pancreatic Cancer Cells with Improved Pharmacokinetic Properties. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30314360/),[ml] / [kg·min],4.23,71079,DB00441,Gemcitabine
,12065559,overall response rate,"Among 34 patients, complete response was observed in three patients and partial response in 15, for an overall response rate of 53% (95% confidence interval, 35% to 70%).",Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12065559/),%,53,72501,DB00441,Gemcitabine
,12065559,time to progression,"The median time to progression was 5.6 months (range, 4 to 10 months).",Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12065559/),month,5.6,72502,DB00441,Gemcitabine
,17023785,duration of response,The median duration of response was 6 months (3-9) for responding patients and 4.9 months (2-7.5) for patients with stable disease.,Gemcitabine and oxaliplatin in patients with metastatic breast cancer resistant to or pretreated with both anthracyclines and taxanes: clinical and pharmacokinetic data. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17023785/),month,6,72863,DB00441,Gemcitabine
,17023785,duration of response,The median duration of response was 6 months (3-9) for responding patients and 4.9 months (2-7.5) for patients with stable disease.,Gemcitabine and oxaliplatin in patients with metastatic breast cancer resistant to or pretreated with both anthracyclines and taxanes: clinical and pharmacokinetic data. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17023785/),month,4.9,72864,DB00441,Gemcitabine
,17023785,survival,"For PR, SD and PD patients, median survival was 18 (10-23+), 13 (8-18), and 6 months (4-13), respectively.",Gemcitabine and oxaliplatin in patients with metastatic breast cancer resistant to or pretreated with both anthracyclines and taxanes: clinical and pharmacokinetic data. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17023785/),month,18,72865,DB00441,Gemcitabine
,17023785,survival,"For PR, SD and PD patients, median survival was 18 (10-23+), 13 (8-18), and 6 months (4-13), respectively.",Gemcitabine and oxaliplatin in patients with metastatic breast cancer resistant to or pretreated with both anthracyclines and taxanes: clinical and pharmacokinetic data. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17023785/),month,13,72866,DB00441,Gemcitabine
,17023785,survival,"For PR, SD and PD patients, median survival was 18 (10-23+), 13 (8-18), and 6 months (4-13), respectively.",Gemcitabine and oxaliplatin in patients with metastatic breast cancer resistant to or pretreated with both anthracyclines and taxanes: clinical and pharmacokinetic data. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17023785/),month,6,72867,DB00441,Gemcitabine
,17159607,overall response rate,"Complete and partial remissions were observed in two and 16 (including three pretreated) patients, respectively, for an overall response rate of 53%.",Docetaxel and gemcitabine combination therapy in advanced transitional cell carcinoma of the urothelium: results of a phase II and pharmacologic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17159607/),%,53,74519,DB00441,Gemcitabine
,17159607,response duration,Median response duration was 5 months (range 1-39+).,Docetaxel and gemcitabine combination therapy in advanced transitional cell carcinoma of the urothelium: results of a phase II and pharmacologic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17159607/),month,5,74520,DB00441,Gemcitabine
,10080682,AUC ratio (AUC peritoneal fluid/AUC plasma),The AUC ratio (AUC peritoneal fluid/AUC plasma) was 12.5+/-3.2 for i.p. delivery as opposed to 0.2+/-0.2 for i.v. delivery (P = 0.0002).,Pharmacokinetics of intraperitoneal gemcitabine in a rat model. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10080682/),,12.5,77629,DB00441,Gemcitabine
,10080682,AUC ratio (AUC peritoneal fluid/AUC plasma),The AUC ratio (AUC peritoneal fluid/AUC plasma) was 12.5+/-3.2 for i.p. delivery as opposed to 0.2+/-0.2 for i.v. delivery (P = 0.0002).,Pharmacokinetics of intraperitoneal gemcitabine in a rat model. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10080682/),,0.2,77630,DB00441,Gemcitabine
,10080682,AUC ratio,The AUC ratio for i.p. gemcitabine at 125 mg/kg was 26.8+/-5.8.,Pharmacokinetics of intraperitoneal gemcitabine in a rat model. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10080682/),,26.8,77631,DB00441,Gemcitabine
,27873130,progression-free survival (PFS),"Responses were durable (median of 8.5 months): overall median progression-free survival (PFS) was 4.2 months (95% CI, 2.7-6.5 months).","Phase I clinical and pharmacokinetic study of PM01183 (a tetrahydroisoquinoline, Lurbinectedin) in combination with gemcitabine in patients with advanced solid tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27873130/),month,4.2,79226,DB00441,Gemcitabine
,10597737,area under the curve (AUC),Carboplatin was administered immediately after gemcitabine at an area under the curve (AUC) of 5 given intravenously on day 1 of an every-4-week cycle.,A phase II study of carboplatin plus gemcitabine in advanced non-small-cell lung cancer (NSCLC): a hoosier oncology group study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10597737/),,5,81546,DB00441,Gemcitabine
,10597737,survival time,Median survival time was 130 days.,A phase II study of carboplatin plus gemcitabine in advanced non-small-cell lung cancer (NSCLC): a hoosier oncology group study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10597737/),d,130,81547,DB00441,Gemcitabine
,8893883,area under the curve (AUC),"Carboplatin dosing was escalated and determined using the Calvert formula, and three patients were treated at the initial predicted dose of area under the curve (AUC) 4 mg/mL/min.",A phase I study of gemcitabine and carboplatin in non-small cell lung cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8893883/),[mg] / [min·ml],4,81677,DB00441,Gemcitabine
,8893883,AUC,Subsequently the carboplatin dose was escalated to a predicted AUC 5.2 mg/mL/min.,A phase I study of gemcitabine and carboplatin in non-small cell lung cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8893883/),[mg] / [min·ml],5.2,81678,DB00441,Gemcitabine
,8893883,AUC,"Dose-limiting myelosuppression was identified at a predicted carboplatin AUC 5.2 mg/mL/min, with two patients developing grade 4 neutropenia and two patients grade 4 thrombocytopenia.",A phase I study of gemcitabine and carboplatin in non-small cell lung cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8893883/),[mg] / [min·ml],5.2,81679,DB00441,Gemcitabine
,18823054,overall disease control rate,"Therefore, the overall disease control rate was 23% (3 of 13 patients).",Phase 1 trial of lipoplatin and gemcitabine as a second-line chemotherapy in patients with nonsmall cell lung carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18823054/),%,23,82389,DB00441,Gemcitabine
,18823054,overall survival,"The median overall survival was 29 weeks (range, 4 weeks-59 weeks) and the median time to disease progression was 12 weeks (range, 3 weeks-36 weeks).",Phase 1 trial of lipoplatin and gemcitabine as a second-line chemotherapy in patients with nonsmall cell lung carcinoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18823054/),weeks,29,82390,DB00441,Gemcitabine
,18823054,time to disease progression,"The median overall survival was 29 weeks (range, 4 weeks-59 weeks) and the median time to disease progression was 12 weeks (range, 3 weeks-36 weeks).",Phase 1 trial of lipoplatin and gemcitabine as a second-line chemotherapy in patients with nonsmall cell lung carcinoma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18823054/),weeks,12,82391,DB00441,Gemcitabine
,34319586,overall response rate,The overall response rate was 20%; the median progression-free survival was 4.8 months.,A phase I study of the anaplastic lymphoma kinase inhibitor ceritinib in combination with gemcitabine-based chemotherapy in patients with advanced solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34319586/),%,20,84852,DB00441,Gemcitabine
,34319586,progression-free survival,The overall response rate was 20%; the median progression-free survival was 4.8 months.,A phase I study of the anaplastic lymphoma kinase inhibitor ceritinib in combination with gemcitabine-based chemotherapy in patients with advanced solid tumors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34319586/),month,4.8,84853,DB00441,Gemcitabine
,32034726,AUC,"In this cohort, the average measured AUC of partial responders was 2.4 mg·min/mL.",Inability of Current Dosing to Achieve Carboplatin Therapeutic Targets in People with Advanced Non-Small Cell Lung Cancer: Impact of Systemic Inflammation on Carboplatin Exposure and Clinical Outcomes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32034726/),[mg·min] / [ml],2.4,84975,DB00441,Gemcitabine
,32034726,AUC,Simulations of the newly developed model-based and Calvert dosing assessed the ability to reach this study's proposed actual target AUC of 2.2-2.6 mg·min/mL.,Inability of Current Dosing to Achieve Carboplatin Therapeutic Targets in People with Advanced Non-Small Cell Lung Cancer: Impact of Systemic Inflammation on Carboplatin Exposure and Clinical Outcomes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32034726/),[mg·min] / [ml],2.2-2.6,84976,DB00441,Gemcitabine
,15150625,time to progression,"The average time to progression and overall survival of the patients was, respectively, 7.26 and 22 months.","A novel biweekly multidrug regimen of gemcitabine, oxaliplatin, 5-fluorouracil (5-FU), and folinic acid (FA) in pretreated patients with advanced colorectal carcinoma. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15150625/),month,7.26,85493,DB00441,Gemcitabine
,15150625,overall survival,"The average time to progression and overall survival of the patients was, respectively, 7.26 and 22 months.","A novel biweekly multidrug regimen of gemcitabine, oxaliplatin, 5-fluorouracil (5-FU), and folinic acid (FA) in pretreated patients with advanced colorectal carcinoma. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15150625/),month,22,85494,DB00441,Gemcitabine
,12926122,overall response rate,The overall response rate was 25% which included 1 of 24 complete responses (4%) and 4 of 24 partial responses (21%).,Gemcitabine and vinorelbine in recurrent head and neck cancer: pharmacokinetic and clinical results. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12926122/),%,25,85985,DB00441,Gemcitabine
,12926122,response duration,"The median response duration was 5.5 months (2-16 months) and the overall median survival was 9 months (range, 2-25+).",Gemcitabine and vinorelbine in recurrent head and neck cancer: pharmacokinetic and clinical results. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12926122/),month,5.5,85986,DB00441,Gemcitabine
,12926122,overall median survival,"The median response duration was 5.5 months (2-16 months) and the overall median survival was 9 months (range, 2-25+).",Gemcitabine and vinorelbine in recurrent head and neck cancer: pharmacokinetic and clinical results. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12926122/),month,9,85987,DB00441,Gemcitabine
,15013588,time to progression,Median time to progression was 36 weeks.,"Trastuzumab in combination with cisplatin and gemcitabine in patients with Her2-overexpressing, untreated, advanced non-small cell lung cancer: report of a phase II trial and findings regarding optimal identification of patients with Her2-overexpressing disease. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15013588/),weeks,36,86142,DB00441,Gemcitabine
>,15013588,shed antigen,Serum Her2 shed antigen was >15 ng/ml in 27/ 288 (9%) patients.,"Trastuzumab in combination with cisplatin and gemcitabine in patients with Her2-overexpressing, untreated, advanced non-small cell lung cancer: report of a phase II trial and findings regarding optimal identification of patients with Her2-overexpressing disease. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15013588/),[ng] / [ml],15,86143,DB00441,Gemcitabine
,29451684,area under the concentration-time curve from time zero to 24 h (AUC0-24 h ),"Both in plasma and in PBMCs, dFdU was present in higher concentrations than gemcitabine [mean intracellular area under the concentration-time curve from time zero to 24 h (AUC0-24 h ) 1650 vs. 95 μM*h].","Intracellular pharmacokinetics of gemcitabine, its deaminated metabolite 2',2'-difluorodeoxyuridine and their nucleotides. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29451684/),h·μM,1650,86611,DB00441,Gemcitabine
,29451684,area under the concentration-time curve from time zero to 24 h (AUC0-24 h ),"Both in plasma and in PBMCs, dFdU was present in higher concentrations than gemcitabine [mean intracellular area under the concentration-time curve from time zero to 24 h (AUC0-24 h ) 1650 vs. 95 μM*h].","Intracellular pharmacokinetics of gemcitabine, its deaminated metabolite 2',2'-difluorodeoxyuridine and their nucleotides. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29451684/),h·μM,95,86612,DB00441,Gemcitabine
,29451684,AUC0-24 h,The mean AUC0-24 h for dFdUTP was 312 μM*h vs. 2640 μM*h for dFdCTP.,"Intracellular pharmacokinetics of gemcitabine, its deaminated metabolite 2',2'-difluorodeoxyuridine and their nucleotides. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29451684/),h·μM,312,86613,DB00441,Gemcitabine
,29451684,AUC0-24 h,The mean AUC0-24 h for dFdUTP was 312 μM*h vs. 2640 μM*h for dFdCTP.,"Intracellular pharmacokinetics of gemcitabine, its deaminated metabolite 2',2'-difluorodeoxyuridine and their nucleotides. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29451684/),h·μM,2640,86614,DB00441,Gemcitabine
,16807444,sat,"After 30 min infusion of 1000 mg/m(2) gemcitabine the plasma concentration remained above the saturation level of 10-20 microM, whereas after 1, 2 or 3 h infusion 300 mg/m(2) gemcitabine it remained below the saturation level for most of the time (being in the range 2.5-10 microM).","Pharmacokinetic evaluation of gemcitabine and 2',2'-difluorodeoxycytidine-5'-triphosphate after prolonged infusion in patients affected by different solid tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16807444/),,10-20,86709,DB00441,Gemcitabine
,28346313,V1,A two-compartment model best fitted the gemcitabine and dFdU PK data (volume of distribution and clearance for gemcitabine: V1 = 45 L and CL1 = 4.03 L/min; for dFdU: V2 = 36 L and CL2 = 0.226 L/min).,"Population Pharmacokinetics of Gemcitabine and dFdU in Pancreatic Cancer Patients Using an Optimal Design, Sparse Sampling Approach. ",V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28346313/),l,45,87509,DB00441,Gemcitabine
,28346313,CL1,A two-compartment model best fitted the gemcitabine and dFdU PK data (volume of distribution and clearance for gemcitabine: V1 = 45 L and CL1 = 4.03 L/min; for dFdU: V2 = 36 L and CL2 = 0.226 L/min).,"Population Pharmacokinetics of Gemcitabine and dFdU in Pancreatic Cancer Patients Using an Optimal Design, Sparse Sampling Approach. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28346313/),[l] / [min],4.03,87510,DB00441,Gemcitabine
,28346313,V2,A two-compartment model best fitted the gemcitabine and dFdU PK data (volume of distribution and clearance for gemcitabine: V1 = 45 L and CL1 = 4.03 L/min; for dFdU: V2 = 36 L and CL2 = 0.226 L/min).,"Population Pharmacokinetics of Gemcitabine and dFdU in Pancreatic Cancer Patients Using an Optimal Design, Sparse Sampling Approach. ",V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28346313/),l,36,87511,DB00441,Gemcitabine
,28346313,CL2,A two-compartment model best fitted the gemcitabine and dFdU PK data (volume of distribution and clearance for gemcitabine: V1 = 45 L and CL1 = 4.03 L/min; for dFdU: V2 = 36 L and CL2 = 0.226 L/min).,"Population Pharmacokinetics of Gemcitabine and dFdU in Pancreatic Cancer Patients Using an Optimal Design, Sparse Sampling Approach. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28346313/),[l] / [min],0.226,87512,DB00441,Gemcitabine
,16515668,clearance,The average gemcitabine clearance was 0.560 L/h.kg and volume of distribution at steady-state of 1.27 L/kg.,Pharmacokinetics of gemcitabine and its primary metabolite in dogs after intravenous bolus dosing and its in vitro pharmacodynamics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16515668/),[l] / [h·kg],0.560,88311,DB00441,Gemcitabine
,16515668,volume of distribution at steady-state,The average gemcitabine clearance was 0.560 L/h.kg and volume of distribution at steady-state of 1.27 L/kg.,Pharmacokinetics of gemcitabine and its primary metabolite in dogs after intravenous bolus dosing and its in vitro pharmacodynamics. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16515668/),[l] / [kg],1.27,88312,DB00441,Gemcitabine
,16515668,terminal elimination half-life,"The average terminal elimination half-life, depending on dose, ranged from 1.75 to 3.23 h.",Pharmacokinetics of gemcitabine and its primary metabolite in dogs after intravenous bolus dosing and its in vitro pharmacodynamics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16515668/),h,1.75 to 3.23,88313,DB00441,Gemcitabine
,20523345,overall clinical response rate,The overall clinical response rate was 33.3%.,Phase II trial of gemcitabine plus cisplatin in patients with advanced non-small cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20523345/),%,33.3,88679,DB00441,Gemcitabine
,20523345,overall survival time,The median overall survival time was 13 months.,Phase II trial of gemcitabine plus cisplatin in patients with advanced non-small cell lung cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20523345/),month,13,88680,DB00441,Gemcitabine
,20523345,time to tumor progression (TTP),"The estimated median time to tumor progression (TTP) was 6.2 months, and the 1-year survival rate was 55.6%.",Phase II trial of gemcitabine plus cisplatin in patients with advanced non-small cell lung cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20523345/),month,6.2,88681,DB00441,Gemcitabine
,10893285,overall response rate,"There were three complete and 20 partial responses, for an overall response rate of 55% (95% confidence interval [CI], 40% to 70%) and a complete response rate of 7%.",Gemcitabine in combination with doxorubicin in advanced breast cancer: final results of a phase II pharmacokinetic trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10893285/),%,55,90122,DB00441,Gemcitabine
,10893285,complete response rate,"There were three complete and 20 partial responses, for an overall response rate of 55% (95% confidence interval [CI], 40% to 70%) and a complete response rate of 7%.",Gemcitabine in combination with doxorubicin in advanced breast cancer: final results of a phase II pharmacokinetic trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10893285/),%,7,90123,DB00441,Gemcitabine
,10893285,survival time,"The median survival time for all 42 patients was 27 months (95% CI, 13.4 to 30.0 months) and the 1-year survival rate was 80%.",Gemcitabine in combination with doxorubicin in advanced breast cancer: final results of a phase II pharmacokinetic trial. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10893285/),month,27,90124,DB00441,Gemcitabine
,22151988,PFS,"Overall 13 patients (30%) achieved a partial response, PFS was 4.2 months (95% CI 2.8-5.8 months), and OS was 6.8 months (95% CI 4.4-10.1 months).",Randomized phase 2 sequencing and pharmacokinetic study of gemcitabine and oxaliplatin in advanced non-small cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22151988/),month,4.2,95938,DB00441,Gemcitabine
,22151988,OS,"Overall 13 patients (30%) achieved a partial response, PFS was 4.2 months (95% CI 2.8-5.8 months), and OS was 6.8 months (95% CI 4.4-10.1 months).",Randomized phase 2 sequencing and pharmacokinetic study of gemcitabine and oxaliplatin in advanced non-small cell lung cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22151988/),month,6.8,95939,DB00441,Gemcitabine
,26633034,interval,"The median interval from surgery to first administration of gemcitabine was 65.5 days (range, 43-83 days).",Pharmacokinetic Study of Adjuvant Gemcitabine Therapy for Biliary Tract Cancer following Major Hepatectomy (KHBO1101). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26633034/),d,65.5,98266,DB00441,Gemcitabine
,19687729,progression-free survival,"Median progression-free survival was 3.7 months, median overall survival was 6 months, and 1-year survival was 32%.",A phase 2 trial of glufosfamide in combination with gemcitabine in chemotherapy-naive pancreatic adenocarcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19687729/),month,3.7,98540,DB00441,Gemcitabine
,19687729,overall survival,"Median progression-free survival was 3.7 months, median overall survival was 6 months, and 1-year survival was 32%.",A phase 2 trial of glufosfamide in combination with gemcitabine in chemotherapy-naive pancreatic adenocarcinoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19687729/),month,6,98541,DB00441,Gemcitabine
,15351574,overall response rate,"The overall response rate was 36% (95% confidence interval 23.4% to 49.6%), and an additional 14 patients had disease stabilization (25%, 95% confidence interval 14.4% to 38.4%).",Gemcitabine and carboplatin combination as first-line treatment in elderly patients and those unfit for cisplatin-based chemotherapy with advanced bladder carcinoma: Phase II study of the Hellenic Co-operative Oncology Group. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15351574/),%,36,105536,DB00441,Gemcitabine
,15351574,time to progression,"The median time to progression was 4.8 months, the median overall survival was 7.2 months, and the 1-year survival rate was 26%.",Gemcitabine and carboplatin combination as first-line treatment in elderly patients and those unfit for cisplatin-based chemotherapy with advanced bladder carcinoma: Phase II study of the Hellenic Co-operative Oncology Group. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15351574/),month,4.8,105537,DB00441,Gemcitabine
,15351574,overall survival,"The median time to progression was 4.8 months, the median overall survival was 7.2 months, and the 1-year survival rate was 26%.",Gemcitabine and carboplatin combination as first-line treatment in elderly patients and those unfit for cisplatin-based chemotherapy with advanced bladder carcinoma: Phase II study of the Hellenic Co-operative Oncology Group. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15351574/),month,7.2,105538,DB00441,Gemcitabine
,30542769,Cmax,"Cmax (mean ± SD) following BAI for gemcitabine, dFdCTP, and dFdU were 7.71 ± 0.13, 66.5 ± 40.6, and 38 ± 6.27 µM and following IV infusion, 17 ± 2.36, 50.8 ± 3.61, and 83.2 ± 12.3 µM, respectively.",Gemcitabine and metabolite pharmacokinetics in advanced NSCLC patients after bronchial artery infusion and intravenous infusion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30542769/),μM,7.71,106905,DB00441,Gemcitabine
,30542769,Cmax,"Cmax (mean ± SD) following BAI for gemcitabine, dFdCTP, and dFdU were 7.71 ± 0.13, 66.5 ± 40.6, and 38 ± 6.27 µM and following IV infusion, 17 ± 2.36, 50.8 ± 3.61, and 83.2 ± 12.3 µM, respectively.",Gemcitabine and metabolite pharmacokinetics in advanced NSCLC patients after bronchial artery infusion and intravenous infusion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30542769/),μM,66.5,106906,DB00441,Gemcitabine
,30542769,Cmax,"Cmax (mean ± SD) following BAI for gemcitabine, dFdCTP, and dFdU were 7.71 ± 0.13, 66.5 ± 40.6, and 38 ± 6.27 µM and following IV infusion, 17 ± 2.36, 50.8 ± 3.61, and 83.2 ± 12.3 µM, respectively.",Gemcitabine and metabolite pharmacokinetics in advanced NSCLC patients after bronchial artery infusion and intravenous infusion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30542769/),μM,38,106907,DB00441,Gemcitabine
,30542769,Cmax,"Cmax (mean ± SD) following BAI for gemcitabine, dFdCTP, and dFdU were 7.71 ± 0.13, 66.5 ± 40.6, and 38 ± 6.27 µM and following IV infusion, 17 ± 2.36, 50.8 ± 3.61, and 83.2 ± 12.3 µM, respectively.",Gemcitabine and metabolite pharmacokinetics in advanced NSCLC patients after bronchial artery infusion and intravenous infusion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30542769/),μM,17,106908,DB00441,Gemcitabine
,30542769,Cmax,"Cmax (mean ± SD) following BAI for gemcitabine, dFdCTP, and dFdU were 7.71 ± 0.13, 66.5 ± 40.6, and 38 ± 6.27 µM and following IV infusion, 17 ± 2.36, 50.8 ± 3.61, and 83.2 ± 12.3 µM, respectively.",Gemcitabine and metabolite pharmacokinetics in advanced NSCLC patients after bronchial artery infusion and intravenous infusion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30542769/),μM,50.8,106909,DB00441,Gemcitabine
,30542769,Cmax,"Cmax (mean ± SD) following BAI for gemcitabine, dFdCTP, and dFdU were 7.71 ± 0.13, 66.5 ± 40.6, and 38 ± 6.27 µM and following IV infusion, 17 ± 2.36, 50.8 ± 3.61, and 83.2 ± 12.3 µM, respectively.",Gemcitabine and metabolite pharmacokinetics in advanced NSCLC patients after bronchial artery infusion and intravenous infusion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30542769/),μM,83.2,106910,DB00441,Gemcitabine
,30542769,AUCinf,"The AUCinf (mean ± SD) following BAI for gemcitabine, dFdCTP, and dFdU were 6.89 ± 1.2, 791.1 ± 551.2, and 829.9 ± 217.8 µM h and following IV infusion, 12.5 ± 3.13, 584 ± 86.6, and 1394.64 ± 682.2 µM h, respectively.",Gemcitabine and metabolite pharmacokinetics in advanced NSCLC patients after bronchial artery infusion and intravenous infusion. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30542769/),h·μM,6.89,106911,DB00441,Gemcitabine
,30542769,AUCinf,"The AUCinf (mean ± SD) following BAI for gemcitabine, dFdCTP, and dFdU were 6.89 ± 1.2, 791.1 ± 551.2, and 829.9 ± 217.8 µM h and following IV infusion, 12.5 ± 3.13, 584 ± 86.6, and 1394.64 ± 682.2 µM h, respectively.",Gemcitabine and metabolite pharmacokinetics in advanced NSCLC patients after bronchial artery infusion and intravenous infusion. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30542769/),h·μM,791.1,106912,DB00441,Gemcitabine
,30542769,AUCinf,"The AUCinf (mean ± SD) following BAI for gemcitabine, dFdCTP, and dFdU were 6.89 ± 1.2, 791.1 ± 551.2, and 829.9 ± 217.8 µM h and following IV infusion, 12.5 ± 3.13, 584 ± 86.6, and 1394.64 ± 682.2 µM h, respectively.",Gemcitabine and metabolite pharmacokinetics in advanced NSCLC patients after bronchial artery infusion and intravenous infusion. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30542769/),h·μM,829.9,106913,DB00441,Gemcitabine
,30542769,AUCinf,"The AUCinf (mean ± SD) following BAI for gemcitabine, dFdCTP, and dFdU were 6.89 ± 1.2, 791.1 ± 551.2, and 829.9 ± 217.8 µM h and following IV infusion, 12.5 ± 3.13, 584 ± 86.6, and 1394.64 ± 682.2 µM h, respectively.",Gemcitabine and metabolite pharmacokinetics in advanced NSCLC patients after bronchial artery infusion and intravenous infusion. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30542769/),h·μM,12.5,106914,DB00441,Gemcitabine
,30542769,AUCinf,"The AUCinf (mean ± SD) following BAI for gemcitabine, dFdCTP, and dFdU were 6.89 ± 1.2, 791.1 ± 551.2, and 829.9 ± 217.8 µM h and following IV infusion, 12.5 ± 3.13, 584 ± 86.6, and 1394.64 ± 682.2 µM h, respectively.",Gemcitabine and metabolite pharmacokinetics in advanced NSCLC patients after bronchial artery infusion and intravenous infusion. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30542769/),h·μM,584,106915,DB00441,Gemcitabine
,30542769,AUCinf,"The AUCinf (mean ± SD) following BAI for gemcitabine, dFdCTP, and dFdU were 6.89 ± 1.2, 791.1 ± 551.2, and 829.9 ± 217.8 µM h and following IV infusion, 12.5 ± 3.13, 584 ± 86.6, and 1394.64 ± 682.2 µM h, respectively.",Gemcitabine and metabolite pharmacokinetics in advanced NSCLC patients after bronchial artery infusion and intravenous infusion. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30542769/),h·μM,1394.64,106916,DB00441,Gemcitabine
,30542769,OS,The median OS was 6.27 months.,Gemcitabine and metabolite pharmacokinetics in advanced NSCLC patients after bronchial artery infusion and intravenous infusion. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30542769/),month,6.27,106917,DB00441,Gemcitabine
,33968430,area under the curve (AUC),The peritoneal surface exposure as measured by pharmacokinetic studies showed the area under the curve (AUC) of intraperitoneal concentration times time divided by plasma concentration times time to be 95-507.,Intraperitoneal gemcitabine chemotherapy is safe for patients with resected pancreatic cancer: final clinical and pharmacologic data from a phase II protocol and recommended future directions. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33968430/),,95-507,107020,DB00441,Gemcitabine
,29163795,Tmax,"In mice orally gavaged with GemC18-SLNs, plasma gemcitabine concentration followed an absorption phase and then clearance phase, with a Tmax of ~2 h.",Oral 4-(N)-stearoyl gemcitabine nanoparticles inhibit tumor growth in mouse models. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29163795/),h,2,108930,DB00441,Gemcitabine
,29163795,absolute oral bioavailability,The absolute oral bioavailability of gemcitabine in the GemC18-SLNs was ~70% (based on AUC0-24 h values).,Oral 4-(N)-stearoyl gemcitabine nanoparticles inhibit tumor growth in mouse models. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29163795/),%,70,108931,DB00441,Gemcitabine
,23235319,Dose levels (DLs),"Dose levels (DLs) 1, 2, 3 and 4 were 50, 75, 100 and 125 mg/day, respectively.",Phase I trial of gemcitabine combined with capecitabine and erlotinib in advanced pancreatic cancer: a clinical and pharmacological study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23235319/),,50,109626,DB00441,Gemcitabine
,23235319,Dose levels (DLs),"Dose levels (DLs) 1, 2, 3 and 4 were 50, 75, 100 and 125 mg/day, respectively.",Phase I trial of gemcitabine combined with capecitabine and erlotinib in advanced pancreatic cancer: a clinical and pharmacological study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23235319/),,75,109627,DB00441,Gemcitabine
,23235319,Dose levels (DLs),"Dose levels (DLs) 1, 2, 3 and 4 were 50, 75, 100 and 125 mg/day, respectively.",Phase I trial of gemcitabine combined with capecitabine and erlotinib in advanced pancreatic cancer: a clinical and pharmacological study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23235319/),,100,109628,DB00441,Gemcitabine
,23235319,Dose levels (DLs),"Dose levels (DLs) 1, 2, 3 and 4 were 50, 75, 100 and 125 mg/day, respectively.",Phase I trial of gemcitabine combined with capecitabine and erlotinib in advanced pancreatic cancer: a clinical and pharmacological study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23235319/),,125,109629,DB00441,Gemcitabine
,20140616,FDR,"At the second cycle, all patients were treated with gemcitabine at 1,200 mg/m(2) 120-min i.v. infusion (FDR of 10 mg/m(2)/min) on days 1 and 8 of a 21-day cycle.","Pharmacokinetic study of gemcitabine, given as prolonged infusion at fixed dose rate, in combination with cisplatin in patients with advanced non-small-cell lung cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20140616/),,10,110926,DB00441,Gemcitabine
<,32603666,half-life,These studies revealed that V-Gem undergoes rapid systemic elimination (half-life < 1 min) and has a low oral bioavailability (<1%).,Pharmacokinetics of gemcitabine and its amino acid ester prodrug following intravenous and oral administrations in mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32603666/),min,1,110928,DB00441,Gemcitabine
<,32603666,oral bioavailability,These studies revealed that V-Gem undergoes rapid systemic elimination (half-life < 1 min) and has a low oral bioavailability (<1%).,Pharmacokinetics of gemcitabine and its amino acid ester prodrug following intravenous and oral administrations in mice. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32603666/),%,1,110929,DB00441,Gemcitabine
,32603666,bioavailability,"Most importantly, the systemic exposure of gemcitabine was not different following oral administration of equimolar doses of gemcitabine (gemcitabine bioavailability of 18.3%) and V-Gem (gemcitabine bioavailability of 16.7%).",Pharmacokinetics of gemcitabine and its amino acid ester prodrug following intravenous and oral administrations in mice. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32603666/),%,18.3,110930,DB00441,Gemcitabine
,32603666,bioavailability,"Most importantly, the systemic exposure of gemcitabine was not different following oral administration of equimolar doses of gemcitabine (gemcitabine bioavailability of 18.3%) and V-Gem (gemcitabine bioavailability of 16.7%).",Pharmacokinetics of gemcitabine and its amino acid ester prodrug following intravenous and oral administrations in mice. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32603666/),%,16.7,110931,DB00441,Gemcitabine
,17124596,time to tumor progression (TTP),"By the close-out date, in our study population, the estimated median time to tumor progression (TTP) was 7 months (95% CI 4-10 months), median overall survival (OS) was 12 months (95% CI 11.2-12.8 months).",The efficacy and relationship between peak concentration and toxicity profile of fixed-dose-rate gemcitabine plus carboplatin in patients with advanced non-small-cell lung cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17124596/),month,7,111648,DB00441,Gemcitabine
,17124596,overall survival (OS),"By the close-out date, in our study population, the estimated median time to tumor progression (TTP) was 7 months (95% CI 4-10 months), median overall survival (OS) was 12 months (95% CI 11.2-12.8 months).",The efficacy and relationship between peak concentration and toxicity profile of fixed-dose-rate gemcitabine plus carboplatin in patients with advanced non-small-cell lung cancer. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17124596/),month,12,111649,DB00441,Gemcitabine
,17124596,C (end of infusion),The mean value of C (end of infusion) of 21 eligible patients was 16.48 +/- 8.07 micromol/l (range 27.43-2.87 micromol/l).,The efficacy and relationship between peak concentration and toxicity profile of fixed-dose-rate gemcitabine plus carboplatin in patients with advanced non-small-cell lung cancer. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17124596/),[μM] / [l],16.48,111650,DB00441,Gemcitabine
,28739504,AUC0-∞ (area under curve),In vivo pharmacokinetics showed the almost 2 fold increase in AUC0-∞ (area under curve) with phospholipid complex (8983.26ngh/ml) as compared with GEM (4371.18ngh/ml) and GEMITA (4689.29ngh/ml).,Improved metabolic stability and therapeutic efficacy of a novel molecular gemcitabine phospholipid complex. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28739504/),[ngh] / [ml],8983.26,111734,DB00441,Gemcitabine
,28739504,AUC0-∞ (area under curve),In vivo pharmacokinetics showed the almost 2 fold increase in AUC0-∞ (area under curve) with phospholipid complex (8983.26ngh/ml) as compared with GEM (4371.18ngh/ml) and GEMITA (4689.29ngh/ml).,Improved metabolic stability and therapeutic efficacy of a novel molecular gemcitabine phospholipid complex. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28739504/),[ngh] / [ml],4371.18,111735,DB00441,Gemcitabine
,28739504,AUC0-∞ (area under curve),In vivo pharmacokinetics showed the almost 2 fold increase in AUC0-∞ (area under curve) with phospholipid complex (8983.26ngh/ml) as compared with GEM (4371.18ngh/ml) and GEMITA (4689.29ngh/ml).,Improved metabolic stability and therapeutic efficacy of a novel molecular gemcitabine phospholipid complex. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28739504/),[ngh] / [ml],4689.29,111736,DB00441,Gemcitabine
,31482224,elimination half-life,Galunisertib was rapidly absorbed with peak concentrations attained within 0.5-2 h and had an elimination half-life of 8 h.,Population pharmacokinetics and exposure-overall survival analysis of the transforming growth factor-β inhibitor galunisertib in patients with pancreatic cancer. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31482224/),h,8,113059,DB00441,Gemcitabine
,22547163,overall survival,The median overall survival was 6.2 months and the 1 year survival 37 %.,"Integrated preclinical and clinical development of S-trans, trans-Farnesylthiosalicylic Acid (FTS, Salirasib) in pancreatic cancer. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22547163/),month,6.2,114641,DB00441,Gemcitabine
,30022224,MTD,"The MTD of this regimen is 100 mg/m2/day of GTI-2040 over 14 days combined with 400 mg/m2/day of gemcitabine administered weekly on days 1, 8, and 15.",A phase I pharmacokinetic and pharmacodynamic study of GTI-2040 in combination with gemcitabine in patients with solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30022224/),[mg] / [m2],100,116265,DB00441,Gemcitabine
,26375684,T1/2,"T1/2 of the slow-release 5-fluorouracil implant was 5475.8±136.4 min, whereas Vd was 45275.0±1028.6 l.",Pharmacokinetic study and clinical evaluation of a slow-release 5-fluorouracil implant in pancreatic cancer patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26375684/),min,5475.8,116267,DB00441,Gemcitabine
,26375684,Vd,"T1/2 of the slow-release 5-fluorouracil implant was 5475.8±136.4 min, whereas Vd was 45275.0±1028.6 l.",Pharmacokinetic study and clinical evaluation of a slow-release 5-fluorouracil implant in pancreatic cancer patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26375684/),l,45275.0,116268,DB00441,Gemcitabine
,31912800,PFS,"In the high IGF-1 cohort, median PFS was 3.6 and 7.3 months in the experimental versus control arms, respectively [hazard ratio (HR) = 1.88, P = 0.027].","Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31912800/),month,3.6,117460,DB00441,Gemcitabine
,31912800,PFS,"In the high IGF-1 cohort, median PFS was 3.6 and 7.3 months in the experimental versus control arms, respectively [hazard ratio (HR) = 1.88, P = 0.027].","Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31912800/),month,7.3,117461,DB00441,Gemcitabine
,31912800,PFS,"In the high IGF-1/HRG+ subgroup (n = 44), median PFS was 4.1 and 7.3 months, respectively (HR = 1.39, P = 0.42).","Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31912800/),month,4.1,117462,DB00441,Gemcitabine
,31912800,PFS,"In the high IGF-1/HRG+ subgroup (n = 44), median PFS was 4.1 and 7.3 months, respectively (HR = 1.39, P = 0.42).","Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31912800/),month,7.3,117463,DB00441,Gemcitabine
,15247710,Retention time,Retention time in the bladder was 60 minutes.,Phase I pharmacokinetic study of a single intravesical instillation of gemcitabine administered immediately after transurethral resection plus multiple random biopsies in patients with superficial bladder cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15247710/),min,60,118748,DB00441,Gemcitabine
,15247710,maximum gemcitabine concentration,Mean maximum gemcitabine concentration was 1.8 microg/ml and the mean last AUC was 158 microg/ml*minute.,Phase I pharmacokinetic study of a single intravesical instillation of gemcitabine administered immediately after transurethral resection plus multiple random biopsies in patients with superficial bladder cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15247710/),[μg] / [ml],1.8,118749,DB00441,Gemcitabine
,15247710,AUC,Mean maximum gemcitabine concentration was 1.8 microg/ml and the mean last AUC was 158 microg/ml*minute.,Phase I pharmacokinetic study of a single intravesical instillation of gemcitabine administered immediately after transurethral resection plus multiple random biopsies in patients with superficial bladder cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15247710/),[μg] / [min·ml],158,118750,DB00441,Gemcitabine
,27815358,MTD,"The MTD of GDC-0425 was 60 mg when administered approximately 24 hours after gemcitabine 1,000 mg/m2 Dose-limiting toxicities included thrombocytopenia (n = 5), neutropenia (n = 4), dyspnea, nausea, pyrexia, syncope, and increased alanine aminotransferase (n = 1 each).","Phase I Study of GDC-0425, a Checkpoint Kinase 1 Inhibitor, in Combination with Gemcitabine in Patients with Refractory Solid Tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27815358/),mg,60,119769,DB00441,Gemcitabine
,27815358,half-life,The GDC-0425 half-life was approximately 15 hours.,"Phase I Study of GDC-0425, a Checkpoint Kinase 1 Inhibitor, in Combination with Gemcitabine in Patients with Refractory Solid Tumors. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27815358/),h,15,119770,DB00441,Gemcitabine
,32968837,d,An optimized GT DcNP composition (d = 59.2 nm ±9.2 nm) was found to be suitable for IV formulation.,Novel Long-Acting Drug Combination Nanoparticles Composed of Gemcitabine and Paclitaxel Enhance Localization of Both Drugs in Metastatic Breast Cancer Nodules. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32968837/),nm,59.2,123547,DB00441,Gemcitabine
,17950919,MTD,"The gemcitabine MTD was defined at 20 hours (total dose 12,000 mg/m2) on both schedules.","Phase I and pharmacokinetic study of gemcitabine administered at fixed-dose rate, combined with docetaxel/melphalan/carboplatin, with autologous hematopoietic progenitor-cell support, in patients with advanced refractory tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17950919/),h,20,124583,DB00441,Gemcitabine
,17950919,tumor response rate,"The tumor response rate was 91%, with 50% complete responses.","Phase I and pharmacokinetic study of gemcitabine administered at fixed-dose rate, combined with docetaxel/melphalan/carboplatin, with autologous hematopoietic progenitor-cell support, in patients with advanced refractory tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17950919/),%,91,124584,DB00441,Gemcitabine
,29855807,Vd,"In rats, injection of gemcitabine loaded CL-pPSL resulted in a slightly smaller Vd (149 ± 27 ml/kg; 170 ± 30 ml/kg) and shorter terminal T1/2 (5.4 ± 0.3 h; 5.8 ± 0.6 h) (both p > 0.05) but a significantly lower AUC (p < 0.01), than pPSL, due to the lower PEGylation degree (1.7 mol%) which means a 'mushroom' configuration of PEG.",PEG-Benzaldehyde-Hydrazone-Lipid Based PEG-Sheddable pH-Sensitive Liposomes: Abilities for Endosomal Escape and Long Circulation. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29855807/),[ml] / [kg],149,125086,DB00441,Gemcitabine
,29855807,Vd,"In rats, injection of gemcitabine loaded CL-pPSL resulted in a slightly smaller Vd (149 ± 27 ml/kg; 170 ± 30 ml/kg) and shorter terminal T1/2 (5.4 ± 0.3 h; 5.8 ± 0.6 h) (both p > 0.05) but a significantly lower AUC (p < 0.01), than pPSL, due to the lower PEGylation degree (1.7 mol%) which means a 'mushroom' configuration of PEG.",PEG-Benzaldehyde-Hydrazone-Lipid Based PEG-Sheddable pH-Sensitive Liposomes: Abilities for Endosomal Escape and Long Circulation. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29855807/),[ml] / [kg],170,125087,DB00441,Gemcitabine
,29855807,terminal T1/2,"In rats, injection of gemcitabine loaded CL-pPSL resulted in a slightly smaller Vd (149 ± 27 ml/kg; 170 ± 30 ml/kg) and shorter terminal T1/2 (5.4 ± 0.3 h; 5.8 ± 0.6 h) (both p > 0.05) but a significantly lower AUC (p < 0.01), than pPSL, due to the lower PEGylation degree (1.7 mol%) which means a 'mushroom' configuration of PEG.",PEG-Benzaldehyde-Hydrazone-Lipid Based PEG-Sheddable pH-Sensitive Liposomes: Abilities for Endosomal Escape and Long Circulation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29855807/),h,5.4,125088,DB00441,Gemcitabine
,29855807,terminal T1/2,"In rats, injection of gemcitabine loaded CL-pPSL resulted in a slightly smaller Vd (149 ± 27 ml/kg; 170 ± 30 ml/kg) and shorter terminal T1/2 (5.4 ± 0.3 h; 5.8 ± 0.6 h) (both p > 0.05) but a significantly lower AUC (p < 0.01), than pPSL, due to the lower PEGylation degree (1.7 mol%) which means a 'mushroom' configuration of PEG.",PEG-Benzaldehyde-Hydrazone-Lipid Based PEG-Sheddable pH-Sensitive Liposomes: Abilities for Endosomal Escape and Long Circulation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29855807/),h,5.8,125089,DB00441,Gemcitabine
,29855807,T1/2,A five-time increase in the dose with CL-pPSL resulted in a 11-fold increase in AUC and a longer T1/2 (8.2 ± 0.5 h).,PEG-Benzaldehyde-Hydrazone-Lipid Based PEG-Sheddable pH-Sensitive Liposomes: Abilities for Endosomal Escape and Long Circulation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29855807/),h,8.2,125090,DB00441,Gemcitabine
,33145616,clearance (CL),"For a typical patient, the estimated clearance (CL) and intercompartmental CL were 65 L/h and 295 L/h, respectively, with central and peripheral volumes estimated to be 118 L and 1030 L, respectively.",Population pharmacokinetics of ATR inhibitor berzosertib in phase I studies for different cancer types. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33145616/),[l] / [h],65,125822,DB00441,Gemcitabine
,33145616,intercompartmental CL,"For a typical patient, the estimated clearance (CL) and intercompartmental CL were 65 L/h and 295 L/h, respectively, with central and peripheral volumes estimated to be 118 L and 1030 L, respectively.",Population pharmacokinetics of ATR inhibitor berzosertib in phase I studies for different cancer types. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33145616/),[l] / [h],295,125823,DB00441,Gemcitabine
,33145616,central,"For a typical patient, the estimated clearance (CL) and intercompartmental CL were 65 L/h and 295 L/h, respectively, with central and peripheral volumes estimated to be 118 L and 1030 L, respectively.",Population pharmacokinetics of ATR inhibitor berzosertib in phase I studies for different cancer types. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33145616/),l,118,125824,DB00441,Gemcitabine
,33145616,peripheral volumes,"For a typical patient, the estimated clearance (CL) and intercompartmental CL were 65 L/h and 295 L/h, respectively, with central and peripheral volumes estimated to be 118 L and 1030 L, respectively.",Population pharmacokinetics of ATR inhibitor berzosertib in phase I studies for different cancer types. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33145616/),l,103,125825,DB00441,Gemcitabine
,1999720,maximum-tolerated dose (MTD),The maximum-tolerated dose (MTD) was 790 mg/m2.,"A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1999720/),[mg] / [m2],790,126190,DB00441,Gemcitabine
,1999720,terminal half-life [t1/2],"Elimination, due mainly to deamination, was rapid (terminal half-life [t1/2], 8.0 minutes) and dose independent.","A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1999720/),min,8.0,126191,DB00441,Gemcitabine
,1999720,terminal phase (t1/2,"The deamination product 2',2'-difluorodeoxyuridine (dFdU) was eliminated with biphasic kinetics characterized by a long terminal phase (t1/2, 14 hours); it was the sole metabolite detected in urine.","A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1999720/),h,14,126192,DB00441,Gemcitabine
,16080482,dwell time,The dwell time was 60 min.,"Intravesical gemcitabine in superficial bladder cancer: a phase II safety, efficacy and pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16080482/),min,60,126313,DB00441,Gemcitabine
never exceeded,16080482,peak plasma concentrations,"The peak plasma concentrations of gemcitabine never exceeded 1000 ng/ml before TUR and 350 ng/ml after TUR, and declined rapidly.","Intravesical gemcitabine in superficial bladder cancer: a phase II safety, efficacy and pharmacokinetic study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16080482/),[ng] / [ml],1000,126314,DB00441,Gemcitabine
,16080482,peak plasma concentrations,"The peak plasma concentrations of gemcitabine never exceeded 1000 ng/ml before TUR and 350 ng/ml after TUR, and declined rapidly.","Intravesical gemcitabine in superficial bladder cancer: a phase II safety, efficacy and pharmacokinetic study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16080482/),[ng] / [ml],350,126315,DB00441,Gemcitabine
,17156477,overall survival,The median overall survival was 6.7 months for Cilengitide and gemcitabine and 7.7 months for gemcitabine alone.,A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17156477/),month,6.7,128202,DB00441,Gemcitabine
,17156477,overall survival,The median overall survival was 6.7 months for Cilengitide and gemcitabine and 7.7 months for gemcitabine alone.,A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17156477/),month,7.7,128203,DB00441,Gemcitabine
,17156477,PFS times,"The median PFS times were 3.6 months and 3.8 months, respectively.",A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17156477/),month,3.6,128204,DB00441,Gemcitabine
,17156477,PFS times,"The median PFS times were 3.6 months and 3.8 months, respectively.",A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17156477/),month,3.8,128205,DB00441,Gemcitabine
,17156477,overall response rates,"The overall response rates were 17% and 14%, and the tumor growth control rates were 54% and 56%, respectively.",A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17156477/),%,17,128206,DB00441,Gemcitabine
,17156477,overall response rates,"The overall response rates were 17% and 14%, and the tumor growth control rates were 54% and 56%, respectively.",A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17156477/),%,14,128207,DB00441,Gemcitabine
,17156477,tumor growth control rates,"The overall response rates were 17% and 14%, and the tumor growth control rates were 54% and 56%, respectively.",A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17156477/),%,54,128208,DB00441,Gemcitabine
,17156477,tumor growth control rates,"The overall response rates were 17% and 14%, and the tumor growth control rates were 54% and 56%, respectively.",A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17156477/),%,56,128209,DB00441,Gemcitabine
,20859741,compliance rate,"No patients were withdrawn from this study because of the intolerability of curcumin, which met the primary endpoint of the phase II study, and the median compliance rate of oral curcumin was 100% (Range 79-100%).",A phase I/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20859741/),%,100,128312,DB00441,Gemcitabine
,20859741,survival time,Median survival time after initiation of curcumin was 161 days (95% confidence interval 109-223 days) and 1-year survival rate was 19% (4.4-41.4%).,A phase I/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20859741/),d,161,128313,DB00441,Gemcitabine
,22078546,clearance,"The mean and interpatient variability of gemcitabine and dFdU clearance was 2.70 L/min (31.0%) and 0.0515 L/min (35.8%), respectively.",[Population pharmacokinetics of gemcitabine applied to personalize the dosage used in cancer patients]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22078546/),[l] / [min],2.70,133810,DB00441,Gemcitabine
,22078546,clearance,"The mean and interpatient variability of gemcitabine and dFdU clearance was 2.70 L/min (31.0%) and 0.0515 L/min (35.8%), respectively.",[Population pharmacokinetics of gemcitabine applied to personalize the dosage used in cancer patients]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22078546/),[l] / [min],0.0515,133811,DB00441,Gemcitabine
,22078546,distribution volume at steady state,The estimated distribution volume at steady state was 30 L for gemcitabine and 238 L for dFdU.,[Population pharmacokinetics of gemcitabine applied to personalize the dosage used in cancer patients]. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22078546/),l,30,133812,DB00441,Gemcitabine
,22078546,distribution volume at steady state,The estimated distribution volume at steady state was 30 L for gemcitabine and 238 L for dFdU.,[Population pharmacokinetics of gemcitabine applied to personalize the dosage used in cancer patients]. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22078546/),l,238,133813,DB00441,Gemcitabine
,27234064,maximum concentration,The maximum concentration in serum of unconjugated (free) genistein was 1 μM.,"A phase I dose escalation trial of AXP107-11, a novel multi-component crystalline form of genistein, in combination with gemcitabine in chemotherapy-naive patients with unresectable pancreatic cancer. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27234064/),μM,1,133901,DB00441,Gemcitabine
,27234064,overall survival time,The median overall survival time was 4.9 months (range 1.5-19.5 months).,"A phase I dose escalation trial of AXP107-11, a novel multi-component crystalline form of genistein, in combination with gemcitabine in chemotherapy-naive patients with unresectable pancreatic cancer. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27234064/),month,4.9,133902,DB00441,Gemcitabine
,28424962,t1/2,Pharmacokinetics of the orally administered milciclib (~t1/2 33 h) was not altered by concomitant treatment with gemcitabine.,Phase I dose-escalation study of milciclib in combination with gemcitabine in patients with refractory solid tumors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28424962/),h,33,133953,DB00441,Gemcitabine
,25620067,blood circulation half-life,"NCP-1 particles effectively avoid uptake by the mononuclear phagocyte system (MPS) in vivo with a long blood circulation half-life of 10.1 ± 3.3h, and potently inhibit tumor growth when compared to NCP particles carrying oxaliplatin or GMP alone.",Self-assembled nanoscale coordination polymers carrying oxaliplatin and gemcitabine for synergistic combination therapy of pancreatic cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25620067/),h,10.1,134972,DB00441,Gemcitabine
,16670205,Response rate,Response rate was 34% in arm A and 42% in arm B.,A multicentre randomised phase II study of carboplatin in combination with gemcitabine at standard rate or fixed dose rate infusion in patients with advanced stage non-small-cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16670205/),%,34,135985,DB00441,Gemcitabine
,16670205,Response rate,Response rate was 34% in arm A and 42% in arm B.,A multicentre randomised phase II study of carboplatin in combination with gemcitabine at standard rate or fixed dose rate infusion in patients with advanced stage non-small-cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16670205/),%,42,135986,DB00441,Gemcitabine
,16670205,plasma Cmax,"Mean plasma Cmax(gemcitabine) and mean dFdCTP AUC in arm A was 20.8 microM +/- 17.2 microM and 35,079 +/- 18,216 microM*min respectively and in arm B, 41.2 +/- 13.9 microM and 32 249 +/- 11 267 microM*min respectively.",A multicentre randomised phase II study of carboplatin in combination with gemcitabine at standard rate or fixed dose rate infusion in patients with advanced stage non-small-cell lung cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16670205/),μM,20.8,135987,DB00441,Gemcitabine
,16670205,plasma Cmax,"Mean plasma Cmax(gemcitabine) and mean dFdCTP AUC in arm A was 20.8 microM +/- 17.2 microM and 35,079 +/- 18,216 microM*min respectively and in arm B, 41.2 +/- 13.9 microM and 32 249 +/- 11 267 microM*min respectively.",A multicentre randomised phase II study of carboplatin in combination with gemcitabine at standard rate or fixed dose rate infusion in patients with advanced stage non-small-cell lung cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16670205/),μM,41.2,135988,DB00441,Gemcitabine
,16670205,AUC,"Mean plasma Cmax(gemcitabine) and mean dFdCTP AUC in arm A was 20.8 microM +/- 17.2 microM and 35,079 +/- 18,216 microM*min respectively and in arm B, 41.2 +/- 13.9 microM and 32 249 +/- 11 267 microM*min respectively.",A multicentre randomised phase II study of carboplatin in combination with gemcitabine at standard rate or fixed dose rate infusion in patients with advanced stage non-small-cell lung cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16670205/),min·μM,"35,079",135989,DB00441,Gemcitabine
,16670205,AUC,"Mean plasma Cmax(gemcitabine) and mean dFdCTP AUC in arm A was 20.8 microM +/- 17.2 microM and 35,079 +/- 18,216 microM*min respectively and in arm B, 41.2 +/- 13.9 microM and 32 249 +/- 11 267 microM*min respectively.",A multicentre randomised phase II study of carboplatin in combination with gemcitabine at standard rate or fixed dose rate infusion in patients with advanced stage non-small-cell lung cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16670205/),min·μM,32 249,135990,DB00441,Gemcitabine
,16596187,MTD,"In combination with gemcitabine, it has an MTD of 100 mg/m2 and shows promising efficacy in refractory pancreatic cancer.",Liposomal cisplatin combined with gemcitabine in pretreated advanced pancreatic cancer patients: a phase I-II study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16596187/),[mg] / [m2],100,136539,DB00441,Gemcitabine
,29348486,response rate,"Response rates were as follows: copanlisib plus gemcitabine, 6.3% (one partial response in a patient with peritoneal carcinoma); copanlisib plus CisGem, 12% (one complete response and three partial responses all in patients with BTC (response rate 17.4% in patients with BTC)).",Phase I dose-escalation study of copanlisib in combination with gemcitabine or cisplatin plus gemcitabine in patients with advanced cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29348486/),%,17.4,136714,DB00441,Gemcitabine
,23098625,MTD,"The MTD of PR-104 was 140 mg/m2 when combined with gemcitabine, 200 mg/m2 when combined with docetaxel 60 mg/m2, 770 mg/m2 when combined with docetaxel 60 mg/m2 plus G-CSF and ≥770 mg/m2 when combined with docetaxel 75 mg/m2 plus G-CSF.",PR-104 a bioreductive pre-prodrug combined with gemcitabine or docetaxel in a phase Ib study of patients with advanced solid tumours. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23098625/),[mg] / [m2],140,137016,DB00441,Gemcitabine
≥,23098625,MTD,"The MTD of PR-104 was 140 mg/m2 when combined with gemcitabine, 200 mg/m2 when combined with docetaxel 60 mg/m2, 770 mg/m2 when combined with docetaxel 60 mg/m2 plus G-CSF and ≥770 mg/m2 when combined with docetaxel 75 mg/m2 plus G-CSF.",PR-104 a bioreductive pre-prodrug combined with gemcitabine or docetaxel in a phase Ib study of patients with advanced solid tumours. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23098625/),[mg] / [m2],770,137017,DB00441,Gemcitabine
,33744463,total run time,"After dilution of the supernatant extract, 1 μL was injected into HPLC system for reverse phase chromatographic separation with a total run time of 8 min.","LC-MS/MS method for quantitation of gemcitabine and its metabolite 2',2'-difluoro-2'-deoxyuridine in mouse plasma and brain tissue: Application to a preclinical pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33744463/),min,8,138172,DB00441,Gemcitabine
,11391856,t1/2,Plasma elimination was rapid with a mean t1/2 of 8 +/- 4 min (mean +/- SD) for gemcitabine and 83 +/- 8 min for dFdU.,Plasma and cerebrospinal fluid pharmacokinetics of gemcitabine after intravenous administration in nonhuman primates. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11391856/),min,8,138702,DB00441,Gemcitabine
,11391856,t1/2,Plasma elimination was rapid with a mean t1/2 of 8 +/- 4 min (mean +/- SD) for gemcitabine and 83 +/- 8 min for dFdU.,Plasma and cerebrospinal fluid pharmacokinetics of gemcitabine after intravenous administration in nonhuman primates. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11391856/),min,83,138703,DB00441,Gemcitabine
,11391856,total body clearance (ClTB),Gemcitabine total body clearance (ClTB) was 177 +/- 40 ml/min per kg and the Vdss was 5.5 +/- 1.0 l/kg.,Plasma and cerebrospinal fluid pharmacokinetics of gemcitabine after intravenous administration in nonhuman primates. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11391856/),[ml] / [kg·min],177,138704,DB00441,Gemcitabine
,11391856,Vdss,Gemcitabine total body clearance (ClTB) was 177 +/- 40 ml/min per kg and the Vdss was 5.5 +/- 1.0 l/kg.,Plasma and cerebrospinal fluid pharmacokinetics of gemcitabine after intravenous administration in nonhuman primates. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11391856/),[l] / [kg],5.5,138705,DB00441,Gemcitabine
,11391856,maximum concentrations (Cmax),"The maximum concentrations (Cmax) and areas under the time concentration curves (AUC) for gemcitabine and dFdU in plasma were 194 +/- 64 microM and 63.8 +/- 14.6 microM.h, and 783 +/- 99 microM and 1725 +/- 186 microM.h, respectively.",Plasma and cerebrospinal fluid pharmacokinetics of gemcitabine after intravenous administration in nonhuman primates. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11391856/),μM,194,138706,DB00441,Gemcitabine
,11391856,maximum concentrations (Cmax),"The maximum concentrations (Cmax) and areas under the time concentration curves (AUC) for gemcitabine and dFdU in plasma were 194 +/- 64 microM and 63.8 +/- 14.6 microM.h, and 783 +/- 99 microM and 1725 +/- 186 microM.h, respectively.",Plasma and cerebrospinal fluid pharmacokinetics of gemcitabine after intravenous administration in nonhuman primates. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11391856/),μM,783,138707,DB00441,Gemcitabine
,11391856,areas under the time concentration curves (AUC),"The maximum concentrations (Cmax) and areas under the time concentration curves (AUC) for gemcitabine and dFdU in plasma were 194 +/- 64 microM and 63.8 +/- 14.6 microM.h, and 783 +/- 99 microM and 1725 +/- 186 microM.h, respectively.",Plasma and cerebrospinal fluid pharmacokinetics of gemcitabine after intravenous administration in nonhuman primates. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11391856/),h·μM,63.8,138708,DB00441,Gemcitabine
,11391856,areas under the time concentration curves (AUC),"The maximum concentrations (Cmax) and areas under the time concentration curves (AUC) for gemcitabine and dFdU in plasma were 194 +/- 64 microM and 63.8 +/- 14.6 microM.h, and 783 +/- 99 microM and 1725 +/- 186 microM.h, respectively.",Plasma and cerebrospinal fluid pharmacokinetics of gemcitabine after intravenous administration in nonhuman primates. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11391856/),h·μM,1725,138709,DB00441,Gemcitabine
,11391856,peak CSF concentrations,"The peak CSF concentrations of gemcitabine and dFdU were 2.5 +/- 1.4 microM and 32 +/- 41 microM, respectively.",Plasma and cerebrospinal fluid pharmacokinetics of gemcitabine after intravenous administration in nonhuman primates. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11391856/),μM,2.5,138710,DB00441,Gemcitabine
,11391856,peak CSF concentrations,"The peak CSF concentrations of gemcitabine and dFdU were 2.5 +/- 1.4 microM and 32 +/- 41 microM, respectively.",Plasma and cerebrospinal fluid pharmacokinetics of gemcitabine after intravenous administration in nonhuman primates. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11391856/),μM,32,138711,DB00441,Gemcitabine
,11391856,CSF:plasma ratio,The mean CSF:plasma ratio was 6.7% for gemcitabine and 23.8% for dFdU.,Plasma and cerebrospinal fluid pharmacokinetics of gemcitabine after intravenous administration in nonhuman primates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11391856/),%,6.7,138712,DB00441,Gemcitabine
,11391856,CSF:plasma ratio,The mean CSF:plasma ratio was 6.7% for gemcitabine and 23.8% for dFdU.,Plasma and cerebrospinal fluid pharmacokinetics of gemcitabine after intravenous administration in nonhuman primates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11391856/),%,23.8,138713,DB00441,Gemcitabine
,12123338,area under the concentration-time curve,"Paclitaxel administration significantly increased the epirubicinol area under the concentration-time curve, from 357+/-146 (epirubicin) to 603+/-107 (EP) and 640+/-81 h x ng/ml (GEP), and reduced the renal clearance of epirubicin and epirubicinol by 38 and 52.2% and 34.5 and 53% in GEP- and EP-treated patients, respectively, compared with epirubicin alone.","Gemcitabine, epirubicin and paclitaxel: pharmacokinetic and pharmacodynamic interactions in advanced breast cancer. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12123338/),[h·ng] / [ml],357,143077,DB00441,Gemcitabine
,12123338,area under the concentration-time curve,"Paclitaxel administration significantly increased the epirubicinol area under the concentration-time curve, from 357+/-146 (epirubicin) to 603+/-107 (EP) and 640+/-81 h x ng/ml (GEP), and reduced the renal clearance of epirubicin and epirubicinol by 38 and 52.2% and 34.5 and 53% in GEP- and EP-treated patients, respectively, compared with epirubicin alone.","Gemcitabine, epirubicin and paclitaxel: pharmacokinetic and pharmacodynamic interactions in advanced breast cancer. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12123338/),[h·ng] / [ml],603,143078,DB00441,Gemcitabine
,12123338,area under the concentration-time curve,"Paclitaxel administration significantly increased the epirubicinol area under the concentration-time curve, from 357+/-146 (epirubicin) to 603+/-107 (EP) and 640+/-81 h x ng/ml (GEP), and reduced the renal clearance of epirubicin and epirubicinol by 38 and 52.2% and 34.5 and 53% in GEP- and EP-treated patients, respectively, compared with epirubicin alone.","Gemcitabine, epirubicin and paclitaxel: pharmacokinetic and pharmacodynamic interactions in advanced breast cancer. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12123338/),[h·ng] / [ml],640,143079,DB00441,Gemcitabine
,12123338,tC0.1,"The only pharmacokinetic/pharmacodynamic relationship observed was between neutropenia and the time spent above the threshold plasma level of 0.1 micromol/l (tC0.1) of paclitaxel, with the time required to obtain a 50% decrease in neutrophil count (Et50) of GEP being 7.8 h, similar to that of EP.","Gemcitabine, epirubicin and paclitaxel: pharmacokinetic and pharmacodynamic interactions in advanced breast cancer. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12123338/),[μM] / [l],0.1,143080,DB00441,Gemcitabine
,18594320,overall response rate,The overall response rate for all patients was 5.6% (Confidence Interval [CI] 0.7-18.7%).,"Phase I/II study of a 3 weekly oral taxane (DJ-927) in patients with recurrent, advanced non-small cell lung cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18594320/),%,5.6,144879,DB00441,Gemcitabine
,18594320,time to progression,The median time to progression was 97 days (CI: 47-167 days) and the median survival time was 120 days (CI: 68-222 days) for the ITT group.,"Phase I/II study of a 3 weekly oral taxane (DJ-927) in patients with recurrent, advanced non-small cell lung cancer. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18594320/),d,97,144880,DB00441,Gemcitabine
,18594320,survival time,The median time to progression was 97 days (CI: 47-167 days) and the median survival time was 120 days (CI: 68-222 days) for the ITT group.,"Phase I/II study of a 3 weekly oral taxane (DJ-927) in patients with recurrent, advanced non-small cell lung cancer. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18594320/),d,120,144881,DB00441,Gemcitabine
,18594320,area under the curve (t = 0-168 hours),Pharmacokinetic analysis showed that the median area under the curve (t = 0-168 hours) was 1752 +/- 1355 ngr/ml/h and the half-life was 167 +/- 77 hours.,"Phase I/II study of a 3 weekly oral taxane (DJ-927) in patients with recurrent, advanced non-small cell lung cancer. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18594320/),[ngr] / [h·ml],1752,144882,DB00441,Gemcitabine
,18594320,half-life,Pharmacokinetic analysis showed that the median area under the curve (t = 0-168 hours) was 1752 +/- 1355 ngr/ml/h and the half-life was 167 +/- 77 hours.,"Phase I/II study of a 3 weekly oral taxane (DJ-927) in patients with recurrent, advanced non-small cell lung cancer. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18594320/),h,167,144883,DB00441,Gemcitabine
,18594320,terminal half-life,"When administered once every 3 weeks, this oral taxane formulation of DJ-927 was well-absorbed with a long terminal half-life of 167 +/- 77 hour.","Phase I/II study of a 3 weekly oral taxane (DJ-927) in patients with recurrent, advanced non-small cell lung cancer. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18594320/),h,167,144884,DB00441,Gemcitabine
,12114450,peak ventricular CSF gemcitabine concentrations,Ventricular delivery of gemcitabine produced peak ventricular CSF gemcitabine concentrations of 297 +/- 105 microg/ml.,Pharmacokinetics of intrathecal gemcitabine in nonhuman primates. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12114450/),[μg] / [ml],297,147068,DB00441,Gemcitabine
,12114450,area(s) under the curve (AUC),"After intraventricular administration, CSF gemcitabine and dFdU area(s) under the curve (AUC) were 251 +/- 85 and 249 +/- 88 microg/ml x h.",Pharmacokinetics of intrathecal gemcitabine in nonhuman primates. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12114450/),[μg] / [h·ml],251,147069,DB00441,Gemcitabine
,12114450,area(s) under the curve (AUC),"After intraventricular administration, CSF gemcitabine and dFdU area(s) under the curve (AUC) were 251 +/- 85 and 249 +/- 88 microg/ml x h.",Pharmacokinetics of intrathecal gemcitabine in nonhuman primates. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12114450/),[μg] / [h·ml],249,147070,DB00441,Gemcitabine
,12114450,AUC,"The plasma gemcitabine AUC associated with 5 mg of intraventricular gemcitabine was 2 mg/ml x h, which was >200-fold lower than the CSF gemcitabine AUC in the same animal.",Pharmacokinetics of intrathecal gemcitabine in nonhuman primates. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12114450/),[mg] / [h·ml],2,147071,DB00441,Gemcitabine
,29788155,half-life,"Maximum concentrations of GDC-0575 were achieved within 2 hours of dosing, and half-life was ∼23 hours.",Phase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine in patients with refractory solid tumors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29788155/),h,∼23,147164,DB00441,Gemcitabine
,3383195,Km,"Several explanations for the different cellular accumulation of the drug triphosphates were established: (a) nucleoside transport studies demonstrated that the membrane permeation of dFdC was 65% more rapid than that of ara-C; (b) deoxycytidine kinase had a higher affinity for dFdC (Km = 3.6 microM) than for ara-C (Km = 8.8 microM), while the Km for deoxycytidine was 1.4 microM; (c) the elimination of intracellular dFdCTP was biphasic with t1/2 alpha = 3.9 and t1/2 beta greater than 16 h while the degradation of ara-CTP was monophasic and significantly faster (t1/2 = 0.7 h).","Comparison of the cellular pharmacokinetics and toxicity of 2',2'-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3383195/),μM,3.6,151768,DB00441,Gemcitabine
,3383195,Km,"Several explanations for the different cellular accumulation of the drug triphosphates were established: (a) nucleoside transport studies demonstrated that the membrane permeation of dFdC was 65% more rapid than that of ara-C; (b) deoxycytidine kinase had a higher affinity for dFdC (Km = 3.6 microM) than for ara-C (Km = 8.8 microM), while the Km for deoxycytidine was 1.4 microM; (c) the elimination of intracellular dFdCTP was biphasic with t1/2 alpha = 3.9 and t1/2 beta greater than 16 h while the degradation of ara-CTP was monophasic and significantly faster (t1/2 = 0.7 h).","Comparison of the cellular pharmacokinetics and toxicity of 2',2'-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3383195/),μM,8.8,151769,DB00441,Gemcitabine
,3383195,Km,"Several explanations for the different cellular accumulation of the drug triphosphates were established: (a) nucleoside transport studies demonstrated that the membrane permeation of dFdC was 65% more rapid than that of ara-C; (b) deoxycytidine kinase had a higher affinity for dFdC (Km = 3.6 microM) than for ara-C (Km = 8.8 microM), while the Km for deoxycytidine was 1.4 microM; (c) the elimination of intracellular dFdCTP was biphasic with t1/2 alpha = 3.9 and t1/2 beta greater than 16 h while the degradation of ara-CTP was monophasic and significantly faster (t1/2 = 0.7 h).","Comparison of the cellular pharmacokinetics and toxicity of 2',2'-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3383195/),μM,1.4,151770,DB00441,Gemcitabine
,3383195,t1/2 alpha,"Several explanations for the different cellular accumulation of the drug triphosphates were established: (a) nucleoside transport studies demonstrated that the membrane permeation of dFdC was 65% more rapid than that of ara-C; (b) deoxycytidine kinase had a higher affinity for dFdC (Km = 3.6 microM) than for ara-C (Km = 8.8 microM), while the Km for deoxycytidine was 1.4 microM; (c) the elimination of intracellular dFdCTP was biphasic with t1/2 alpha = 3.9 and t1/2 beta greater than 16 h while the degradation of ara-CTP was monophasic and significantly faster (t1/2 = 0.7 h).","Comparison of the cellular pharmacokinetics and toxicity of 2',2'-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3383195/),,3.9,151771,DB00441,Gemcitabine
greater,3383195,t1/2 beta,"Several explanations for the different cellular accumulation of the drug triphosphates were established: (a) nucleoside transport studies demonstrated that the membrane permeation of dFdC was 65% more rapid than that of ara-C; (b) deoxycytidine kinase had a higher affinity for dFdC (Km = 3.6 microM) than for ara-C (Km = 8.8 microM), while the Km for deoxycytidine was 1.4 microM; (c) the elimination of intracellular dFdCTP was biphasic with t1/2 alpha = 3.9 and t1/2 beta greater than 16 h while the degradation of ara-CTP was monophasic and significantly faster (t1/2 = 0.7 h).","Comparison of the cellular pharmacokinetics and toxicity of 2',2'-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3383195/),h,16,151772,DB00441,Gemcitabine
,3383195,t1/2,"Several explanations for the different cellular accumulation of the drug triphosphates were established: (a) nucleoside transport studies demonstrated that the membrane permeation of dFdC was 65% more rapid than that of ara-C; (b) deoxycytidine kinase had a higher affinity for dFdC (Km = 3.6 microM) than for ara-C (Km = 8.8 microM), while the Km for deoxycytidine was 1.4 microM; (c) the elimination of intracellular dFdCTP was biphasic with t1/2 alpha = 3.9 and t1/2 beta greater than 16 h while the degradation of ara-CTP was monophasic and significantly faster (t1/2 = 0.7 h).","Comparison of the cellular pharmacokinetics and toxicity of 2',2'-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3383195/),h,0.7,151773,DB00441,Gemcitabine
,10499642,T1/2,"The T1/2 (+/- SD) for intravesical and i.v. administration of 350 mg was 328 (+/-6.8) min and 99.3 (+/-5.2) min, respectively (P<0.001).",Toxicology and pharmacokinetics of intravesical gemcitabine: a preclinical study in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10499642/),min,328,152066,DB00441,Gemcitabine
,10499642,T1/2,"The T1/2 (+/- SD) for intravesical and i.v. administration of 350 mg was 328 (+/-6.8) min and 99.3 (+/-5.2) min, respectively (P<0.001).",Toxicology and pharmacokinetics of intravesical gemcitabine: a preclinical study in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10499642/),min,99.3,152067,DB00441,Gemcitabine
,33741651,PFS,Median PFS was 27.1 weeks.,"A Phase Ib Open-Label, Dose-Escalation Study of NUC-1031 in Combination with Carboplatin for Recurrent Ovarian Cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33741651/),weeks,27.1,152548,DB00441,Gemcitabine
,30299542,overall response rate,The overall response rate was 4%; the rate of disease control was 67% in patients who were pretreated with gemcitabine.,"A phase 1, open-label, dose escalation study of intravenous paricalcitol in combination with gemcitabine in patients with advanced malignancies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30299542/),%,4,152692,DB00441,Gemcitabine
,30299542,Progression-free,"Progression-free and overall survival were 3.4 months and 6.5 months, respectively.","A phase 1, open-label, dose escalation study of intravenous paricalcitol in combination with gemcitabine in patients with advanced malignancies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30299542/),month,3.4,152693,DB00441,Gemcitabine
,30299542,overall survival,"Progression-free and overall survival were 3.4 months and 6.5 months, respectively.","A phase 1, open-label, dose escalation study of intravenous paricalcitol in combination with gemcitabine in patients with advanced malignancies. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30299542/),month,6.5,152694,DB00441,Gemcitabine
,31970932,area under the plasma concentration-time curve (AUC0-8 ),The mean area under the plasma concentration-time curve (AUC0-8 ) of gemcitabine after microdosing was 0.00074 h·mg/L and after therapeutic dosing was 16 h·mg/L.,Pilot Study to Predict Pharmacokinetics of a Therapeutic Gemcitabine Dose From a Microdose. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31970932/),[h·mg] / [l],0.00074,152829,DB00441,Gemcitabine
,31970932,area under the plasma concentration-time curve (AUC0-8 ),The mean area under the plasma concentration-time curve (AUC0-8 ) of gemcitabine after microdosing was 0.00074 h·mg/L and after therapeutic dosing was 16 h·mg/L.,Pilot Study to Predict Pharmacokinetics of a Therapeutic Gemcitabine Dose From a Microdose. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31970932/),[h·mg] / [l],16,152830,DB00441,Gemcitabine
,31970932,AUC0-8,"The mean AUC0-8 of dFdU following the microdose and therapeutic dose were 0.022 h·mg/L and 169 h·mg/L, respectively.",Pilot Study to Predict Pharmacokinetics of a Therapeutic Gemcitabine Dose From a Microdose. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31970932/),[h·mg] / [l],0.022,152831,DB00441,Gemcitabine
,31970932,AUC0-8,"The mean AUC0-8 of dFdU following the microdose and therapeutic dose were 0.022 h·mg/L and 169 h·mg/L, respectively.",Pilot Study to Predict Pharmacokinetics of a Therapeutic Gemcitabine Dose From a Microdose. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31970932/),[h·mg] / [l],169,152832,DB00441,Gemcitabine
,31970932,volume of distribution,"However, the shape of the concentration-time curve was different, as reflected by poor scalability in volume of distribution (939 L versus 222 L).",Pilot Study to Predict Pharmacokinetics of a Therapeutic Gemcitabine Dose From a Microdose. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31970932/),l,939,152833,DB00441,Gemcitabine
,31970932,volume of distribution,"However, the shape of the concentration-time curve was different, as reflected by poor scalability in volume of distribution (939 L versus 222 L).",Pilot Study to Predict Pharmacokinetics of a Therapeutic Gemcitabine Dose From a Microdose. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31970932/),l,222,152834,DB00441,Gemcitabine
,32878766,objective response rate,"The objective response rate was 21.3% and median progression-free survival was 8.7 months (95% confidence interval, 5.4-10.3 months).",Phase I and Biomarker Study of the Wnt Pathway Modulator DKN-01 in Combination with Gemcitabine/Cisplatin in Advanced Biliary Tract Cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32878766/),%,21.3,152905,DB00441,Gemcitabine
,32878766,progression-free survival,"The objective response rate was 21.3% and median progression-free survival was 8.7 months (95% confidence interval, 5.4-10.3 months).",Phase I and Biomarker Study of the Wnt Pathway Modulator DKN-01 in Combination with Gemcitabine/Cisplatin in Advanced Biliary Tract Cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32878766/),month,8.7,152906,DB00441,Gemcitabine
,34256103,zeta potential,"The zeta potential was found to be 36.1 and 37.5 mV for CS-NPs-I and CS-NPs-II, respectively.",Building and behavior of a pH-stimuli responsive chitosan nanoparticles loaded with folic acid conjugated gemcitabine silver colloids in MDA-MB-453 metastatic breast cancer cell line and pharmacokinetics in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34256103/),mv,36.1,153320,DB00441,Gemcitabine
,34256103,zeta potential,"The zeta potential was found to be 36.1 and 37.5 mV for CS-NPs-I and CS-NPs-II, respectively.",Building and behavior of a pH-stimuli responsive chitosan nanoparticles loaded with folic acid conjugated gemcitabine silver colloids in MDA-MB-453 metastatic breast cancer cell line and pharmacokinetics in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34256103/),mv,37.5,153321,DB00441,Gemcitabine
,34256103,polydispersity index (PDI),"CS-NPs-I and CS-NPs-II showed a polydispersity index (PDI) of 0.240 and 0.261, respectively.",Building and behavior of a pH-stimuli responsive chitosan nanoparticles loaded with folic acid conjugated gemcitabine silver colloids in MDA-MB-453 metastatic breast cancer cell line and pharmacokinetics in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34256103/),,0.240,153322,DB00441,Gemcitabine
,34256103,polydispersity index (PDI),"CS-NPs-I and CS-NPs-II showed a polydispersity index (PDI) of 0.240 and 0.261, respectively.",Building and behavior of a pH-stimuli responsive chitosan nanoparticles loaded with folic acid conjugated gemcitabine silver colloids in MDA-MB-453 metastatic breast cancer cell line and pharmacokinetics in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34256103/),,0.261,153323,DB00441,Gemcitabine
,14529980,rate,"In vivo 48 Wag/Rij rats underwent BFO with GCB at a rate of 0.2 mL/min and 0.5 mL/min during 10, 20, 30, and 40 minutes.",Pharmacokinetics after pulmonary artery perfusion with gemcitabine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14529980/),[ml] / [min],0.2,153491,DB00441,Gemcitabine
,14529980,rate,"In vivo 48 Wag/Rij rats underwent BFO with GCB at a rate of 0.2 mL/min and 0.5 mL/min during 10, 20, 30, and 40 minutes.",Pharmacokinetics after pulmonary artery perfusion with gemcitabine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14529980/),[ml] / [min],0.5,153492,DB00441,Gemcitabine
,14529980,flow rate,"In vivo, no significant difference in lung levels of GCB was observed between a flow rate of 0.2 mL/min compared with 0.5 mL/min at any exposure time point (p < 0.05).",Pharmacokinetics after pulmonary artery perfusion with gemcitabine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14529980/),[ml] / [min],0.2,153493,DB00441,Gemcitabine
,14529980,flow rate,"In vivo, no significant difference in lung levels of GCB was observed between a flow rate of 0.2 mL/min compared with 0.5 mL/min at any exposure time point (p < 0.05).",Pharmacokinetics after pulmonary artery perfusion with gemcitabine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14529980/),[ml] / [min],0.5,153494,DB00441,Gemcitabine
,16584929,flow rate,"The mobile phase (flow rate, 1.0 mL/min) consists of 10:90 (v/v) acetonitrile-aqueous buffer (50 mM sodium phosphate and 3.0 mM octyl sulfonic acid, pH 2.9).","High-performance liquid chromatographic method for the determination of gemcitabine and 2',2'-difluorodeoxyuridine in plasma and tissue culture media. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16584929/),[ml] / [min],1.0,153519,DB00441,Gemcitabine
,22011284,half-life,Mean lonafarnib half-life ranged from 4 to 7 hr; median T(max) values ranged from 4 to 8 hr.,A phase I multicenter study of continuous oral administration of lonafarnib (SCH 66336) and intravenous gemcitabine in patients with advanced cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22011284/),h,4 to 7,154152,DB00441,Gemcitabine
,22011284,T(max),Mean lonafarnib half-life ranged from 4 to 7 hr; median T(max) values ranged from 4 to 8 hr.,A phase I multicenter study of continuous oral administration of lonafarnib (SCH 66336) and intravenous gemcitabine in patients with advanced cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22011284/),h,4 to 8,154153,DB00441,Gemcitabine
above,12750842,Plasma concentrations,"Plasma concentrations, however, were above 10 micro mol/l between 20 and 90 min in all patients.",Phase I trial of fixed dose-rate gemcitabine in combination with carboplatin in chemonaive advanced non-small-cell lung cancer: a Cancer Therapeutics Research Group study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12750842/),[μmol] / [l],10,154381,DB00441,Gemcitabine
,20523087,area under the curve (AUC),"Carboplatin area under the curve (AUC) 5 ml/min on day 1 with gemcitabine 1,250 mg/m(2) on day 1 and day 8 is a widely used regimen in advanced non-small cell lung cancer.",A randomized phase II study comparing two schedules of the 21-day regimen of gemcitabine and carboplatin in advanced non-small cell lung cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20523087/),[ml] / [min],5,155605,DB00441,Gemcitabine
>,32104361,recovery,"In this study, gradient elution with small particles size solid phase was applied to effectively separate gemcitabine and JDR, and protein precipitation pretreatment was adopted to remove plasma protein and extract the analytes with high recovery(>81%).",Development and validation of a UPLC-MS/MS assay for the determination of gemcitabine and its L-carnitine ester derivative in rat plasma and its application in oral pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32104361/),%,81,157131,DB00441,Gemcitabine
,12721761,plasma steady-state concentrations,Gemcitabine administered at a fixed dose rate of 10 mg/m(2) per min has been reported to achieve plasma steady-state concentrations ranging from 10 to 20 microM in patients with acute leukemia.,Gemcitabine pharmacokinetics and interaction with paclitaxel in patients with advanced non-small-cell lung cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12721761/),μM,10 to 20,157189,DB00441,Gemcitabine
,20855828,AUC,"For example, an AUC of 5 mg/mL · min is associated with a risk of grade 3 or 4 thrombocytopenia of 2% in combination with paclitaxel versus 38% with gemcitabine in a non-pretreated patient.",Factors for hematopoietic toxicity of carboplatin: refining the targeting of carboplatin systemic exposure. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20855828/),[mg] / [min·ml],5,157411,DB00441,Gemcitabine
,18519780,bioavailability,Systemic exposure to dFdC was low with an estimated bioavailability of 10%.,Oral administration of gemcitabine in patients with refractory tumors: a clinical and pharmacologic study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18519780/),%,10,157878,DB00441,Gemcitabine
,18519780,terminal half-life,"dFdC was highly converted to dFdU, probably via first pass metabolism and dFdU had a long terminal half-life ( approximately 89 h).",Oral administration of gemcitabine in patients with refractory tumors: a clinical and pharmacologic study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18519780/),h,89,157879,DB00441,Gemcitabine
,28750271,disease control rate,"Among the efficacy-evaluable population, two patients (5%) had a partial response; the disease control rate was 74% at cycle 2.","Safety, tolerability and antitumour activity of LY2780301 (p70S6K/AKT inhibitor) in combination with gemcitabine in molecularly selected patients with advanced or metastatic cancer: a phase IB dose escalation study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28750271/),%,74,159270,DB00441,Gemcitabine
,18823053,response rate,"The response rate was approximately 25% (all partial responses [PRs], 12 patients; 95% confidence interval [95% CI], 13-39).",Phase 2 study of gemcitabine and irinotecan in metastatic breast cancer with correlatives to determine topoisomerase I localization as a predictor of response. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18823053/),%,25,159956,DB00441,Gemcitabine
,18823053,clinical benefit rate,Six patients had stable disease (SD) for > or =6 months for a clinical benefit rate (PR + SD) of 39%.,Phase 2 study of gemcitabine and irinotecan in metastatic breast cancer with correlatives to determine topoisomerase I localization as a predictor of response. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18823053/),,39,159957,DB00441,Gemcitabine
,18823053,time to disease progression,"The median time to disease progression was 3.7 months (95% CI, 2.5 months-4.6 months), and median survival was 11.6 months (95% CI, 8.9 months-15 months).",Phase 2 study of gemcitabine and irinotecan in metastatic breast cancer with correlatives to determine topoisomerase I localization as a predictor of response. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18823053/),month,3.7,159958,DB00441,Gemcitabine
,18823053,survival,"The median time to disease progression was 3.7 months (95% CI, 2.5 months-4.6 months), and median survival was 11.6 months (95% CI, 8.9 months-15 months).",Phase 2 study of gemcitabine and irinotecan in metastatic breast cancer with correlatives to determine topoisomerase I localization as a predictor of response. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18823053/),month,11.6,159959,DB00441,Gemcitabine
,21175992,overall survival,"The median overall survival, the 1-year survival rate and median progression-free survival were 9.23 months, 33.0% and 3.48 months, respectively.",Phase II study of erlotinib plus gemcitabine in Japanese patients with unresectable pancreatic cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21175992/),month,9.23,161000,DB00441,Gemcitabine
,21175992,survival rate,"The median overall survival, the 1-year survival rate and median progression-free survival were 9.23 months, 33.0% and 3.48 months, respectively.",Phase II study of erlotinib plus gemcitabine in Japanese patients with unresectable pancreatic cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21175992/),%,33.0,161001,DB00441,Gemcitabine
,21175992,survival rate,"The median overall survival, the 1-year survival rate and median progression-free survival were 9.23 months, 33.0% and 3.48 months, respectively.",Phase II study of erlotinib plus gemcitabine in Japanese patients with unresectable pancreatic cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21175992/),month,3.48,161002,DB00441,Gemcitabine
,21175992,progression-free survival,"The median overall survival, the 1-year survival rate and median progression-free survival were 9.23 months, 33.0% and 3.48 months, respectively.",Phase II study of erlotinib plus gemcitabine in Japanese patients with unresectable pancreatic cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21175992/),month,3.48,161003,DB00441,Gemcitabine
,21175992,overall response,"The overall response and disease control rates were 20.3% and 50.0%, respectively.",Phase II study of erlotinib plus gemcitabine in Japanese patients with unresectable pancreatic cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21175992/),%,20.3,161004,DB00441,Gemcitabine
,21175992,disease control rates,"The overall response and disease control rates were 20.3% and 50.0%, respectively.",Phase II study of erlotinib plus gemcitabine in Japanese patients with unresectable pancreatic cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21175992/),%,50.0,161005,DB00441,Gemcitabine
,15933419,Cmax,Cmax was 22.2 microg/ml (t(max) = 24 min) in the MONO and 24.6 microg/ml (t(max) = 23 min) in the TMAB schedule.,Pharmacokinetics of gemcitabine combined with trastuzumab in patients with advanced breast cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15933419/),[μg] / [ml],22.2,161705,DB00441,Gemcitabine
,15933419,Cmax,Cmax was 22.2 microg/ml (t(max) = 24 min) in the MONO and 24.6 microg/ml (t(max) = 23 min) in the TMAB schedule.,Pharmacokinetics of gemcitabine combined with trastuzumab in patients with advanced breast cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15933419/),[μg] / [ml],24.6,161706,DB00441,Gemcitabine
,15933419,t(max),Cmax was 22.2 microg/ml (t(max) = 24 min) in the MONO and 24.6 microg/ml (t(max) = 23 min) in the TMAB schedule.,Pharmacokinetics of gemcitabine combined with trastuzumab in patients with advanced breast cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15933419/),min,24,161707,DB00441,Gemcitabine
,15933419,t(max),Cmax was 22.2 microg/ml (t(max) = 24 min) in the MONO and 24.6 microg/ml (t(max) = 23 min) in the TMAB schedule.,Pharmacokinetics of gemcitabine combined with trastuzumab in patients with advanced breast cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15933419/),[μg] / [ml],24.6,161708,DB00441,Gemcitabine
,15933419,t(max),Cmax was 22.2 microg/ml (t(max) = 24 min) in the MONO and 24.6 microg/ml (t(max) = 23 min) in the TMAB schedule.,Pharmacokinetics of gemcitabine combined with trastuzumab in patients with advanced breast cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15933419/),min,23,161709,DB00441,Gemcitabine
,15933419,t1/2el,Gemcitabine distributed rapidly from plasma within a few minutes and was eliminated with a t1/2el of about 80 min in both arms of the study.,Pharmacokinetics of gemcitabine combined with trastuzumab in patients with advanced breast cancer. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15933419/),min,80,161710,DB00441,Gemcitabine
,15933419,t1/2appin,"The metabolite difluorodeoxyuridine (dFdU) appeared in plasma with t1/2appin = 12.8 min (MONO) or t1/2appin = 10.2 min (TMAB) reaching a mean peak concentration of 35.9 microg/ml (MONO) or 30.4 microg/ml (TMAB), respectively.",Pharmacokinetics of gemcitabine combined with trastuzumab in patients with advanced breast cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15933419/),min,12.8,161711,DB00441,Gemcitabine
,15933419,t1/2appin,"The metabolite difluorodeoxyuridine (dFdU) appeared in plasma with t1/2appin = 12.8 min (MONO) or t1/2appin = 10.2 min (TMAB) reaching a mean peak concentration of 35.9 microg/ml (MONO) or 30.4 microg/ml (TMAB), respectively.",Pharmacokinetics of gemcitabine combined with trastuzumab in patients with advanced breast cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15933419/),min,10.2,161712,DB00441,Gemcitabine
,15933419,peak concentration,"The metabolite difluorodeoxyuridine (dFdU) appeared in plasma with t1/2appin = 12.8 min (MONO) or t1/2appin = 10.2 min (TMAB) reaching a mean peak concentration of 35.9 microg/ml (MONO) or 30.4 microg/ml (TMAB), respectively.",Pharmacokinetics of gemcitabine combined with trastuzumab in patients with advanced breast cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15933419/),[μg] / [ml],35.9,161713,DB00441,Gemcitabine
,15933419,peak concentration,"The metabolite difluorodeoxyuridine (dFdU) appeared in plasma with t1/2appin = 12.8 min (MONO) or t1/2appin = 10.2 min (TMAB) reaching a mean peak concentration of 35.9 microg/ml (MONO) or 30.4 microg/ml (TMAB), respectively.",Pharmacokinetics of gemcitabine combined with trastuzumab in patients with advanced breast cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15933419/),[μg] / [ml],30.4,161714,DB00441,Gemcitabine
,12439592,maximum tolerated dose,The gemcitabine maximum tolerated dose was established at 750 mg/m(2) on days 2 and 9.,Phase I pharmacodynamic study of time and sequence dependency of hydroxyurea in combination with gemcitabine: a California Cancer Consortium Trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12439592/),mg,750,164423,DB00441,Gemcitabine
,24744161,maximum tolerated dose (MTD),The maximum tolerated dose (MTD) was identified to be 10 mg/day.,Phase 1 dose escalation and pharmacokinetic evaluation of oral gemcitabine prodrug (LY2334737) in combination with docetaxel in patients with advanced solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24744161/),[mg] / [d],10,166285,DB00441,Gemcitabine
,24744161,MTD,Combination of LY2334737 at doses up to 30 mg/day QD for 14 days per cycle with docetaxel 75 mg/m(2) q3w resulted in an undesirable toxicity profile and a low MTD of 10 mg/day.,Phase 1 dose escalation and pharmacokinetic evaluation of oral gemcitabine prodrug (LY2334737) in combination with docetaxel in patients with advanced solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24744161/),[mg] / [d],10,166286,DB00441,Gemcitabine
,25260842,Cmax,"Patients received escalating doses of tasisulam (3 + 3 schema; target Cmax 300-400 μg/mL) every 28 days plus 1,000 mg/m(2) gemcitabine HCl (days 1 and 15), 60 mg/m(2) docetaxel, 200 mg/m(2)/day temozolomide, 75 mg/m(2) cisplatin, or 150 mg/day erlotinib.","An innovative, multi-arm, complete phase 1b study of the novel anti-cancer agent tasisulam in patients with advanced solid tumors. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25260842/),[μg] / [ml],300-400,170080,DB00441,Gemcitabine
,25260842,AUCalb),"Because tasisulam is highly albumin-bound, patients in the tumor-specific confirmation arms were dosed targeting specific albumin-corrected exposure ranges (AUCalb) identified during dose-escalation (3,500 h*μg/mL [75th percentile] for docetaxel, temozolomide, and cisplatin; 4,000 h*μg/mL for gemcitabine and erlotinib).","An innovative, multi-arm, complete phase 1b study of the novel anti-cancer agent tasisulam in patients with advanced solid tumors. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25260842/),[h·μg] / [ml],"3,500",170081,DB00441,Gemcitabine
,25260842,AUCalb),"Because tasisulam is highly albumin-bound, patients in the tumor-specific confirmation arms were dosed targeting specific albumin-corrected exposure ranges (AUCalb) identified during dose-escalation (3,500 h*μg/mL [75th percentile] for docetaxel, temozolomide, and cisplatin; 4,000 h*μg/mL for gemcitabine and erlotinib).","An innovative, multi-arm, complete phase 1b study of the novel anti-cancer agent tasisulam in patients with advanced solid tumors. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25260842/),[h·μg] / [ml],"4,000",170082,DB00441,Gemcitabine
,28804517,progression-free survival,"It is the first, second-line treatment approved by the US Food and Drug Administration to treat patients with MPC based on results of the NAnoliPOsomaL Irinotecan (NAPOLI-1) study, which showed that this regimen significantly prolonged progression-free survival (3.1 months versus 1.5 months) and overall survival (6.2 months versus 4.1 months) compared with 5-FU/folinic acid alone.",Update on the role of nanoliposomal irinotecan in the treatment of metastatic pancreatic cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28804517/),month,3.1,170253,DB00441,Gemcitabine
,28804517,progression-free survival,"It is the first, second-line treatment approved by the US Food and Drug Administration to treat patients with MPC based on results of the NAnoliPOsomaL Irinotecan (NAPOLI-1) study, which showed that this regimen significantly prolonged progression-free survival (3.1 months versus 1.5 months) and overall survival (6.2 months versus 4.1 months) compared with 5-FU/folinic acid alone.",Update on the role of nanoliposomal irinotecan in the treatment of metastatic pancreatic cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28804517/),month,1.5,170254,DB00441,Gemcitabine
,28804517,overall survival,"It is the first, second-line treatment approved by the US Food and Drug Administration to treat patients with MPC based on results of the NAnoliPOsomaL Irinotecan (NAPOLI-1) study, which showed that this regimen significantly prolonged progression-free survival (3.1 months versus 1.5 months) and overall survival (6.2 months versus 4.1 months) compared with 5-FU/folinic acid alone.",Update on the role of nanoliposomal irinotecan in the treatment of metastatic pancreatic cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28804517/),month,6.2,170255,DB00441,Gemcitabine
,28804517,overall survival,"It is the first, second-line treatment approved by the US Food and Drug Administration to treat patients with MPC based on results of the NAnoliPOsomaL Irinotecan (NAPOLI-1) study, which showed that this regimen significantly prolonged progression-free survival (3.1 months versus 1.5 months) and overall survival (6.2 months versus 4.1 months) compared with 5-FU/folinic acid alone.",Update on the role of nanoliposomal irinotecan in the treatment of metastatic pancreatic cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28804517/),month,4.1,170256,DB00441,Gemcitabine
,21726412,AUC,The Calvert-Crokcoft-Gault formula was employed to calculate a dose of carboplatin with a target AUC of 5 mg/min./mL in patients under 70 years and 4 mg/min./mL in patients aged 70 or older.,Effect of age on systemic exposure and haematological toxicity of carboplatin in advanced non-small cell lung cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21726412/),[mg] / [·min·ml],5,170591,DB00441,Gemcitabine
,21726412,AUC,The Calvert-Crokcoft-Gault formula was employed to calculate a dose of carboplatin with a target AUC of 5 mg/min./mL in patients under 70 years and 4 mg/min./mL in patients aged 70 or older.,Effect of age on systemic exposure and haematological toxicity of carboplatin in advanced non-small cell lung cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21726412/),[mg] / [·min·ml],4,170592,DB00441,Gemcitabine
,21726412,AUC,"The carboplatin systemic exposure measured by the AUC (mg/min./mL) was 5.98 (5.45; 6.51) and 5.36 (5.02; 5.69) for the younger patients and older groups, respectively.",Effect of age on systemic exposure and haematological toxicity of carboplatin in advanced non-small cell lung cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21726412/),[mg] / [·min·ml],5.98,170593,DB00441,Gemcitabine
,21726412,AUC,"The carboplatin systemic exposure measured by the AUC (mg/min./mL) was 5.98 (5.45; 6.51) and 5.36 (5.02; 5.69) for the younger patients and older groups, respectively.",Effect of age on systemic exposure and haematological toxicity of carboplatin in advanced non-small cell lung cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21726412/),[mg] / [·min·ml],5.36,170594,DB00441,Gemcitabine
,21726412,AUC,"In clinical practice, a target AUC of 4 mg/min./mL carboplatin is applied to patients aged 70 and over, but the actual systemic exposure to the drug is higher.",Effect of age on systemic exposure and haematological toxicity of carboplatin in advanced non-small cell lung cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21726412/),[mg] / [·min·ml],4,170595,DB00441,Gemcitabine
,21726412,AUC,This supports a target AUC of 4 mg/min./mL carboplatin for patients older than 70 years when the dose is calculated by means of the Calvert-Crokcoft-Gault formula.,Effect of age on systemic exposure and haematological toxicity of carboplatin in advanced non-small cell lung cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21726412/),[mg] / [·min·ml],4,170596,DB00441,Gemcitabine
,19546035,run time,"In addition, the relatively small sample volume (50 microL) and a run time of 1.5 min facilitate automation and allow for high-throughput analysis.","Development of a sensitive and selective LC-MS/MS method for simultaneous determination of gemcitabine and 2,2-difluoro-2-deoxyuridine in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19546035/),min,1.5,173549,DB00441,Gemcitabine
,17434832,plasma peak levels,"Gemcitabine and its deaminated metabolite difluorodeoxyuridine (dFdU), measured with HPLC, reached plasma peak levels of 2-3 microM at 40 mg/m(2) which increased to 512 microM at 5700 mg/m(2).","Clinical phase I and pharmacology study of gemcitabine (2', 2'-difluorodeoxycytidine) administered in a two-weekly schedule. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17434832/),μM,2-3,173955,DB00441,Gemcitabine
,17434832,plasma peak levels,"Gemcitabine and its deaminated metabolite difluorodeoxyuridine (dFdU), measured with HPLC, reached plasma peak levels of 2-3 microM at 40 mg/m(2) which increased to 512 microM at 5700 mg/m(2).","Clinical phase I and pharmacology study of gemcitabine (2', 2'-difluorodeoxycytidine) administered in a two-weekly schedule. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17434832/),μM,512,173956,DB00441,Gemcitabine
,17434832,t(1/2) beta,"Gemcitabine was eliminated rapidly with a t(1/2) beta of 2.3-15.8 min in the 40-5700 mg/m(2) dose range, with one exception of 38 min at 4500 mg/m(2) .","Clinical phase I and pharmacology study of gemcitabine (2', 2'-difluorodeoxycytidine) administered in a two-weekly schedule. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17434832/),min,2.3-15.8,173957,DB00441,Gemcitabine
,17434832,t(1/2) beta,"Gemcitabine was eliminated rapidly with a t(1/2) beta of 2.3-15.8 min in the 40-5700 mg/m(2) dose range, with one exception of 38 min at 4500 mg/m(2) .","Clinical phase I and pharmacology study of gemcitabine (2', 2'-difluorodeoxycytidine) administered in a two-weekly schedule. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17434832/),min,38,173958,DB00441,Gemcitabine
,17434832,clearance,Gemcitabine clearance varied between 1.5-12.6 l/min and was 1.5-fold higher in males than in females (p= 0.024); its volume of distribution was 45.2-248 l.,"Clinical phase I and pharmacology study of gemcitabine (2', 2'-difluorodeoxycytidine) administered in a two-weekly schedule. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17434832/),[l] / [min],1.5-12.6,173959,DB00441,Gemcitabine
,17434832,volume of distribution,Gemcitabine clearance varied between 1.5-12.6 l/min and was 1.5-fold higher in males than in females (p= 0.024); its volume of distribution was 45.2-248 l.,"Clinical phase I and pharmacology study of gemcitabine (2', 2'-difluorodeoxycytidine) administered in a two-weekly schedule. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17434832/),l,45.2-248,173960,DB00441,Gemcitabine
,17434832,peak levels,In lymphocytes peak levels of the active metabolite dFdCTP were 100-380 pmol/10( 6 )cells in the first course.,"Clinical phase I and pharmacology study of gemcitabine (2', 2'-difluorodeoxycytidine) administered in a two-weekly schedule. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17434832/),[pM] / [10(·6],100-380,173961,DB00441,Gemcitabine
,15911238,overall response rate,Nine partial responses and one complete response were achieved in 31 assessable patients and corresponded to an overall response rate of 32.3% [95% CI:17%-51%].,Multicentre EORTC study 16997: feasibility and phase II trial of farnesyl transferase inhibitor & gemcitabine combination in salvage treatment of advanced urothelial tract cancers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15911238/),%,32.3,175908,DB00441,Gemcitabine
,24857345,overall survival rate,"Median survival was 3.8 months, and 6 month overall survival rate was 32% (95% CI 19-47%).",A phase II study of erlotinib in gemcitabine refractory advanced pancreatic cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24857345/),%,32,180087,DB00441,Gemcitabine
,27601554,area under the curve,"In part 2, patients received AZD1775 as a single dose (part 2A) or as five twice per day doses or two once per day doses (part 2B) in combination with one of the following chemotherapy agents: gemcitabine (1,000 mg/m2), cisplatin (75 mg/m2), or carboplatin (area under the curve, 5 mg/mL⋅min).","Phase I Study Evaluating WEE1 Inhibitor AZD1775 As Monotherapy and in Combination With Gemcitabine, Cisplatin, or Carboplatin in Patients With Advanced Solid Tumors. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27601554/),[mg] / [min·ml],5,183607,DB00441,Gemcitabine
,27601554,response rate,The response rate in TP53-mutated patients (n = 19) was 21% compared with 12% in TP53 wild-type patients (n = 33).,"Phase I Study Evaluating WEE1 Inhibitor AZD1775 As Monotherapy and in Combination With Gemcitabine, Cisplatin, or Carboplatin in Patients With Advanced Solid Tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27601554/),%,21,183608,DB00441,Gemcitabine
,27601554,response rate,The response rate in TP53-mutated patients (n = 19) was 21% compared with 12% in TP53 wild-type patients (n = 33).,"Phase I Study Evaluating WEE1 Inhibitor AZD1775 As Monotherapy and in Combination With Gemcitabine, Cisplatin, or Carboplatin in Patients With Advanced Solid Tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27601554/),%,12,183609,DB00441,Gemcitabine
,21753156,MTD,The MTD was 40 mg LY2334737.,Phase I study of Oral gemcitabine prodrug (LY2334737) alone and in combination with erlotinib in patients with advanced solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21753156/),mg,40,185075,DB00441,Gemcitabine
,21753156,accumulation index,"The metabolite 2',2'-difluorodeoxyuridine accumulated with an accumulation index of 4.3 (coefficient of variation: 20%).",Phase I study of Oral gemcitabine prodrug (LY2334737) alone and in combination with erlotinib in patients with advanced solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21753156/),,4.3,185076,DB00441,Gemcitabine
,21753156,MTD,LY2334737 displays linear pharmacokinetics and the MTD is 40 mg with or without daily administration of 100 mg erlotinib.,Phase I study of Oral gemcitabine prodrug (LY2334737) alone and in combination with erlotinib in patients with advanced solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21753156/),mg,40,185077,DB00441,Gemcitabine
,19263052,IC(50),"In vitro analysis of antitumor activity against human PC cell lines, BXPC-3 and PSN-1, showed a significant time- and dose-dependent reduction of cell viability following exposure to L-GEM as compared to free GEM [at 72 h, IC(50): 0.009 vs. 0.027 microM (P = 0.003) for BXPC-3 and 0.003 vs. 0.009 microM (P < 0.001) for PSN1, respectively].",In vivo activity of gemcitabine-loaded PEGylated small unilamellar liposomes against pancreatic cancer. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19263052/),μM,0.009,185439,DB00441,Gemcitabine
,19263052,IC(50),"In vitro analysis of antitumor activity against human PC cell lines, BXPC-3 and PSN-1, showed a significant time- and dose-dependent reduction of cell viability following exposure to L-GEM as compared to free GEM [at 72 h, IC(50): 0.009 vs. 0.027 microM (P = 0.003) for BXPC-3 and 0.003 vs. 0.009 microM (P < 0.001) for PSN1, respectively].",In vivo activity of gemcitabine-loaded PEGylated small unilamellar liposomes against pancreatic cancer. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19263052/),μM,0.027,185440,DB00441,Gemcitabine
,19263052,IC(50),"In vitro analysis of antitumor activity against human PC cell lines, BXPC-3 and PSN-1, showed a significant time- and dose-dependent reduction of cell viability following exposure to L-GEM as compared to free GEM [at 72 h, IC(50): 0.009 vs. 0.027 microM (P = 0.003) for BXPC-3 and 0.003 vs. 0.009 microM (P < 0.001) for PSN1, respectively].",In vivo activity of gemcitabine-loaded PEGylated small unilamellar liposomes against pancreatic cancer. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19263052/),μM,0.003,185441,DB00441,Gemcitabine
,19263052,t (1/2),Pharmacokinetic studies showed enhancement of systemic bioavailability of L-GEM (t (1/2) = 8 h) versus to GEM (t (1/2) = 1.5 h).,In vivo activity of gemcitabine-loaded PEGylated small unilamellar liposomes against pancreatic cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19263052/),h,8,185442,DB00441,Gemcitabine
,19263052,t (1/2),Pharmacokinetic studies showed enhancement of systemic bioavailability of L-GEM (t (1/2) = 8 h) versus to GEM (t (1/2) = 1.5 h).,In vivo activity of gemcitabine-loaded PEGylated small unilamellar liposomes against pancreatic cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19263052/),h,1.5,185443,DB00441,Gemcitabine
,27404580,zeta potential,"The mPEG-PLGA NPs (size: 267±10nm, zeta potential: -17.5±0.2mV) exhibited sustained drug release profile and were found to be compatible with blood.",Long-circulatory nanoparticles for gemcitabine delivery: Development and investigation of pharmacokinetics and in-vivo anticancer efficacy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27404580/),m,-,185706,DB00441,Gemcitabine
,27404580,zeta potential,"The mPEG-PLGA NPs (size: 267±10nm, zeta potential: -17.5±0.2mV) exhibited sustained drug release profile and were found to be compatible with blood.",Long-circulatory nanoparticles for gemcitabine delivery: Development and investigation of pharmacokinetics and in-vivo anticancer efficacy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27404580/),m,17.5,185707,DB00441,Gemcitabine
,21436695,response rate,"The response rate was 42.8% (95% confidence interval [CI], 34.5%-51.1%), with 17.1% (6/35) complete responses and 25.7% (9/35) partial responses.",Pegylated liposomal doxorubicin and gemcitabine in a fixed dose rate infusion for the treatment of patients with poor prognosis of recurrent ovarian cancer: a phase Ib study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21436695/),%,42.8,185846,DB00441,Gemcitabine
,21436695,progression-free survival,"The median progression-free survival was 7.7 months (95% CI, 2.2-13.1).",Pegylated liposomal doxorubicin and gemcitabine in a fixed dose rate infusion for the treatment of patients with poor prognosis of recurrent ovarian cancer: a phase Ib study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21436695/),month,7.7,185847,DB00441,Gemcitabine
,21436695,overall survival,"The median overall survival was 13.9 months (95% CI, 9.4-18.4).",Pegylated liposomal doxorubicin and gemcitabine in a fixed dose rate infusion for the treatment of patients with poor prognosis of recurrent ovarian cancer: a phase Ib study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21436695/),month,13.9,185848,DB00441,Gemcitabine
,17443325,AUC (area under the plasma concentration--time curve,"At doses equivalent to 10, 25 and 100 mg/kg, the brain ECF gemcitabine AUC (area under the plasma concentration--time curve measured over the last sampling time point) values were 2.46 +/- 0.7, 3.20 +/- 1.1, and 9.06 +/- 3.0 microg h/ml, respectively.",Pharmacokinetics of gemcitabine in tumor and non-tumor extracellular fluid of brain: an in vivo assessment in rats employing intracerebral microdialysis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17443325/),[h·μg] / [ml],2.46,188400,DB00441,Gemcitabine
,17443325,AUC (area under the plasma concentration--time curve,"At doses equivalent to 10, 25 and 100 mg/kg, the brain ECF gemcitabine AUC (area under the plasma concentration--time curve measured over the last sampling time point) values were 2.46 +/- 0.7, 3.20 +/- 1.1, and 9.06 +/- 3.0 microg h/ml, respectively.",Pharmacokinetics of gemcitabine in tumor and non-tumor extracellular fluid of brain: an in vivo assessment in rats employing intracerebral microdialysis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17443325/),[h·μg] / [ml],3.20,188401,DB00441,Gemcitabine
,17443325,AUC (area under the plasma concentration--time curve,"At doses equivalent to 10, 25 and 100 mg/kg, the brain ECF gemcitabine AUC (area under the plasma concentration--time curve measured over the last sampling time point) values were 2.46 +/- 0.7, 3.20 +/- 1.1, and 9.06 +/- 3.0 microg h/ml, respectively.",Pharmacokinetics of gemcitabine in tumor and non-tumor extracellular fluid of brain: an in vivo assessment in rats employing intracerebral microdialysis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17443325/),[h·μg] / [ml],9.06,188402,DB00441,Gemcitabine
,17443325,relative brain distribution coefficient (AUC brainECF/AUC plasma),"At the three doses evaluated, the relative brain distribution coefficient (AUC brainECF/AUC plasma) of gemcitabine ranged from 0.07 to 0.09 suggesting limited gemcitabine availability to brain tissues.",Pharmacokinetics of gemcitabine in tumor and non-tumor extracellular fluid of brain: an in vivo assessment in rats employing intracerebral microdialysis. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17443325/),,0.07 to 0.09,188403,DB00441,Gemcitabine
,17443325,AUC,"Studies on C6 glioma-bearing rats revealed that following an intravenous dose of 25 mg/kg, the AUC values in the tumor-free and tumor-brain regions were 4.52 +/- 2.4, and 9.82 +/- 3.3 microg h/ml, respectively.",Pharmacokinetics of gemcitabine in tumor and non-tumor extracellular fluid of brain: an in vivo assessment in rats employing intracerebral microdialysis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17443325/),[h·μg] / [ml],4.52,188404,DB00441,Gemcitabine
,17443325,AUC,"Studies on C6 glioma-bearing rats revealed that following an intravenous dose of 25 mg/kg, the AUC values in the tumor-free and tumor-brain regions were 4.52 +/- 2.4, and 9.82 +/- 3.3 microg h/ml, respectively.",Pharmacokinetics of gemcitabine in tumor and non-tumor extracellular fluid of brain: an in vivo assessment in rats employing intracerebral microdialysis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17443325/),[h·μg] / [ml],9.82,188405,DB00441,Gemcitabine
<,17443325,relative brain distribution coefficient,Our findings suggest that the overall brain exposure to gemcitabine is likely to be low as evident from the relative brain distribution coefficient of <0.1.,Pharmacokinetics of gemcitabine in tumor and non-tumor extracellular fluid of brain: an in vivo assessment in rats employing intracerebral microdialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17443325/),,0.1,188406,DB00441,Gemcitabine
,16597550,elimination half-life,Plasma pharmacokinetics were dose-linear with an elimination half-life of 2.2 h.,Safety assessment of 4'-thio-beta-D-arabinofuranosylcytosine in the beagle dog suggests a drug-induced centrally mediated effect on the hypothalamic-pituitary-adrenal axis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16597550/),h,2.2,188462,DB00441,Gemcitabine
,15645422,IC(50),"Potent in vitro anti-proliferative effects were observed against pancreatic (Capan-1, MIA-PaCa-2, BxPC-3) and ovarian (SK-OV-3, OVCAR-3, ES-2) cancer cell lines with IC(50) of 0.01-0.2 microM.",Anti-tumor efficacy of the nucleoside analog 1-(2-deoxy-2-fluoro-4-thio-beta-D-arabinofuranosyl) cytosine (4'-thio-FAC) in human pancreatic and ovarian tumor xenograft models. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15645422/),μM,0.01-0.2,188564,DB00441,Gemcitabine
,16515669,overall clearance,"The overall clearance, volume of distribution at steady-state, and terminal elimination half-life (t(1/2)) for gemcitabine were 0.421 L/h.kg, 0.822 L/kg, and 1.49 h, respectively.",Pharmacokinetics of gemcitabine and its primary metabolite in dogs after intravenous infusion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16515669/),[l] / [h·kg],0.421,189210,DB00441,Gemcitabine
,16515669,volume of distribution at steady-state,"The overall clearance, volume of distribution at steady-state, and terminal elimination half-life (t(1/2)) for gemcitabine were 0.421 L/h.kg, 0.822 L/kg, and 1.49 h, respectively.",Pharmacokinetics of gemcitabine and its primary metabolite in dogs after intravenous infusion. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16515669/),[l] / [kg],0.822,189211,DB00441,Gemcitabine
,16515669,terminal elimination half-life (t(1/2)),"The overall clearance, volume of distribution at steady-state, and terminal elimination half-life (t(1/2)) for gemcitabine were 0.421 L/h.kg, 0.822 L/kg, and 1.49 h, respectively.",Pharmacokinetics of gemcitabine and its primary metabolite in dogs after intravenous infusion. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16515669/),h,1.49,189212,DB00441,Gemcitabine
,16515669,t(1/2),Plasma concentrations of dFdU peaked at approximately 2 h postdosing and had a t(1/2) of 14.9 h.,Pharmacokinetics of gemcitabine and its primary metabolite in dogs after intravenous infusion. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16515669/),h,14.9,189213,DB00441,Gemcitabine
,24726286,progression-free survival,"The median progression-free survival and overall survival for 25 evaluable patients were 10.6 and 12.6 months, respectively.",Phase 1 pharmacogenetic and pharmacodynamic study of sorafenib with concurrent radiation therapy and gemcitabine in locally advanced unresectable pancreatic cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24726286/),month,10.6,192008,DB00441,Gemcitabine
,24726286,overall survival,"The median progression-free survival and overall survival for 25 evaluable patients were 10.6 and 12.6 months, respectively.",Phase 1 pharmacogenetic and pharmacodynamic study of sorafenib with concurrent radiation therapy and gemcitabine in locally advanced unresectable pancreatic cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24726286/),month,12.6,192009,DB00441,Gemcitabine
,24726286,overall survival,"The median overall survival for patients with VEGF-A -2578 AA, -1498 CC, and -1154 AA versus alternate genotypes was 21.6 versus 14.7 months.",Phase 1 pharmacogenetic and pharmacodynamic study of sorafenib with concurrent radiation therapy and gemcitabine in locally advanced unresectable pancreatic cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24726286/),month,21.6,192010,DB00441,Gemcitabine
,24726286,overall survival,"The median overall survival for patients with VEGF-A -2578 AA, -1498 CC, and -1154 AA versus alternate genotypes was 21.6 versus 14.7 months.",Phase 1 pharmacogenetic and pharmacodynamic study of sorafenib with concurrent radiation therapy and gemcitabine in locally advanced unresectable pancreatic cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24726286/),month,14.7,192011,DB00441,Gemcitabine
,15487572,total radiation dose,"The average total radiation dose was 50 Gy for dogs and 54 Gy for cats given Monday-Friday (planned dose of 54 and 57 Gy, respectively).",Unexpected toxicity following use of gemcitabine as a radiosensitizer in head and neck carcinomas: a veterinary radiation therapy oncology group pilot study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15487572/),gy,50,193317,DB00441,Gemcitabine
,15487572,total radiation dose,"The average total radiation dose was 50 Gy for dogs and 54 Gy for cats given Monday-Friday (planned dose of 54 and 57 Gy, respectively).",Unexpected toxicity following use of gemcitabine as a radiosensitizer in head and neck carcinomas: a veterinary radiation therapy oncology group pilot study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15487572/),gy,54,193318,DB00441,Gemcitabine
,17909812,flow rate,"FTS was isolated from mouse plasma by liquid chromatography on a Columbus 5-mum particle size, 50 x 2 mm id column with a methanol/5 mM ammonium acetate (80/20) mobile phase (isocratic elution) at a flow rate of 0.3 ml/min.",Orally administered FTS (salirasib) inhibits human pancreatic tumor growth in nude mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17909812/),[ml] / [min],0.3,193889,DB00441,Gemcitabine
,17909812,m/z),MS/MS was performed on a PE Sciex API 365 with Turbo Ion Spray as interface and negative ion ionization; parent ion (m/z): 357.2; daughter ion (m/z) 153.2; retention time 2.3 min.,Orally administered FTS (salirasib) inhibits human pancreatic tumor growth in nude mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17909812/),,357.2,193890,DB00441,Gemcitabine
,17909812,m/z),MS/MS was performed on a PE Sciex API 365 with Turbo Ion Spray as interface and negative ion ionization; parent ion (m/z): 357.2; daughter ion (m/z) 153.2; retention time 2.3 min.,Orally administered FTS (salirasib) inhibits human pancreatic tumor growth in nude mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17909812/),min,153.2,193891,DB00441,Gemcitabine
,17909812,retention time,MS/MS was performed on a PE Sciex API 365 with Turbo Ion Spray as interface and negative ion ionization; parent ion (m/z): 357.2; daughter ion (m/z) 153.2; retention time 2.3 min.,Orally administered FTS (salirasib) inhibits human pancreatic tumor growth in nude mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17909812/),min,2.3,193892,DB00441,Gemcitabine
,17909812,detection limit,Salirasib was readily detected in mouse plasma by LC-MS/MS at a detection limit of 3 ng/ml.,Orally administered FTS (salirasib) inhibits human pancreatic tumor growth in nude mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17909812/),[ng] / [ml],3,193893,DB00441,Gemcitabine
,17909812,t (max),"For each route of administration, t (max) was 1 h and t (1/2) ranged from 1.86 to 2.66 h.",Orally administered FTS (salirasib) inhibits human pancreatic tumor growth in nude mice. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17909812/),h,1,193894,DB00441,Gemcitabine
,17909812,t (1/2),"For each route of administration, t (max) was 1 h and t (1/2) ranged from 1.86 to 2.66 h.",Orally administered FTS (salirasib) inhibits human pancreatic tumor growth in nude mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17909812/),h,1.86 to 2.66,193895,DB00441,Gemcitabine
,17909812,oral bioavailabilty,"Compared to IP administration, the oral bioavailabilty of FTS was 69.5% for oral CMC and 55% for oral corn oil suspensions, while clearance and volume of distribution were higher in both oral preparations.",Orally administered FTS (salirasib) inhibits human pancreatic tumor growth in nude mice. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17909812/),%,69.5,193896,DB00441,Gemcitabine
,17909812,oral bioavailabilty,"Compared to IP administration, the oral bioavailabilty of FTS was 69.5% for oral CMC and 55% for oral corn oil suspensions, while clearance and volume of distribution were higher in both oral preparations.",Orally administered FTS (salirasib) inhibits human pancreatic tumor growth in nude mice. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17909812/),%,55,193897,DB00441,Gemcitabine
,25394095,concentration,Plasma concentrations of raltegravir in eight patients showed a median concentration of 143 ng/mL (79-455).,"Efficacy, safety, and lack of interactions with the use of raltegravir in HIV-infected patients undergoing antineoplastic chemotherapy. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25394095/),[ng] / [ml],143,195476,DB00441,Gemcitabine
,18766965,MTD,The duration of MTD for gemcitabine was 12 h.,"Phase I evaluation of gemcitabine, mitoxantrone, and their effect on plasma disposition of fludarabine in patients with relapsed or refractory acute myeloid leukemia. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18766965/),h,12,195846,DB00441,Gemcitabine
,19726456,"area under the concentration-time curve, 0-51 hours","Double-sided nephrectomy and hemodialysis had no influence on gemcitabine pharmacokinetics; however, a high exposure was seen for the main metabolite, difluordeoxyuridine (dFdU) (area under the concentration-time curve, 0-51 hours, 844 microg/ml.hour).",Pharmacokinetics of gemcitabine and metabolites in a patient with double-sided nephrectomy: a case report and review of the literature. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19726456/),[μg] / [h·ml],844,196380,DB00441,Gemcitabine
,19556122,MTD,The MTD was 180 mg/m(2) with thrombocytopaenia as the dose-limiting toxicity.,A phase I and pharmacokinetic study of gemcitabine given by 24-h hepatic arterial infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19556122/),[mg] / [m],180,196725,DB00441,Gemcitabine
,19556122,maximum gemcitabine plasma concentration (C(max),"Pharmacokinetic analysis showed a significantly lower maximum gemcitabine plasma concentration (C(max): HAI, 26, 80 and 128 nM, respectively; IV, 229, 264 and 293 nM, respectively) and area under the plasma-concentration-versus-time curve (AUC(0-24h): HAI, 386, 1247 and 2033 nmol x h/L, respectively; IV, 3526, 4818 and 5363 nmol x h/L, respectively) during HAI, compared with intravenous infusion (both P<0.001).",A phase I and pharmacokinetic study of gemcitabine given by 24-h hepatic arterial infusion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19556122/),nM,"26,",196726,DB00441,Gemcitabine
,19556122,maximum gemcitabine plasma concentration (C(max),"Pharmacokinetic analysis showed a significantly lower maximum gemcitabine plasma concentration (C(max): HAI, 26, 80 and 128 nM, respectively; IV, 229, 264 and 293 nM, respectively) and area under the plasma-concentration-versus-time curve (AUC(0-24h): HAI, 386, 1247 and 2033 nmol x h/L, respectively; IV, 3526, 4818 and 5363 nmol x h/L, respectively) during HAI, compared with intravenous infusion (both P<0.001).",A phase I and pharmacokinetic study of gemcitabine given by 24-h hepatic arterial infusion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19556122/),nM,80,196727,DB00441,Gemcitabine
,19556122,maximum gemcitabine plasma concentration (C(max),"Pharmacokinetic analysis showed a significantly lower maximum gemcitabine plasma concentration (C(max): HAI, 26, 80 and 128 nM, respectively; IV, 229, 264 and 293 nM, respectively) and area under the plasma-concentration-versus-time curve (AUC(0-24h): HAI, 386, 1247 and 2033 nmol x h/L, respectively; IV, 3526, 4818 and 5363 nmol x h/L, respectively) during HAI, compared with intravenous infusion (both P<0.001).",A phase I and pharmacokinetic study of gemcitabine given by 24-h hepatic arterial infusion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19556122/),nM,128,196728,DB00441,Gemcitabine
,19556122,maximum gemcitabine plasma concentration (C(max),"Pharmacokinetic analysis showed a significantly lower maximum gemcitabine plasma concentration (C(max): HAI, 26, 80 and 128 nM, respectively; IV, 229, 264 and 293 nM, respectively) and area under the plasma-concentration-versus-time curve (AUC(0-24h): HAI, 386, 1247 and 2033 nmol x h/L, respectively; IV, 3526, 4818 and 5363 nmol x h/L, respectively) during HAI, compared with intravenous infusion (both P<0.001).",A phase I and pharmacokinetic study of gemcitabine given by 24-h hepatic arterial infusion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19556122/),nM,229,196729,DB00441,Gemcitabine
,19556122,maximum gemcitabine plasma concentration (C(max),"Pharmacokinetic analysis showed a significantly lower maximum gemcitabine plasma concentration (C(max): HAI, 26, 80 and 128 nM, respectively; IV, 229, 264 and 293 nM, respectively) and area under the plasma-concentration-versus-time curve (AUC(0-24h): HAI, 386, 1247 and 2033 nmol x h/L, respectively; IV, 3526, 4818 and 5363 nmol x h/L, respectively) during HAI, compared with intravenous infusion (both P<0.001).",A phase I and pharmacokinetic study of gemcitabine given by 24-h hepatic arterial infusion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19556122/),nM,264,196730,DB00441,Gemcitabine
,19556122,maximum gemcitabine plasma concentration (C(max),"Pharmacokinetic analysis showed a significantly lower maximum gemcitabine plasma concentration (C(max): HAI, 26, 80 and 128 nM, respectively; IV, 229, 264 and 293 nM, respectively) and area under the plasma-concentration-versus-time curve (AUC(0-24h): HAI, 386, 1247 and 2033 nmol x h/L, respectively; IV, 3526, 4818 and 5363 nmol x h/L, respectively) during HAI, compared with intravenous infusion (both P<0.001).",A phase I and pharmacokinetic study of gemcitabine given by 24-h hepatic arterial infusion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19556122/),nM,293,196731,DB00441,Gemcitabine
,19556122,area under the plasma-concentration-versus-time curve (AUC(0-24h),"Pharmacokinetic analysis showed a significantly lower maximum gemcitabine plasma concentration (C(max): HAI, 26, 80 and 128 nM, respectively; IV, 229, 264 and 293 nM, respectively) and area under the plasma-concentration-versus-time curve (AUC(0-24h): HAI, 386, 1247 and 2033 nmol x h/L, respectively; IV, 3526, 4818 and 5363 nmol x h/L, respectively) during HAI, compared with intravenous infusion (both P<0.001).",A phase I and pharmacokinetic study of gemcitabine given by 24-h hepatic arterial infusion. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19556122/),[h·nM] / [l],386,196732,DB00441,Gemcitabine
,19556122,area under the plasma-concentration-versus-time curve (AUC(0-24h),"Pharmacokinetic analysis showed a significantly lower maximum gemcitabine plasma concentration (C(max): HAI, 26, 80 and 128 nM, respectively; IV, 229, 264 and 293 nM, respectively) and area under the plasma-concentration-versus-time curve (AUC(0-24h): HAI, 386, 1247 and 2033 nmol x h/L, respectively; IV, 3526, 4818 and 5363 nmol x h/L, respectively) during HAI, compared with intravenous infusion (both P<0.001).",A phase I and pharmacokinetic study of gemcitabine given by 24-h hepatic arterial infusion. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19556122/),[h·nM] / [l],1247,196733,DB00441,Gemcitabine
,19556122,area under the plasma-concentration-versus-time curve (AUC(0-24h),"Pharmacokinetic analysis showed a significantly lower maximum gemcitabine plasma concentration (C(max): HAI, 26, 80 and 128 nM, respectively; IV, 229, 264 and 293 nM, respectively) and area under the plasma-concentration-versus-time curve (AUC(0-24h): HAI, 386, 1247 and 2033 nmol x h/L, respectively; IV, 3526, 4818 and 5363 nmol x h/L, respectively) during HAI, compared with intravenous infusion (both P<0.001).",A phase I and pharmacokinetic study of gemcitabine given by 24-h hepatic arterial infusion. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19556122/),[h·nM] / [l],2033,196734,DB00441,Gemcitabine
,19556122,area under the plasma-concentration-versus-time curve (AUC(0-24h),"Pharmacokinetic analysis showed a significantly lower maximum gemcitabine plasma concentration (C(max): HAI, 26, 80 and 128 nM, respectively; IV, 229, 264 and 293 nM, respectively) and area under the plasma-concentration-versus-time curve (AUC(0-24h): HAI, 386, 1247 and 2033 nmol x h/L, respectively; IV, 3526, 4818 and 5363 nmol x h/L, respectively) during HAI, compared with intravenous infusion (both P<0.001).",A phase I and pharmacokinetic study of gemcitabine given by 24-h hepatic arterial infusion. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19556122/),[h·nM] / [l],3526,196735,DB00441,Gemcitabine
,19556122,area under the plasma-concentration-versus-time curve (AUC(0-24h),"Pharmacokinetic analysis showed a significantly lower maximum gemcitabine plasma concentration (C(max): HAI, 26, 80 and 128 nM, respectively; IV, 229, 264 and 293 nM, respectively) and area under the plasma-concentration-versus-time curve (AUC(0-24h): HAI, 386, 1247 and 2033 nmol x h/L, respectively; IV, 3526, 4818 and 5363 nmol x h/L, respectively) during HAI, compared with intravenous infusion (both P<0.001).",A phase I and pharmacokinetic study of gemcitabine given by 24-h hepatic arterial infusion. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19556122/),[h·nM] / [l],4818,196736,DB00441,Gemcitabine
,19556122,area under the plasma-concentration-versus-time curve (AUC(0-24h),"Pharmacokinetic analysis showed a significantly lower maximum gemcitabine plasma concentration (C(max): HAI, 26, 80 and 128 nM, respectively; IV, 229, 264 and 293 nM, respectively) and area under the plasma-concentration-versus-time curve (AUC(0-24h): HAI, 386, 1247 and 2033 nmol x h/L, respectively; IV, 3526, 4818 and 5363 nmol x h/L, respectively) during HAI, compared with intravenous infusion (both P<0.001).",A phase I and pharmacokinetic study of gemcitabine given by 24-h hepatic arterial infusion. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19556122/),[h·nM] / [l],5363,196737,DB00441,Gemcitabine
,19556122,hepatic extraction ratios,"Additionally, the mean hepatic extraction ratios of gemcitabine at the 75, 135 and 180 mg/m(2) dose level were 0.89, 0.75 and 0.55, respectively.",A phase I and pharmacokinetic study of gemcitabine given by 24-h hepatic arterial infusion. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19556122/),,0.89,196738,DB00441,Gemcitabine
,19556122,hepatic extraction ratios,"Additionally, the mean hepatic extraction ratios of gemcitabine at the 75, 135 and 180 mg/m(2) dose level were 0.89, 0.75 and 0.55, respectively.",A phase I and pharmacokinetic study of gemcitabine given by 24-h hepatic arterial infusion. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19556122/),,0.75,196739,DB00441,Gemcitabine
,19556122,hepatic extraction ratios,"Additionally, the mean hepatic extraction ratios of gemcitabine at the 75, 135 and 180 mg/m(2) dose level were 0.89, 0.75 and 0.55, respectively.",A phase I and pharmacokinetic study of gemcitabine given by 24-h hepatic arterial infusion. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19556122/),,0.55,196740,DB00441,Gemcitabine
,18587581,C (max) levels,"Very high levels of gemcitabine were rapidly reached in the extracorporeal circuit during the 20 min of stop-flow perfusion, with C (max) levels in the abdominal circuit of 246 (+/-37%), 2,039 (+/-77%) and 4,780 (+/-7.3%) mug/ml for the three dose levels 500, 750 and 1,125 mg/m(2), respectively.",A phase I pharmacokinetic study of hypoxic abdominal stop-flow perfusion with gemcitabine in patients with advanced pancreatic cancer and refractory malignant ascites. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18587581/),[μg] / [ml],246,196996,DB00441,Gemcitabine
,18587581,C (max) levels,"Very high levels of gemcitabine were rapidly reached in the extracorporeal circuit during the 20 min of stop-flow perfusion, with C (max) levels in the abdominal circuit of 246 (+/-37%), 2,039 (+/-77%) and 4,780 (+/-7.3%) mug/ml for the three dose levels 500, 750 and 1,125 mg/m(2), respectively.",A phase I pharmacokinetic study of hypoxic abdominal stop-flow perfusion with gemcitabine in patients with advanced pancreatic cancer and refractory malignant ascites. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18587581/),[μg] / [ml],"2,039",196997,DB00441,Gemcitabine
,18587581,C (max) levels,"Very high levels of gemcitabine were rapidly reached in the extracorporeal circuit during the 20 min of stop-flow perfusion, with C (max) levels in the abdominal circuit of 246 (+/-37%), 2,039 (+/-77%) and 4,780 (+/-7.3%) mug/ml for the three dose levels 500, 750 and 1,125 mg/m(2), respectively.",A phase I pharmacokinetic study of hypoxic abdominal stop-flow perfusion with gemcitabine in patients with advanced pancreatic cancer and refractory malignant ascites. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18587581/),[μg] / [ml],"4,780",196998,DB00441,Gemcitabine
,23564376,absolute bioavailability,"The absolute bioavailability for the sum of gemcitabine was 32.2 % for intravenous and 22.2 % for oral administration with SL-01, respectively.","Pharmacokinetics and metabolism of SL-01, a prodrug of gemcitabine, in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23564376/),%,32.2,198566,DB00441,Gemcitabine
,23564376,absolute bioavailability,"The absolute bioavailability for the sum of gemcitabine was 32.2 % for intravenous and 22.2 % for oral administration with SL-01, respectively.","Pharmacokinetics and metabolism of SL-01, a prodrug of gemcitabine, in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23564376/),%,22.2,198567,DB00441,Gemcitabine
,18008070,terminal half-life,"THU, at 100 mg/kg iv had a 73 min terminal half-life and produced plasma THU concentrations >1 microg/ml, the concentration shown to effectively block deamination, for 4 h.","Plasma pharmacokinetics and oral bioavailability of 3,4,5,6-tetrahydrouridine, a cytidine deaminase inhibitor, in mice. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18008070/),min,73,198623,DB00441,Gemcitabine
,18008070,Clearance,"Clearance was 9.1 ml/min/kg, and the distribution volume was 0.95 l/kg.","Plasma pharmacokinetics and oral bioavailability of 3,4,5,6-tetrahydrouridine, a cytidine deaminase inhibitor, in mice. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18008070/),[ml] / [kg·min],9.1,198624,DB00441,Gemcitabine
,18008070,distribution volume,"Clearance was 9.1 ml/min/kg, and the distribution volume was 0.95 l/kg.","Plasma pharmacokinetics and oral bioavailability of 3,4,5,6-tetrahydrouridine, a cytidine deaminase inhibitor, in mice. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18008070/),[l] / [kg],0.95,198625,DB00441,Gemcitabine
,18008070,half-life,"THU, at 100 mg/kg po, produced a concentration versus time profile with a plateau of approximately 10 mug/ml from 0.5-3 h, followed by a decline with an 85 min half-life.","Plasma pharmacokinetics and oral bioavailability of 3,4,5,6-tetrahydrouridine, a cytidine deaminase inhibitor, in mice. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18008070/),min,85,198626,DB00441,Gemcitabine
,18008070,oral bioavailability,The oral bioavailability of THU was approximately 20%.,"Plasma pharmacokinetics and oral bioavailability of 3,4,5,6-tetrahydrouridine, a cytidine deaminase inhibitor, in mice. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18008070/),%,20,198627,DB00441,Gemcitabine
,11249051,progression-free,"At five years progression-free and overall survival rates are 37.5% and 65%, respectively.",High-dose thiotepa and melphalan with hemopoietic progenitor support following induction therapy with epirubicin-paclitaxel-containing regimens in metastatic breast cancer (MBC). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11249051/),%,37.,199261,DB00441,Gemcitabine
,11249051,overall survival,"At five years progression-free and overall survival rates are 37.5% and 65%, respectively.",High-dose thiotepa and melphalan with hemopoietic progenitor support following induction therapy with epirubicin-paclitaxel-containing regimens in metastatic breast cancer (MBC). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11249051/),%,65,199262,DB00441,Gemcitabine
,31172407,progression-free survival,"ORR was 34.1% (95% CI 23.9-44.4%) vs. 29.6% (95% CI 19.7-39.6%) and median progression-free survival was 5.5 months (95% CI 4.2-5.7) vs. 4.3 months (95% CI 3.0-5.8) for GC+w-iniparib and GC+tw-iniparib, respectively.",Iniparib administered weekly or twice-weekly in combination with gemcitabine/carboplatin in patients with metastatic triple-negative breast cancer: a phase II randomized open-label study with pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31172407/),month,5.5,206635,DB00441,Gemcitabine
,31172407,progression-free survival,"ORR was 34.1% (95% CI 23.9-44.4%) vs. 29.6% (95% CI 19.7-39.6%) and median progression-free survival was 5.5 months (95% CI 4.2-5.7) vs. 4.3 months (95% CI 3.0-5.8) for GC+w-iniparib and GC+tw-iniparib, respectively.",Iniparib administered weekly or twice-weekly in combination with gemcitabine/carboplatin in patients with metastatic triple-negative breast cancer: a phase II randomized open-label study with pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31172407/),month,4.3,206636,DB00441,Gemcitabine
<,31172407,terminal half-life,"Iniparib and its metabolites were cleared rapidly with a terminal half-life of < 1 h, without accumulation.",Iniparib administered weekly or twice-weekly in combination with gemcitabine/carboplatin in patients with metastatic triple-negative breast cancer: a phase II randomized open-label study with pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31172407/),h,1,206637,DB00441,Gemcitabine
,12586808,Dwell time,Dwell time was 2 hours.,Intravesical gemcitabine therapy for superficial transitional cell carcinoma of the bladder: a phase I and pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12586808/),h,2,210164,DB00441,Gemcitabine
,30138704,drug,"The drug tumor accumulation ratio in the l-Gem group relative to the free gemcitabine group was 9.9 at 36 h, while the tumor AUC ratio was 15.8.",Poly (l-glutamic acid)-g-methoxy poly (ethylene glycol)-gemcitabine conjugate improves the anticancer efficacy of gemcitabine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30138704/),,9.9,211029,DB00441,Gemcitabine
,30138704,tumor accumulation ratio,"The drug tumor accumulation ratio in the l-Gem group relative to the free gemcitabine group was 9.9 at 36 h, while the tumor AUC ratio was 15.8.",Poly (l-glutamic acid)-g-methoxy poly (ethylene glycol)-gemcitabine conjugate improves the anticancer efficacy of gemcitabine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30138704/),,9.9,211030,DB00441,Gemcitabine
,30138704,tumor AUC ratio,"The drug tumor accumulation ratio in the l-Gem group relative to the free gemcitabine group was 9.9 at 36 h, while the tumor AUC ratio was 15.8.",Poly (l-glutamic acid)-g-methoxy poly (ethylene glycol)-gemcitabine conjugate improves the anticancer efficacy of gemcitabine. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30138704/),,15.8,211031,DB00441,Gemcitabine
,15986033,MTD,Toxicities were mild or moderate; the only patient treated at 7000 mg m(-2) died because of toxicity; therefore; the MTD was established at 6500 mg m(-2).,Prolonged fixed dose rate infusion of gemcitabine with autologous haemopoietic support in advanced pancreatic adenocarcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15986033/),mg,6500,211505,DB00441,Gemcitabine
,15986033,overall response rate,The overall response rate was 22.2%.,Prolonged fixed dose rate infusion of gemcitabine with autologous haemopoietic support in advanced pancreatic adenocarcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15986033/),%,22.2,211506,DB00441,Gemcitabine
,15447994,combined response rate,"Fourteen of 39 evaluable patients in the original cohort had a response rate (1 complete response and 13 partial responses; response, 36%), whereas 2 of 9 evaluable patients in the expanded cohort experienced partial response (combined response rate, 33%).","A phase I/II study of LY900003, an antisense inhibitor of protein kinase C-alpha, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15447994/),%,33,212245,DB00441,Gemcitabine
,15447994,time to treatment failure,"The median time to treatment failure was 3.9 months, whereas the median time response to progression for the 48 patients with evaluable response was 4.4 months (confidence interval, 3.5-5.5 months).","A phase I/II study of LY900003, an antisense inhibitor of protein kinase C-alpha, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15447994/),month,3.9,212246,DB00441,Gemcitabine
,15447994,time response to progression,"The median time to treatment failure was 3.9 months, whereas the median time response to progression for the 48 patients with evaluable response was 4.4 months (confidence interval, 3.5-5.5 months).","A phase I/II study of LY900003, an antisense inhibitor of protein kinase C-alpha, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15447994/),month,4.4,212247,DB00441,Gemcitabine
,15447994,median survival time,Intent to treat median survival time was 8.9 months.,"A phase I/II study of LY900003, an antisense inhibitor of protein kinase C-alpha, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15447994/),month,8.9,212248,DB00441,Gemcitabine
,10561275,area under the concentration-time curve [AUC],"Gemcitabine did not influence paclitaxel pharmacokinetics at 150 and 200 mg/m(2) (area under the concentration-time curve [AUC], 7.7 and 8.8 micromol/ L. h, respectively; maximum plasma concentration [C(max)], 3.2 and 4.0 micromol/L, respectively), and paclitaxel did not influence that of gemcitabine (C(max), 30 +/- 3 micromol/L) and 2',2'-difluorodeoxyuridine.",Gemcitabine and paclitaxel: pharmacokinetic and pharmacodynamic interactions in patients with non-small-cell lung cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10561275/),[μM] / [h·l],7.7,213912,DB00441,Gemcitabine
,10561275,area under the concentration-time curve [AUC],"Gemcitabine did not influence paclitaxel pharmacokinetics at 150 and 200 mg/m(2) (area under the concentration-time curve [AUC], 7.7 and 8.8 micromol/ L. h, respectively; maximum plasma concentration [C(max)], 3.2 and 4.0 micromol/L, respectively), and paclitaxel did not influence that of gemcitabine (C(max), 30 +/- 3 micromol/L) and 2',2'-difluorodeoxyuridine.",Gemcitabine and paclitaxel: pharmacokinetic and pharmacodynamic interactions in patients with non-small-cell lung cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10561275/),[μM] / [h·l],8.8,213913,DB00441,Gemcitabine
,10561275,maximum plasma concentration [C(max)],"Gemcitabine did not influence paclitaxel pharmacokinetics at 150 and 200 mg/m(2) (area under the concentration-time curve [AUC], 7.7 and 8.8 micromol/ L. h, respectively; maximum plasma concentration [C(max)], 3.2 and 4.0 micromol/L, respectively), and paclitaxel did not influence that of gemcitabine (C(max), 30 +/- 3 micromol/L) and 2',2'-difluorodeoxyuridine.",Gemcitabine and paclitaxel: pharmacokinetic and pharmacodynamic interactions in patients with non-small-cell lung cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10561275/),[μM] / [l],3.2,213914,DB00441,Gemcitabine
,10561275,maximum plasma concentration [C(max)],"Gemcitabine did not influence paclitaxel pharmacokinetics at 150 and 200 mg/m(2) (area under the concentration-time curve [AUC], 7.7 and 8.8 micromol/ L. h, respectively; maximum plasma concentration [C(max)], 3.2 and 4.0 micromol/L, respectively), and paclitaxel did not influence that of gemcitabine (C(max), 30 +/- 3 micromol/L) and 2',2'-difluorodeoxyuridine.",Gemcitabine and paclitaxel: pharmacokinetic and pharmacodynamic interactions in patients with non-small-cell lung cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10561275/),[μM] / [l],4.0,213915,DB00441,Gemcitabine
,10561275,C(max),"Gemcitabine did not influence paclitaxel pharmacokinetics at 150 and 200 mg/m(2) (area under the concentration-time curve [AUC], 7.7 and 8.8 micromol/ L. h, respectively; maximum plasma concentration [C(max)], 3.2 and 4.0 micromol/L, respectively), and paclitaxel did not influence that of gemcitabine (C(max), 30 +/- 3 micromol/L) and 2',2'-difluorodeoxyuridine.",Gemcitabine and paclitaxel: pharmacokinetic and pharmacodynamic interactions in patients with non-small-cell lung cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10561275/),[μM] / [l],30,213916,DB00441,Gemcitabine
,10561275,C(max),"Paclitaxel, however, dose-dependently increased the C(max) of gemcitabine triphosphate (dFdCTP), the active metabolite of gemcitabine, from 55 +/- 10 to 106 +/- 16 pmol/10(6) cells.( )No significant difference in the AUC of dFdCTP was observed.",Gemcitabine and paclitaxel: pharmacokinetic and pharmacodynamic interactions in patients with non-small-cell lung cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10561275/),[pM] / [10(6)·cells],55,213917,DB00441,Gemcitabine
,10561275,C(max),"Paclitaxel, however, dose-dependently increased the C(max) of gemcitabine triphosphate (dFdCTP), the active metabolite of gemcitabine, from 55 +/- 10 to 106 +/- 16 pmol/10(6) cells.( )No significant difference in the AUC of dFdCTP was observed.",Gemcitabine and paclitaxel: pharmacokinetic and pharmacodynamic interactions in patients with non-small-cell lung cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10561275/),[pM] / [10(6)·cells],106,213918,DB00441,Gemcitabine
,16736150,Response rate,"Response rate in 23 patients was 4% (95% CI: 0-24%), and in 8 of 11 patients stable disease lasted > 6 months.",Phase II study with the combination of gemcitabine and DTIC in patients with advanced soft tissue sarcomas. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16736150/),%,4,214233,DB00441,Gemcitabine
,16736150,Progression-free rate (PFR),"Progression-free rate (PFR) at 3 and 6 months was, respectively, 48 and 28%, and median overall survival 37 weeks.",Phase II study with the combination of gemcitabine and DTIC in patients with advanced soft tissue sarcomas. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16736150/),%,48,214234,DB00441,Gemcitabine
,16736150,Progression-free rate (PFR),"Progression-free rate (PFR) at 3 and 6 months was, respectively, 48 and 28%, and median overall survival 37 weeks.",Phase II study with the combination of gemcitabine and DTIC in patients with advanced soft tissue sarcomas. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16736150/),%,28,214235,DB00441,Gemcitabine
,16736150,overall survival,"Progression-free rate (PFR) at 3 and 6 months was, respectively, 48 and 28%, and median overall survival 37 weeks.",Phase II study with the combination of gemcitabine and DTIC in patients with advanced soft tissue sarcomas. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16736150/),weeks,37,214236,DB00441,Gemcitabine
,18432290,Absolute bioavailability,"Absolute bioavailability of gemcitabine after i.t.t. and i.t.o. administration was 91% and 65%, respectively.",Pulmonary gemcitabine delivery for treating lung cancer: pharmacokinetics and acute lung injury aspects in animals. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18432290/),%,91,215096,DB00441,Gemcitabine
,18432290,Absolute bioavailability,"Absolute bioavailability of gemcitabine after i.t.t. and i.t.o. administration was 91% and 65%, respectively.",Pulmonary gemcitabine delivery for treating lung cancer: pharmacokinetics and acute lung injury aspects in animals. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18432290/),%,65,215097,DB00441,Gemcitabine
,30632800,polydispersity index,"Optimized nanoparticles showed a particle size of 258 ± 2.4 nm, polydispersity index of 0.32 ± 0.052, and zeta potential of -12.5 mV.","Co-delivery of gemcitabine and simvastatin through PLGA polymeric nanoparticles for the treatment of pancreatic cancer: in-vitro characterization, cellular uptake, and pharmacokinetic studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30632800/),,0.32,216759,DB00441,Gemcitabine
,30632800,zeta potential,"Optimized nanoparticles showed a particle size of 258 ± 2.4 nm, polydispersity index of 0.32 ± 0.052, and zeta potential of -12.5 mV.","Co-delivery of gemcitabine and simvastatin through PLGA polymeric nanoparticles for the treatment of pancreatic cancer: in-vitro characterization, cellular uptake, and pharmacokinetic studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30632800/),mv,-12.5,216760,DB00441,Gemcitabine
,30632800,entrapment efficiency,"The entrapment efficiency of GM and SV in the nanoparticles was 38.5 ± 4.5% and 72.2 ± 5.6%, respectively.","Co-delivery of gemcitabine and simvastatin through PLGA polymeric nanoparticles for the treatment of pancreatic cancer: in-vitro characterization, cellular uptake, and pharmacokinetic studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30632800/),%,38.5,216761,DB00441,Gemcitabine
,30632800,entrapment efficiency,"The entrapment efficiency of GM and SV in the nanoparticles was 38.5 ± 4.5% and 72.2 ± 5.6%, respectively.","Co-delivery of gemcitabine and simvastatin through PLGA polymeric nanoparticles for the treatment of pancreatic cancer: in-vitro characterization, cellular uptake, and pharmacokinetic studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30632800/),%,72.2,216762,DB00441,Gemcitabine
,23892959,maximum tolerated dose,"The maximum tolerated dose of AZD7762 in combination with gemcitabine, 1,000 mg/m(2) was determined as 21 mg in Japanese patients.","Phase I, dose-escalation study of AZD7762 alone and in combination with gemcitabine in Japanese patients with advanced solid tumours. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23892959/),mg,21,217025,DB00441,Gemcitabine
,28451833,progression-free survival,"The clinical response [complete response (CR), partial response (PR), or stable disease] rate was 42.9%, and the median progression-free survival was 64 days; no CR/PR were achieved.",Phase 1b study of galunisertib in combination with gemcitabine in Japanese patients with metastatic or locally advanced pancreatic cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28451833/),d,64,218461,DB00441,Gemcitabine
,17717833,Cmax,The mean value of Cmax in 21 eligible patients was(4.95+/-2.42) microg *ml(-1).,[Peak concentration of gemcitabine at fixed-dose-rate and its hematological toxicity profile]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17717833/),[μg] / [ml],4.95,218554,DB00441,Gemcitabine
,17717833,percentage,"The mean percentages of reduction of WBC, NEC, PLTC and Hb of 21 patients were (38.3+/-38.1)%, (31.3+/-73.6)%, (31.8+/-53.5)% and (12.0+/-12.2)%, respectively.",[Peak concentration of gemcitabine at fixed-dose-rate and its hematological toxicity profile]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17717833/),%,38,218555,DB00441,Gemcitabine
,17717833,percentage,"The mean percentages of reduction of WBC, NEC, PLTC and Hb of 21 patients were (38.3+/-38.1)%, (31.3+/-73.6)%, (31.8+/-53.5)% and (12.0+/-12.2)%, respectively.",[Peak concentration of gemcitabine at fixed-dose-rate and its hematological toxicity profile]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17717833/),%,31.3,218556,DB00441,Gemcitabine
,17717833,percentage,"The mean percentages of reduction of WBC, NEC, PLTC and Hb of 21 patients were (38.3+/-38.1)%, (31.3+/-73.6)%, (31.8+/-53.5)% and (12.0+/-12.2)%, respectively.",[Peak concentration of gemcitabine at fixed-dose-rate and its hematological toxicity profile]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17717833/),%,31.8,218557,DB00441,Gemcitabine
,17717833,percentage,"The mean percentages of reduction of WBC, NEC, PLTC and Hb of 21 patients were (38.3+/-38.1)%, (31.3+/-73.6)%, (31.8+/-53.5)% and (12.0+/-12.2)%, respectively.",[Peak concentration of gemcitabine at fixed-dose-rate and its hematological toxicity profile]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17717833/),%,12.0,218558,DB00441,Gemcitabine
,1998982,steady-state dFdC levels,"The rate of dFdCTP accumulation and the peak cellular concentration were highest at a dose rate of 350 mg/m2 per 30 min, during which steady-state dFdC levels of 15-20 microM were achieved in plasma.","Saturation of 2',2'-difluorodeoxycytidine 5'-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1998982/),μM,15-20,221061,DB00441,Gemcitabine
,34417914,overall response rate (ORR),The overall response rate (ORR) was 23.1% and disease control rate (DCR) 74.4%.,"A multicenter phase 1/2 study investigating the safety, pharmacokinetics, pharmacodynamics and efficacy of a small molecule antimetabolite, RX-3117, plus nab-paclitaxel in pancreatic adenocarcinoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34417914/),%,23.1,223081,DB00441,Gemcitabine
,32948918,AUC,"In vivo carboplatin exposure was not significantly affected by iohexol co-administration (platinum AUC combination vs alone: plasma ultrafiltrate 1,791 vs 1920 µg/mL min; kidney 8367 vs 9757 µg/g min; bone marrow 12.7 vs 12.7 µg/mg-protein min).","Evaluation of the pharmacokinetic drug-drug interaction potential of iohexol, a renal filtration marker. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32948918/),[μg] / [min·ml],"1,791",227126,DB00441,Gemcitabine
,32948918,AUC,"In vivo carboplatin exposure was not significantly affected by iohexol co-administration (platinum AUC combination vs alone: plasma ultrafiltrate 1,791 vs 1920 µg/mL min; kidney 8367 vs 9757 µg/g min; bone marrow 12.7 vs 12.7 µg/mg-protein min).","Evaluation of the pharmacokinetic drug-drug interaction potential of iohexol, a renal filtration marker. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32948918/),[μg] / [min·ml],1920,227127,DB00441,Gemcitabine
,32948918,AUC,"In vivo carboplatin exposure was not significantly affected by iohexol co-administration (platinum AUC combination vs alone: plasma ultrafiltrate 1,791 vs 1920 µg/mL min; kidney 8367 vs 9757 µg/g min; bone marrow 12.7 vs 12.7 µg/mg-protein min).","Evaluation of the pharmacokinetic drug-drug interaction potential of iohexol, a renal filtration marker. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32948918/),[μg] / [g·min],8367,227128,DB00441,Gemcitabine
,32948918,AUC,"In vivo carboplatin exposure was not significantly affected by iohexol co-administration (platinum AUC combination vs alone: plasma ultrafiltrate 1,791 vs 1920 µg/mL min; kidney 8367 vs 9757 µg/g min; bone marrow 12.7 vs 12.7 µg/mg-protein min).","Evaluation of the pharmacokinetic drug-drug interaction potential of iohexol, a renal filtration marker. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32948918/),[μg] / [g·min],9757,227129,DB00441,Gemcitabine
,32948918,AUC,"In vivo carboplatin exposure was not significantly affected by iohexol co-administration (platinum AUC combination vs alone: plasma ultrafiltrate 1,791 vs 1920 µg/mL min; kidney 8367 vs 9757 µg/g min; bone marrow 12.7 vs 12.7 µg/mg-protein min).","Evaluation of the pharmacokinetic drug-drug interaction potential of iohexol, a renal filtration marker. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32948918/),[μg] / [mg-·min],12.7,227130,DB00441,Gemcitabine
,32948918,plasma ultrafiltrate,"In vivo carboplatin exposure was not significantly affected by iohexol co-administration (platinum AUC combination vs alone: plasma ultrafiltrate 1,791 vs 1920 µg/mL min; kidney 8367 vs 9757 µg/g min; bone marrow 12.7 vs 12.7 µg/mg-protein min).","Evaluation of the pharmacokinetic drug-drug interaction potential of iohexol, a renal filtration marker. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32948918/),[μg] / [min·ml],"1,791",227131,DB00441,Gemcitabine
,32948918,plasma ultrafiltrate,"In vivo carboplatin exposure was not significantly affected by iohexol co-administration (platinum AUC combination vs alone: plasma ultrafiltrate 1,791 vs 1920 µg/mL min; kidney 8367 vs 9757 µg/g min; bone marrow 12.7 vs 12.7 µg/mg-protein min).","Evaluation of the pharmacokinetic drug-drug interaction potential of iohexol, a renal filtration marker. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32948918/),[μg] / [min·ml],1920,227132,DB00441,Gemcitabine
,32948918,kidney,"In vivo carboplatin exposure was not significantly affected by iohexol co-administration (platinum AUC combination vs alone: plasma ultrafiltrate 1,791 vs 1920 µg/mL min; kidney 8367 vs 9757 µg/g min; bone marrow 12.7 vs 12.7 µg/mg-protein min).","Evaluation of the pharmacokinetic drug-drug interaction potential of iohexol, a renal filtration marker. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32948918/),[μg] / [g·min],8367,227133,DB00441,Gemcitabine
,32948918,kidney,"In vivo carboplatin exposure was not significantly affected by iohexol co-administration (platinum AUC combination vs alone: plasma ultrafiltrate 1,791 vs 1920 µg/mL min; kidney 8367 vs 9757 µg/g min; bone marrow 12.7 vs 12.7 µg/mg-protein min).","Evaluation of the pharmacokinetic drug-drug interaction potential of iohexol, a renal filtration marker. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32948918/),[μg] / [g·min],9757,227134,DB00441,Gemcitabine
,32948918,bone marrow,"In vivo carboplatin exposure was not significantly affected by iohexol co-administration (platinum AUC combination vs alone: plasma ultrafiltrate 1,791 vs 1920 µg/mL min; kidney 8367 vs 9757 µg/g min; bone marrow 12.7 vs 12.7 µg/mg-protein min).","Evaluation of the pharmacokinetic drug-drug interaction potential of iohexol, a renal filtration marker. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32948918/),[μg] / [mg-·min],12.7,227135,DB00441,Gemcitabine
,32948918,microsomal metabolism,Paclitaxel microsomal metabolism was not impacted (combination vs alone: 6-α-OH-paclitaxel 38.3 versus 39.4 ng/mL/60 min; 3-p-OH-paclitaxel 26.2 versus 27.7 ng/mL/60 min).,"Evaluation of the pharmacokinetic drug-drug interaction potential of iohexol, a renal filtration marker. ",fm enzyme-Q5,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32948918/),[ng] / [60·min·ml],38.3,227136,DB00441,Gemcitabine
,32948918,microsomal metabolism,Paclitaxel microsomal metabolism was not impacted (combination vs alone: 6-α-OH-paclitaxel 38.3 versus 39.4 ng/mL/60 min; 3-p-OH-paclitaxel 26.2 versus 27.7 ng/mL/60 min).,"Evaluation of the pharmacokinetic drug-drug interaction potential of iohexol, a renal filtration marker. ",fm enzyme-Q5,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32948918/),[ng] / [60·min·ml],39.4,227137,DB00441,Gemcitabine
,32948918,microsomal metabolism,Paclitaxel microsomal metabolism was not impacted (combination vs alone: 6-α-OH-paclitaxel 38.3 versus 39.4 ng/mL/60 min; 3-p-OH-paclitaxel 26.2 versus 27.7 ng/mL/60 min).,"Evaluation of the pharmacokinetic drug-drug interaction potential of iohexol, a renal filtration marker. ",fm enzyme-Q5,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32948918/),[ng] / [60·min·ml],26.2,227138,DB00441,Gemcitabine
,32948918,microsomal metabolism,Paclitaxel microsomal metabolism was not impacted (combination vs alone: 6-α-OH-paclitaxel 38.3 versus 39.4 ng/mL/60 min; 3-p-OH-paclitaxel 26.2 versus 27.7 ng/mL/60 min).,"Evaluation of the pharmacokinetic drug-drug interaction potential of iohexol, a renal filtration marker. ",fm enzyme-Q5,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32948918/),[ng] / [60·min·ml],27.7,227139,DB00441,Gemcitabine
,32948918,AUC,Gemcitabine human cytosolic elimination was not impacted (AUC combination vs gemcitabine alone: dFdU 24.1 versus 23.7 µg/mL/30 min).,"Evaluation of the pharmacokinetic drug-drug interaction potential of iohexol, a renal filtration marker. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32948918/),[μg] / [30·min·ml],24.1,227140,DB00441,Gemcitabine
,32948918,AUC,Gemcitabine human cytosolic elimination was not impacted (AUC combination vs gemcitabine alone: dFdU 24.1 versus 23.7 µg/mL/30 min).,"Evaluation of the pharmacokinetic drug-drug interaction potential of iohexol, a renal filtration marker. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32948918/),[μg] / [30·min·ml],23.7,227141,DB00441,Gemcitabine
,17542057,Qualified response rate,Qualified response rate in our study was 33.3% for standard arm and 50% for FDR arm.,"Comparison of pharmacokinetics, efficacy and toxicity profile of gemcitabine using two different administration regimens in Chinese patients with non-small-cell lung cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17542057/),%,33.3,227252,DB00441,Gemcitabine
,17542057,Qualified response rate,Qualified response rate in our study was 33.3% for standard arm and 50% for FDR arm.,"Comparison of pharmacokinetics, efficacy and toxicity profile of gemcitabine using two different administration regimens in Chinese patients with non-small-cell lung cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17542057/),%,50,227253,DB00441,Gemcitabine
,25663325,plasma clearance,"Both pre and post-inserted PSL resulted in significant reductions (p < 0.05) in plasma clearance (58.6 and 38.4 ml/h/kg), increases in the area-under-the-concentration-time curve (56.9 and 87.1 μM · h) and half-life (6.1 and 6.2 h) compared to gemcitabine solution (152.9 ml/h/kg, 22.2 μM · h and 1.4 h).","Enhanced pH-Responsiveness, Cellular Trafficking, Cytotoxicity and Long-circulation of PEGylated Liposomes with Post-insertion Technique Using Gemcitabine as a Model Drug. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25663325/),[ml] / [h·kg],58.6,227759,DB00441,Gemcitabine
,25663325,plasma clearance,"Both pre and post-inserted PSL resulted in significant reductions (p < 0.05) in plasma clearance (58.6 and 38.4 ml/h/kg), increases in the area-under-the-concentration-time curve (56.9 and 87.1 μM · h) and half-life (6.1 and 6.2 h) compared to gemcitabine solution (152.9 ml/h/kg, 22.2 μM · h and 1.4 h).","Enhanced pH-Responsiveness, Cellular Trafficking, Cytotoxicity and Long-circulation of PEGylated Liposomes with Post-insertion Technique Using Gemcitabine as a Model Drug. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25663325/),[ml] / [h·kg],38.4,227760,DB00441,Gemcitabine
,25663325,area-under-the-concentration-time curve,"Both pre and post-inserted PSL resulted in significant reductions (p < 0.05) in plasma clearance (58.6 and 38.4 ml/h/kg), increases in the area-under-the-concentration-time curve (56.9 and 87.1 μM · h) and half-life (6.1 and 6.2 h) compared to gemcitabine solution (152.9 ml/h/kg, 22.2 μM · h and 1.4 h).","Enhanced pH-Responsiveness, Cellular Trafficking, Cytotoxicity and Long-circulation of PEGylated Liposomes with Post-insertion Technique Using Gemcitabine as a Model Drug. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25663325/),h·μM,56.9,227761,DB00441,Gemcitabine
,25663325,area-under-the-concentration-time curve,"Both pre and post-inserted PSL resulted in significant reductions (p < 0.05) in plasma clearance (58.6 and 38.4 ml/h/kg), increases in the area-under-the-concentration-time curve (56.9 and 87.1 μM · h) and half-life (6.1 and 6.2 h) compared to gemcitabine solution (152.9 ml/h/kg, 22.2 μM · h and 1.4 h).","Enhanced pH-Responsiveness, Cellular Trafficking, Cytotoxicity and Long-circulation of PEGylated Liposomes with Post-insertion Technique Using Gemcitabine as a Model Drug. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25663325/),h·μM,87.1,227762,DB00441,Gemcitabine
,25663325,half-life,"Both pre and post-inserted PSL resulted in significant reductions (p < 0.05) in plasma clearance (58.6 and 38.4 ml/h/kg), increases in the area-under-the-concentration-time curve (56.9 and 87.1 μM · h) and half-life (6.1 and 6.2 h) compared to gemcitabine solution (152.9 ml/h/kg, 22.2 μM · h and 1.4 h).","Enhanced pH-Responsiveness, Cellular Trafficking, Cytotoxicity and Long-circulation of PEGylated Liposomes with Post-insertion Technique Using Gemcitabine as a Model Drug. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25663325/),h,6.1,227763,DB00441,Gemcitabine
,25663325,half-life,"Both pre and post-inserted PSL resulted in significant reductions (p < 0.05) in plasma clearance (58.6 and 38.4 ml/h/kg), increases in the area-under-the-concentration-time curve (56.9 and 87.1 μM · h) and half-life (6.1 and 6.2 h) compared to gemcitabine solution (152.9 ml/h/kg, 22.2 μM · h and 1.4 h).","Enhanced pH-Responsiveness, Cellular Trafficking, Cytotoxicity and Long-circulation of PEGylated Liposomes with Post-insertion Technique Using Gemcitabine as a Model Drug. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25663325/),h,6.2,227764,DB00441,Gemcitabine
,25663325,half-life,"Both pre and post-inserted PSL resulted in significant reductions (p < 0.05) in plasma clearance (58.6 and 38.4 ml/h/kg), increases in the area-under-the-concentration-time curve (56.9 and 87.1 μM · h) and half-life (6.1 and 6.2 h) compared to gemcitabine solution (152.9 ml/h/kg, 22.2 μM · h and 1.4 h).","Enhanced pH-Responsiveness, Cellular Trafficking, Cytotoxicity and Long-circulation of PEGylated Liposomes with Post-insertion Technique Using Gemcitabine as a Model Drug. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25663325/),[ml] / [h·kg],152.9,227765,DB00441,Gemcitabine
,25663325,half-life,"Both pre and post-inserted PSL resulted in significant reductions (p < 0.05) in plasma clearance (58.6 and 38.4 ml/h/kg), increases in the area-under-the-concentration-time curve (56.9 and 87.1 μM · h) and half-life (6.1 and 6.2 h) compared to gemcitabine solution (152.9 ml/h/kg, 22.2 μM · h and 1.4 h).","Enhanced pH-Responsiveness, Cellular Trafficking, Cytotoxicity and Long-circulation of PEGylated Liposomes with Post-insertion Technique Using Gemcitabine as a Model Drug. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25663325/),h·μM,22.2,227766,DB00441,Gemcitabine
,25663325,half-life,"Both pre and post-inserted PSL resulted in significant reductions (p < 0.05) in plasma clearance (58.6 and 38.4 ml/h/kg), increases in the area-under-the-concentration-time curve (56.9 and 87.1 μM · h) and half-life (6.1 and 6.2 h) compared to gemcitabine solution (152.9 ml/h/kg, 22.2 μM · h and 1.4 h).","Enhanced pH-Responsiveness, Cellular Trafficking, Cytotoxicity and Long-circulation of PEGylated Liposomes with Post-insertion Technique Using Gemcitabine as a Model Drug. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25663325/),h,1.4,227767,DB00441,Gemcitabine
,27293990,clearance,"In mice, Zt/g4-DM1 pharmacokinetics in the linear dose range fitted into a two-compartment model with clearance in 0.21 ml/day/kg and terminal half-life at 6.05 days.",Therapeutic evaluation of monoclonal antibody-maytansinoid conjugate as a model of RON-targeted drug delivery for pancreatic cancer treatment. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27293990/),[ml] / [d·kg],0.21,227929,DB00441,Gemcitabine
,27293990,terminal half-life,"In mice, Zt/g4-DM1 pharmacokinetics in the linear dose range fitted into a two-compartment model with clearance in 0.21 ml/day/kg and terminal half-life at 6.05 days.",Therapeutic evaluation of monoclonal antibody-maytansinoid conjugate as a model of RON-targeted drug delivery for pancreatic cancer treatment. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27293990/),d,6.05,227930,DB00441,Gemcitabine
,15197207,clearance,"Mean gemcitabine clearance and half-life values were 2140 mL/min/m(2) and 13.7 minutes, respectively.",Phase I trial and pharmacokinetics of gemcitabine in children with advanced solid tumors. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15197207/),[min·ml] / [m(2],2140,228094,DB00441,Gemcitabine
,15197207,half-life,"Mean gemcitabine clearance and half-life values were 2140 mL/min/m(2) and 13.7 minutes, respectively.",Phase I trial and pharmacokinetics of gemcitabine in children with advanced solid tumors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15197207/),min,13.7,228095,DB00441,Gemcitabine
,11561783,IC50,"All PBR-GEM conjugates demonstrated appreciable receptor binding affinity and cytotoxicity with mean IC50 values ranging from 248 to 376 nM and 5.6 to 29.1 nM, respectively.",Targeted delivery of a peripheral benzodiazepine receptor ligand-gemcitabine conjugate to brain tumors in a xenograft model. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11561783/),nM,248 to 376,228459,DB00441,Gemcitabine
,11561783,IC50,"All PBR-GEM conjugates demonstrated appreciable receptor binding affinity and cytotoxicity with mean IC50 values ranging from 248 to 376 nM and 5.6 to 29.1 nM, respectively.",Targeted delivery of a peripheral benzodiazepine receptor ligand-gemcitabine conjugate to brain tumors in a xenograft model. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11561783/),nM,5.6 to 29.1,228460,DB00441,Gemcitabine
,11561783,IC50,The cytotoxicity of GEM was comparable with a mean IC50 value of 5.9 nM.,Targeted delivery of a peripheral benzodiazepine receptor ligand-gemcitabine conjugate to brain tumors in a xenograft model. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11561783/),nM,5.9,228461,DB00441,Gemcitabine
,11561783,total clearance,"Following administration of single 8 mg/kg doses of PK11195-GEM to rats (n=4), PK11195-GEM had a mean total clearance of 126.3 +/- 29.6 ml/min per kg, and a volume of distribution at steady-state of 1,261.9 +/- 31.05 ml/kg that resulted in a very short elimination half-life of 16.1 +/- 5.8 min.",Targeted delivery of a peripheral benzodiazepine receptor ligand-gemcitabine conjugate to brain tumors in a xenograft model. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11561783/),[ml] / [kg·min],126.3,228462,DB00441,Gemcitabine
,11561783,volume of distribution at steady-state,"Following administration of single 8 mg/kg doses of PK11195-GEM to rats (n=4), PK11195-GEM had a mean total clearance of 126.3 +/- 29.6 ml/min per kg, and a volume of distribution at steady-state of 1,261.9 +/- 31.05 ml/kg that resulted in a very short elimination half-life of 16.1 +/- 5.8 min.",Targeted delivery of a peripheral benzodiazepine receptor ligand-gemcitabine conjugate to brain tumors in a xenograft model. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11561783/),[ml] / [kg],"1,261.9",228463,DB00441,Gemcitabine
,11561783,elimination half-life,"Following administration of single 8 mg/kg doses of PK11195-GEM to rats (n=4), PK11195-GEM had a mean total clearance of 126.3 +/- 29.6 ml/min per kg, and a volume of distribution at steady-state of 1,261.9 +/- 31.05 ml/kg that resulted in a very short elimination half-life of 16.1 +/- 5.8 min.",Targeted delivery of a peripheral benzodiazepine receptor ligand-gemcitabine conjugate to brain tumors in a xenograft model. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11561783/),min,16.1,228464,DB00441,Gemcitabine
,11561783,volume of distribution,"In comparison GEM had a similar volume of distribution (993.8 +/- 131.6 ml/kg), reduced clearance (3.4 +/- 0.8 ml/ min per kg), and longer half-life (235.6 +/- 26.7 min).",Targeted delivery of a peripheral benzodiazepine receptor ligand-gemcitabine conjugate to brain tumors in a xenograft model. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11561783/),[ml] / [kg],993.8,228465,DB00441,Gemcitabine
,11561783,clearance,"In comparison GEM had a similar volume of distribution (993.8 +/- 131.6 ml/kg), reduced clearance (3.4 +/- 0.8 ml/ min per kg), and longer half-life (235.6 +/- 26.7 min).",Targeted delivery of a peripheral benzodiazepine receptor ligand-gemcitabine conjugate to brain tumors in a xenograft model. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11561783/),[ml] / [kg·min],3.4,228466,DB00441,Gemcitabine
,11561783,half-life,"In comparison GEM had a similar volume of distribution (993.8 +/- 131.6 ml/kg), reduced clearance (3.4 +/- 0.8 ml/ min per kg), and longer half-life (235.6 +/- 26.7 min).",Targeted delivery of a peripheral benzodiazepine receptor ligand-gemcitabine conjugate to brain tumors in a xenograft model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11561783/),min,235.6,228467,DB00441,Gemcitabine
,11561783,steady-state tumor/plasma,"In nude rats bearing intracerebral tumors, mean steady-state tumor/plasma, tumor/right brain, and tumor/left brain PK 11195-GEM concentration ratios were 1.75 +/- 0.46, 5.49 +/- 5.2, and 9.96 +/- 3.2, respectively.",Targeted delivery of a peripheral benzodiazepine receptor ligand-gemcitabine conjugate to brain tumors in a xenograft model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11561783/),,1.75,228468,DB00441,Gemcitabine
,11561783,concentration ratios,"In nude rats bearing intracerebral tumors, mean steady-state tumor/plasma, tumor/right brain, and tumor/left brain PK 11195-GEM concentration ratios were 1.75 +/- 0.46, 5.49 +/- 5.2, and 9.96 +/- 3.2, respectively.",Targeted delivery of a peripheral benzodiazepine receptor ligand-gemcitabine conjugate to brain tumors in a xenograft model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11561783/),,1.75,228469,DB00441,Gemcitabine
,11561783,concentration ratios,"In nude rats bearing intracerebral tumors, mean steady-state tumor/plasma, tumor/right brain, and tumor/left brain PK 11195-GEM concentration ratios were 1.75 +/- 0.46, 5.49 +/- 5.2, and 9.96 +/- 3.2, respectively.",Targeted delivery of a peripheral benzodiazepine receptor ligand-gemcitabine conjugate to brain tumors in a xenograft model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11561783/),,5.49,228470,DB00441,Gemcitabine
,11561783,concentration ratios,"In nude rats bearing intracerebral tumors, mean steady-state tumor/plasma, tumor/right brain, and tumor/left brain PK 11195-GEM concentration ratios were 1.75 +/- 0.46, 5.49 +/- 5.2, and 9.96 +/- 3.2, respectively.",Targeted delivery of a peripheral benzodiazepine receptor ligand-gemcitabine conjugate to brain tumors in a xenograft model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11561783/),,9.96,228471,DB00441,Gemcitabine
,26964546,DL,The highest DL of 4.5 ± 0.1% was achieved for gemcitabine in PSL with 145 ± 5 nm diameter.,Development of Long-Circulating pH-Sensitive Liposomes to Circumvent Gemcitabine Resistance in Pancreatic Cancer Cells. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26964546/),%,4.5,229032,DB00441,Gemcitabine
,26964546,IC50,"The IC50 (48 h) of PSL (DL 0.5 and 4.5%) and non pH-sensitive liposomes (NPSL, DL 4.2%) were 1.1 ± 0.1, 0.7 ± 0.1 and 37.0 ± 7.5 μM, respectively.",Development of Long-Circulating pH-Sensitive Liposomes to Circumvent Gemcitabine Resistance in Pancreatic Cancer Cells. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26964546/),μM,1.1,229033,DB00441,Gemcitabine
,26964546,IC50,"The IC50 (48 h) of PSL (DL 0.5 and 4.5%) and non pH-sensitive liposomes (NPSL, DL 4.2%) were 1.1 ± 0.1, 0.7 ± 0.1 and 37.0 ± 7.5 μM, respectively.",Development of Long-Circulating pH-Sensitive Liposomes to Circumvent Gemcitabine Resistance in Pancreatic Cancer Cells. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26964546/),μM,0.7,229034,DB00441,Gemcitabine
,26964546,IC50,"The IC50 (48 h) of PSL (DL 0.5 and 4.5%) and non pH-sensitive liposomes (NPSL, DL 4.2%) were 1.1 ± 0.1, 0.7 ± 0.1 and 37.0 ± 7.5 μM, respectively.",Development of Long-Circulating pH-Sensitive Liposomes to Circumvent Gemcitabine Resistance in Pancreatic Cancer Cells. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26964546/),μM,37.0,229035,DB00441,Gemcitabine
,26964546,elimination half-life,The PSL resulted in a 4.2-fold increase in its elimination half-life (6.2 h) compared to gemcitabine solution (1.4 h) in rats.,Development of Long-Circulating pH-Sensitive Liposomes to Circumvent Gemcitabine Resistance in Pancreatic Cancer Cells. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26964546/),h,6.2,229036,DB00441,Gemcitabine
,26964546,elimination half-life,The PSL resulted in a 4.2-fold increase in its elimination half-life (6.2 h) compared to gemcitabine solution (1.4 h) in rats.,Development of Long-Circulating pH-Sensitive Liposomes to Circumvent Gemcitabine Resistance in Pancreatic Cancer Cells. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26964546/),h,1.4,229037,DB00441,Gemcitabine
,20443002,terminal half-life,"THU, after 150 mg/kg taTHU i.v., had a 235-min terminal half-life and produced plasma THU concentrations >1 μg/mL, the concentration shown to inhibit CD, for 10 h.","Plasma pharmacokinetics and oral bioavailability of the 3,4,5,6-tetrahydrouridine (THU) prodrug, triacetyl-THU (taTHU), in mice. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20443002/),min,235,229048,DB00441,Gemcitabine
,20443002,half-life,"taTHU, at 150 mg/kg p.o., produced a concentration versus time profile with a plateau of approximately 10 μg/mL from 0.5-2 h, followed by a decline with a 122-min half-life.","Plasma pharmacokinetics and oral bioavailability of the 3,4,5,6-tetrahydrouridine (THU) prodrug, triacetyl-THU (taTHU), in mice. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20443002/),min,122,229049,DB00441,Gemcitabine
,20443002,availability,"The availability of THU after p.o. taTHU is 30%, when compared to the 20% achieved with p.o.","Plasma pharmacokinetics and oral bioavailability of the 3,4,5,6-tetrahydrouridine (THU) prodrug, triacetyl-THU (taTHU), in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20443002/),%,30,229050,DB00441,Gemcitabine
,20443002,availability,"The availability of THU after p.o. taTHU is 30%, when compared to the 20% achieved with p.o.","Plasma pharmacokinetics and oral bioavailability of the 3,4,5,6-tetrahydrouridine (THU) prodrug, triacetyl-THU (taTHU), in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20443002/),%,20,229051,DB00441,Gemcitabine
,21791058,MTD,The MTD of motesanib in combination with gemcitabine and erlotinib was 100 mg QD.,Safety and pharmacokinetics of motesanib in combination with gemcitabine and erlotinib for the treatment of solid tumors: a phase 1b study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21791058/),mg,100,229474,DB00441,Gemcitabine
,11551423,survival,"Median survival was 11.2 months (95% CI [8.3-13.2]), and the 1-year survival rate was 45%.","Dose-finding, pharmacokinetic and phase II study of docetaxel in combination with gemcitabine in patients with inoperable non-small cell lung cancer. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11551423/),month,11,231814,DB00441,Gemcitabine
,30844808,international normalized ratio,Target international normalized ratio (between 2.0-3.0) was achieved following PCI-27483 treatment.,"A Phase 2 Study of PCI-27483, a Factor VIIa Inhibitor in Combination with Gemcitabine for Advanced Pancreatic Cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30844808/),,2.0-3.0,232031,DB00441,Gemcitabine
,16340743,progression-free survival,"Median progression-free survival and overall survival were 5.5 and 9.5 months, respectively.",Gemcitabine and oxaliplatin in patients with pancreatic adenocarcinoma: clinical and pharmacokinetic data. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16340743/),month,5.5,232375,DB00441,Gemcitabine
,16340743,overall survival,"Median progression-free survival and overall survival were 5.5 and 9.5 months, respectively.",Gemcitabine and oxaliplatin in patients with pancreatic adenocarcinoma: clinical and pharmacokinetic data. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16340743/),month,9.5,232376,DB00441,Gemcitabine
,18594002,apparent half-life,The apparent half-life for the effect of gemcitabine was 7.67 weeks.,A pharmacodynamic model for the time course of tumor shrinkage by gemcitabine + carboplatin in non-small cell lung cancer patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18594002/),weeks,7.67,234257,DB00441,Gemcitabine
,18594002,tumor turnover time constant,The tumor turnover time constant was 21.8 week.cm.,A pharmacodynamic model for the time course of tumor shrinkage by gemcitabine + carboplatin in non-small cell lung cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18594002/),cm·week,21.8,234258,DB00441,Gemcitabine
,11976829,plasma AUC,"In the PK study, GemLip achieved a 35-fold higher plasma AUC (1680 mg x h/ml) than GemConv (47.6 mg x h/ml).",Change in pharmacokinetic and pharmacodynamic behavior of gemcitabine in human tumor xenografts upon entrapment in vesicular phospholipid gels. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11976829/),[h·mg] / [ml],1680,237233,DB00441,Gemcitabine
,11976829,plasma AUC,"In the PK study, GemLip achieved a 35-fold higher plasma AUC (1680 mg x h/ml) than GemConv (47.6 mg x h/ml).",Change in pharmacokinetic and pharmacodynamic behavior of gemcitabine in human tumor xenografts upon entrapment in vesicular phospholipid gels. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11976829/),[h·mg] / [ml],47.6,237234,DB00441,Gemcitabine
,11976829,serum half-lives,The serum half-lives were 0.15 h for free gemcitabine and 13.3 h for liposomal gemcitabine (6 mg/kg each i.v.).,Change in pharmacokinetic and pharmacodynamic behavior of gemcitabine in human tumor xenografts upon entrapment in vesicular phospholipid gels. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11976829/),h,0.15,237235,DB00441,Gemcitabine
,11976829,serum half-lives,The serum half-lives were 0.15 h for free gemcitabine and 13.3 h for liposomal gemcitabine (6 mg/kg each i.v.).,Change in pharmacokinetic and pharmacodynamic behavior of gemcitabine in human tumor xenografts upon entrapment in vesicular phospholipid gels. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11976829/),h,13.3,237236,DB00441,Gemcitabine
,17075318,(maximum) concentration,"The mean (maximum) concentration of gemcitabine on days 1 and 8 was 13.57 (+/-7.42) and 10.23 (+/-5.21) mg/l, respectively (P=0.28), and the mean half-life was 0.32 and 0.44 h, respectively (P=0.40).",Coadministration of oxaliplatin does not influence the pharmacokinetics of gemcitabine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17075318/),[mg] / [l],13.57,237543,DB00441,Gemcitabine
,17075318,(maximum) concentration,"The mean (maximum) concentration of gemcitabine on days 1 and 8 was 13.57 (+/-7.42) and 10.23 (+/-5.21) mg/l, respectively (P=0.28), and the mean half-life was 0.32 and 0.44 h, respectively (P=0.40).",Coadministration of oxaliplatin does not influence the pharmacokinetics of gemcitabine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17075318/),[mg] / [l],10.23,237544,DB00441,Gemcitabine
,17075318,half-life,"The mean (maximum) concentration of gemcitabine on days 1 and 8 was 13.57 (+/-7.42) and 10.23 (+/-5.21) mg/l, respectively (P=0.28), and the mean half-life was 0.32 and 0.44 h, respectively (P=0.40).",Coadministration of oxaliplatin does not influence the pharmacokinetics of gemcitabine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17075318/),h,0.32,237545,DB00441,Gemcitabine
,17075318,half-life,"The mean (maximum) concentration of gemcitabine on days 1 and 8 was 13.57 (+/-7.42) and 10.23 (+/-5.21) mg/l, respectively (P=0.28), and the mean half-life was 0.32 and 0.44 h, respectively (P=0.40).",Coadministration of oxaliplatin does not influence the pharmacokinetics of gemcitabine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17075318/),h,0.44,237546,DB00441,Gemcitabine
,31183244,flow rate,Chromatographic separation was achieved on a C18 column using a gradient mode containing water (containing 20 mM NaH2PO4 and 0.1% FA) and methanol at a flow rate of 0.8 mL/min.,Evaluation of the Effects of Astragalus membranaceus on the Pharmacokinetics of Pemetrexed Disodium and Gemcitabine in Rats by a Simple High-Performance Liquid Chromatography/UV Method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31183244/),[ml] / [min],0.8,238200,DB00441,Gemcitabine
,31183244,AUC(0-t),"The AUC(0-t), AUC(0-∞), and MRT of gemcitabine decreased from 15747.12 ± 497.11 to 12312.41 ± 594.21 mg/L·min, 15976.18 ± 511.33 to 12489.59 ± 682.01 mg/L·min, and 97.83 ± 5.82 to 84.37 ± 2.79 min, respectively.",Evaluation of the Effects of Astragalus membranaceus on the Pharmacokinetics of Pemetrexed Disodium and Gemcitabine in Rats by a Simple High-Performance Liquid Chromatography/UV Method. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31183244/),[mg] / [l·min],15747.12,238201,DB00441,Gemcitabine
,31183244,AUC(0-∞),"The AUC(0-t), AUC(0-∞), and MRT of gemcitabine decreased from 15747.12 ± 497.11 to 12312.41 ± 594.21 mg/L·min, 15976.18 ± 511.33 to 12489.59 ± 682.01 mg/L·min, and 97.83 ± 5.82 to 84.37 ± 2.79 min, respectively.",Evaluation of the Effects of Astragalus membranaceus on the Pharmacokinetics of Pemetrexed Disodium and Gemcitabine in Rats by a Simple High-Performance Liquid Chromatography/UV Method. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31183244/),[mg] / [l·min],12312.41,238202,DB00441,Gemcitabine
,31183244,AUC(0-∞),"The AUC(0-t), AUC(0-∞), and MRT of gemcitabine decreased from 15747.12 ± 497.11 to 12312.41 ± 594.21 mg/L·min, 15976.18 ± 511.33 to 12489.59 ± 682.01 mg/L·min, and 97.83 ± 5.82 to 84.37 ± 2.79 min, respectively.",Evaluation of the Effects of Astragalus membranaceus on the Pharmacokinetics of Pemetrexed Disodium and Gemcitabine in Rats by a Simple High-Performance Liquid Chromatography/UV Method. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31183244/),[mg] / [l·min],15976.18,238203,DB00441,Gemcitabine
,31183244,AUC(0-∞),"The AUC(0-t), AUC(0-∞), and MRT of gemcitabine decreased from 15747.12 ± 497.11 to 12312.41 ± 594.21 mg/L·min, 15976.18 ± 511.33 to 12489.59 ± 682.01 mg/L·min, and 97.83 ± 5.82 to 84.37 ± 2.79 min, respectively.",Evaluation of the Effects of Astragalus membranaceus on the Pharmacokinetics of Pemetrexed Disodium and Gemcitabine in Rats by a Simple High-Performance Liquid Chromatography/UV Method. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31183244/),[mg] / [l·min],12489.59,238204,DB00441,Gemcitabine
,31183244,MRT,"The AUC(0-t), AUC(0-∞), and MRT of gemcitabine decreased from 15747.12 ± 497.11 to 12312.41 ± 594.21 mg/L·min, 15976.18 ± 511.33 to 12489.59 ± 682.01 mg/L·min, and 97.83 ± 5.82 to 84.37 ± 2.79 min, respectively.",Evaluation of the Effects of Astragalus membranaceus on the Pharmacokinetics of Pemetrexed Disodium and Gemcitabine in Rats by a Simple High-Performance Liquid Chromatography/UV Method. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31183244/),[mg] / [l·min],12489.59,238205,DB00441,Gemcitabine
,31183244,MRT,"The AUC(0-t), AUC(0-∞), and MRT of gemcitabine decreased from 15747.12 ± 497.11 to 12312.41 ± 594.21 mg/L·min, 15976.18 ± 511.33 to 12489.59 ± 682.01 mg/L·min, and 97.83 ± 5.82 to 84.37 ± 2.79 min, respectively.",Evaluation of the Effects of Astragalus membranaceus on the Pharmacokinetics of Pemetrexed Disodium and Gemcitabine in Rats by a Simple High-Performance Liquid Chromatography/UV Method. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31183244/),min,97.83,238206,DB00441,Gemcitabine
,31183244,MRT,"The AUC(0-t), AUC(0-∞), and MRT of gemcitabine decreased from 15747.12 ± 497.11 to 12312.41 ± 594.21 mg/L·min, 15976.18 ± 511.33 to 12489.59 ± 682.01 mg/L·min, and 97.83 ± 5.82 to 84.37 ± 2.79 min, respectively.",Evaluation of the Effects of Astragalus membranaceus on the Pharmacokinetics of Pemetrexed Disodium and Gemcitabine in Rats by a Simple High-Performance Liquid Chromatography/UV Method. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31183244/),min,84.37,238207,DB00441,Gemcitabine
,31183244,Cl,The Cl of gemcitabine increased from 0.019 ± 0.0067 to 0.024 ± 0.0013 L/min/kg.,Evaluation of the Effects of Astragalus membranaceus on the Pharmacokinetics of Pemetrexed Disodium and Gemcitabine in Rats by a Simple High-Performance Liquid Chromatography/UV Method. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31183244/),[l] / [kg·min],0.019,238208,DB00441,Gemcitabine
,31183244,Cl,The Cl of gemcitabine increased from 0.019 ± 0.0067 to 0.024 ± 0.0013 L/min/kg.,Evaluation of the Effects of Astragalus membranaceus on the Pharmacokinetics of Pemetrexed Disodium and Gemcitabine in Rats by a Simple High-Performance Liquid Chromatography/UV Method. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31183244/),[l] / [kg·min],0.024,238209,DB00441,Gemcitabine
,24810394,half life,"Commercially, the drug is available as i.v. infusion due to its short half life (8-17 min), rapid metabolism and limited tumor uptake.",Enhanced bioavailability and intestinal uptake of Gemcitabine HCl loaded PLGA nanoparticles after oral delivery. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24810394/),min,8-17,239921,DB00441,Gemcitabine
,24810394,particle size,"Optimized formulation had particle size of 166.4±2.42 nm, and entrapment of 56.48±3.63%.",Enhanced bioavailability and intestinal uptake of Gemcitabine HCl loaded PLGA nanoparticles after oral delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24810394/),nm,166.4,239922,DB00441,Gemcitabine
,24810394,entrapment,"Optimized formulation had particle size of 166.4±2.42 nm, and entrapment of 56.48±3.63%.",Enhanced bioavailability and intestinal uptake of Gemcitabine HCl loaded PLGA nanoparticles after oral delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24810394/),%,56.48,239923,DB00441,Gemcitabine
,17429628,E Max,"The E Max for cells 48 h after treatment was 50% and after 144 h, 93% (P = 0.022; t test), while flow cytometry showed complete DNA degradation by 120 h.",Pharmacodynamic characterization of gemcitabine cytotoxicity in an in vitro cell culture bioreactor system. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17429628/),%,50,242590,DB00441,Gemcitabine
,17429628,E Max,"The E Max for cells 48 h after treatment was 50% and after 144 h, 93% (P = 0.022; t test), while flow cytometry showed complete DNA degradation by 120 h.",Pharmacodynamic characterization of gemcitabine cytotoxicity in an in vitro cell culture bioreactor system. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17429628/),%,93,242591,DB00441,Gemcitabine
,17429628,area under the concentration-time curve (AUC),The gemcitabine area under the concentration-time curve (AUC) was 56.4 microM h and the maximum concentration was 87.5 +/- 2.65 microM.,Pharmacodynamic characterization of gemcitabine cytotoxicity in an in vitro cell culture bioreactor system. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17429628/),h·μM,56.4,242592,DB00441,Gemcitabine
,17429628,maximum concentration,The gemcitabine area under the concentration-time curve (AUC) was 56.4 microM h and the maximum concentration was 87.5 +/- 2.65 microM.,Pharmacodynamic characterization of gemcitabine cytotoxicity in an in vitro cell culture bioreactor system. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17429628/),μM,87.5,242593,DB00441,Gemcitabine
,16122282,area under the plasma concentration-time curve from 0 to 270 minutes,The plasma concentration-time curve of gemcitabine during and after cessation of intra-arterial pancreatic target administration through the proximal splenic artery showed a profile with an area under the plasma concentration-time curve from 0 to 270 minutes (intra-arterial 29.0 +/- 0.4 vs intravenous 331.0 +/- 2.7 ng.min/mL; p < 0.0001) and peak plasma concentration (intra-arterial 1.1 +/- 0.2 vs intravenous 7.6 +/- 2.0 ng/mL; p < 0.0001) significantly lower than that for the corresponding systemic intravenous route.,Comparative pharmacokinetics and metabolic pathway of gemcitabine during intravenous and intra-arterial delivery in unresectable pancreatic cancer patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16122282/),[min·ng] / [ml],29.0,251363,DB00441,Gemcitabine
,16122282,area under the plasma concentration-time curve from 0 to 270 minutes,The plasma concentration-time curve of gemcitabine during and after cessation of intra-arterial pancreatic target administration through the proximal splenic artery showed a profile with an area under the plasma concentration-time curve from 0 to 270 minutes (intra-arterial 29.0 +/- 0.4 vs intravenous 331.0 +/- 2.7 ng.min/mL; p < 0.0001) and peak plasma concentration (intra-arterial 1.1 +/- 0.2 vs intravenous 7.6 +/- 2.0 ng/mL; p < 0.0001) significantly lower than that for the corresponding systemic intravenous route.,Comparative pharmacokinetics and metabolic pathway of gemcitabine during intravenous and intra-arterial delivery in unresectable pancreatic cancer patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16122282/),[min·ng] / [ml],331.0,251364,DB00441,Gemcitabine
,16122282,peak plasma concentration,The plasma concentration-time curve of gemcitabine during and after cessation of intra-arterial pancreatic target administration through the proximal splenic artery showed a profile with an area under the plasma concentration-time curve from 0 to 270 minutes (intra-arterial 29.0 +/- 0.4 vs intravenous 331.0 +/- 2.7 ng.min/mL; p < 0.0001) and peak plasma concentration (intra-arterial 1.1 +/- 0.2 vs intravenous 7.6 +/- 2.0 ng/mL; p < 0.0001) significantly lower than that for the corresponding systemic intravenous route.,Comparative pharmacokinetics and metabolic pathway of gemcitabine during intravenous and intra-arterial delivery in unresectable pancreatic cancer patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16122282/),[ng] / [ml],1.1,251365,DB00441,Gemcitabine
,16122282,peak plasma concentration,The plasma concentration-time curve of gemcitabine during and after cessation of intra-arterial pancreatic target administration through the proximal splenic artery showed a profile with an area under the plasma concentration-time curve from 0 to 270 minutes (intra-arterial 29.0 +/- 0.4 vs intravenous 331.0 +/- 2.7 ng.min/mL; p < 0.0001) and peak plasma concentration (intra-arterial 1.1 +/- 0.2 vs intravenous 7.6 +/- 2.0 ng/mL; p < 0.0001) significantly lower than that for the corresponding systemic intravenous route.,Comparative pharmacokinetics and metabolic pathway of gemcitabine during intravenous and intra-arterial delivery in unresectable pancreatic cancer patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16122282/),[ng] / [ml],7.6,251366,DB00441,Gemcitabine
,16122282,pseudo first-order rate constant,"Furthermore, during intravenous administration a pseudo first-order rate constant ( approximately 0.20 min(-)(1)) for in vivo conversion of gemcitabine to dFdU was estimated, indicating a rapid cellular deamination which was not shown in the intra-arterial route.",Comparative pharmacokinetics and metabolic pathway of gemcitabine during intravenous and intra-arterial delivery in unresectable pancreatic cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16122282/),min(-)(1),0.20,251367,DB00441,Gemcitabine
,16122282,time to disease progression,The median time to disease progression was 4 months and the median overall survival was 5 months.,Comparative pharmacokinetics and metabolic pathway of gemcitabine during intravenous and intra-arterial delivery in unresectable pancreatic cancer patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16122282/),month,4,251368,DB00441,Gemcitabine
,16122282,overall survival,The median time to disease progression was 4 months and the median overall survival was 5 months.,Comparative pharmacokinetics and metabolic pathway of gemcitabine during intravenous and intra-arterial delivery in unresectable pancreatic cancer patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16122282/),month,5,251369,DB00441,Gemcitabine
,27975152,objective response rate,The objective response rate was 23% and the disease control rate was 73%.,Phase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27975152/),%,23,252896,DB00441,Gemcitabine
,27975152,Overall response rate,"Overall response rate, disease control rate, progression-free survival, and overall survival were higher in patients without detectable KRAS mutations (48% vs. 28%, 81% vs. 69%, 8.8 vs. 5.3 months, and 18.2 vs. 6.6 months, respectively).",Phase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27975152/),%,48,252897,DB00441,Gemcitabine
,27975152,overall survival,"Overall response rate, disease control rate, progression-free survival, and overall survival were higher in patients without detectable KRAS mutations (48% vs. 28%, 81% vs. 69%, 8.8 vs. 5.3 months, and 18.2 vs. 6.6 months, respectively).",Phase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27975152/),month,5.3,252898,DB00441,Gemcitabine
,27975152,overall survival,"Overall response rate, disease control rate, progression-free survival, and overall survival were higher in patients without detectable KRAS mutations (48% vs. 28%, 81% vs. 69%, 8.8 vs. 5.3 months, and 18.2 vs. 6.6 months, respectively).",Phase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27975152/),month,18.2,252899,DB00441,Gemcitabine
,27975152,overall survival,"Overall response rate, disease control rate, progression-free survival, and overall survival were higher in patients without detectable KRAS mutations (48% vs. 28%, 81% vs. 69%, 8.8 vs. 5.3 months, and 18.2 vs. 6.6 months, respectively).",Phase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27975152/),month,6.6,252900,DB00441,Gemcitabine
,27685612,progression-free,"The median progression-free and overall survival of the patients were 1.1 and 5.7 months, respectively.",Phase I trial of GBS-01 for advanced pancreatic cancer refractory to gemcitabine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27685612/),month,1.1,254647,DB00441,Gemcitabine
,27685612,overall survival,"The median progression-free and overall survival of the patients were 1.1 and 5.7 months, respectively.",Phase I trial of GBS-01 for advanced pancreatic cancer refractory to gemcitabine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27685612/),month,5.7,254648,DB00441,Gemcitabine
,7900411,Plasma protein binding ratios,4. Plasma protein binding ratios were 10-16 and 1-7% between 5 min and 8 h after administration to the male rat and dog respectively.,"Placental transfer, lacteal transfer and plasma protein binding of gemcitabine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7900411/),%,10-16,255268,DB00441,Gemcitabine
,7900411,Plasma protein binding ratios,4. Plasma protein binding ratios were 10-16 and 1-7% between 5 min and 8 h after administration to the male rat and dog respectively.,"Placental transfer, lacteal transfer and plasma protein binding of gemcitabine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7900411/),%,1-7,255269,DB00441,Gemcitabine
,7900411,plasma protein binding ratios,"When fresh plasma from male rat, dog and adult man was spiked with 14C-gemcitabine at concentrations of 0.1-25 micrograms/ml, the plasma protein binding ratios were about 7% in both rat and dog, and 10% in man.","Placental transfer, lacteal transfer and plasma protein binding of gemcitabine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7900411/),%,7,255270,DB00441,Gemcitabine
,7900411,plasma protein binding ratios,"When fresh plasma from male rat, dog and adult man was spiked with 14C-gemcitabine at concentrations of 0.1-25 micrograms/ml, the plasma protein binding ratios were about 7% in both rat and dog, and 10% in man.","Placental transfer, lacteal transfer and plasma protein binding of gemcitabine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7900411/),%,10,255271,DB00441,Gemcitabine
,19773039,concentrations,The highest mean gemcitabine concentrations were 1.38 microg/mL in small and 2.47 microg/mL in large resections.,Systemic absorption and pharmacokinetics of single-dose intravesical gemcitabine after transurethral resection of the bladder in non-muscle-invasive bladder cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19773039/),[μg] / [ml],1.38,255315,DB00441,Gemcitabine
,19773039,concentrations,The highest mean gemcitabine concentrations were 1.38 microg/mL in small and 2.47 microg/mL in large resections.,Systemic absorption and pharmacokinetics of single-dose intravesical gemcitabine after transurethral resection of the bladder in non-muscle-invasive bladder cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19773039/),[μg] / [ml],2.47,255316,DB00441,Gemcitabine
,31096017,zeta potential,"HA-pSL with an HA density of 179 μg/μmol had a larger size (152.3 vs 136.3 nm), and higher zeta potential (-46.8 vs -10.5 mV) than pSL.",Can intracellular drug delivery using hyaluronic acid functionalised pH-sensitive liposomes overcome gemcitabine resistance in pancreatic cancer? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31096017/),mv,-,258054,DB00441,Gemcitabine
,31096017,zeta potential,"HA-pSL with an HA density of 179 μg/μmol had a larger size (152.3 vs 136.3 nm), and higher zeta potential (-46.8 vs -10.5 mV) than pSL.",Can intracellular drug delivery using hyaluronic acid functionalised pH-sensitive liposomes overcome gemcitabine resistance in pancreatic cancer? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31096017/),mv,46.8,258055,DB00441,Gemcitabine
,31096017,zeta potential,"HA-pSL with an HA density of 179 μg/μmol had a larger size (152.3 vs 136.3 nm), and higher zeta potential (-46.8 vs -10.5 mV) than pSL.",Can intracellular drug delivery using hyaluronic acid functionalised pH-sensitive liposomes overcome gemcitabine resistance in pancreatic cancer? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31096017/),mv,10.5,258056,DB00441,Gemcitabine
,22990652,objective response rate,The objective response rate was 37.0% for patients receiving axitinib/paclitaxel/carboplatin (n=27) and 23.8% for patients receiving axitinib/gemcitabine/cisplatin (n=21).,Phase I trial of axitinib combined with platinum doublets in patients with advanced non-small cell lung cancer and other solid tumours. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22990652/),%,37.0,259454,DB00441,Gemcitabine
,22990652,objective response rate,The objective response rate was 37.0% for patients receiving axitinib/paclitaxel/carboplatin (n=27) and 23.8% for patients receiving axitinib/gemcitabine/cisplatin (n=21).,Phase I trial of axitinib combined with platinum doublets in patients with advanced non-small cell lung cancer and other solid tumours. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22990652/),%,23.8,259455,DB00441,Gemcitabine
,17149608,progression-free survival,"Patients with unresectable or metastatic pancreatic cancer (n = 15) had a median progression-free survival of 289 days, the estimated overall survival of 389 days (12.5 months), and a 1-year survival rate of 51%.",Erlotinib plus gemcitabine in patients with unresectable pancreatic cancer and other solid tumors: phase IB trial. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17149608/),d,289,259700,DB00441,Gemcitabine
,17149608,overall survival,"Patients with unresectable or metastatic pancreatic cancer (n = 15) had a median progression-free survival of 289 days, the estimated overall survival of 389 days (12.5 months), and a 1-year survival rate of 51%.",Erlotinib plus gemcitabine in patients with unresectable pancreatic cancer and other solid tumors: phase IB trial. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17149608/),d,389,259701,DB00441,Gemcitabine
,15567500,EE,A maximum EE of 98% was determined for 4-(N)-stearoyl-gemcitabine incorporated in DSPC/DSPG 9:1.,"Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing lipophilic gemcitabine prodrugs. ",Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15567500/),%,98,265047,DB00441,Gemcitabine
,18500521,AUC,"Thirty patients with advanced non-small cell lung cancer (NSCLC) received gemcitabine, 1,000 mg/m(2) on days 1 and 8, and carboplatin, AUC 5.5 on day 1.",Intensive anti-inflammatory therapy with dexamethasone in patients with non-small cell lung cancer: effect on chemotherapy toxicity and efficacy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18500521/),,5.5,265370,DB00441,Gemcitabine
,28202004,OS,"The median OS (months) was 7.8 (range, 0.3-18.9) with LY2603618/gemcitabine and 8.3 (range, 0.8-19.1+) with gemcitabine.",A phase II study to evaluate LY2603618 in combination with gemcitabine in pancreatic cancer patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28202004/),month,7.8,265772,DB00441,Gemcitabine
,28202004,OS,"The median OS (months) was 7.8 (range, 0.3-18.9) with LY2603618/gemcitabine and 8.3 (range, 0.8-19.1+) with gemcitabine.",A phase II study to evaluate LY2603618 in combination with gemcitabine in pancreatic cancer patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28202004/),month,8.3,265773,DB00441,Gemcitabine
≥,28202004,AUC(0-∞),"The LY2603618 exposure targets (AUC(0-∞) ≥21,000 ng∙hr/mL and Cmax ≥2000 ng/mL) predicted for maximum pharmacodynamic response were achieved after 230 mg of LY2603618.",A phase II study to evaluate LY2603618 in combination with gemcitabine in pancreatic cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28202004/),[ng∙hr] / [ml],"21,000",265774,DB00441,Gemcitabine
≥,28202004,Cmax,"The LY2603618 exposure targets (AUC(0-∞) ≥21,000 ng∙hr/mL and Cmax ≥2000 ng/mL) predicted for maximum pharmacodynamic response were achieved after 230 mg of LY2603618.",A phase II study to evaluate LY2603618 in combination with gemcitabine in pancreatic cancer patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28202004/),[ng] / [ml],2000,265775,DB00441,Gemcitabine
,29558739,flow rate,"Column was at 40 °C for separation using an eluent with acetonitrile and 0.1% formic acid, 1 mM ammonium formate at a flow rate of 0.2 mL/min.","Simultaneous determination of gemcitabine prodrug, gemcitabine and its major metabolite 2', 2'-difluorodeoxyuridine in rat plasma by UFLC-MS/MS. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29558739/),[ml] / [min],0.2,265776,DB00441,Gemcitabine
,29558739,m,"Detection was performed using ESI source in positive ion selected reaction monitoring mode by monitoring the following ion transitions m/z 398.1 → 202.2 (Cbz-dFdC), m/z 264.1 → 112.0 (dFdC), m/z 265.3 → 113.2 (dFdU) and m/z 246.1 → 112.0 (IS).","Simultaneous determination of gemcitabine prodrug, gemcitabine and its major metabolite 2', 2'-difluorodeoxyuridine in rat plasma by UFLC-MS/MS. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29558739/),,265.3,265777,DB00441,Gemcitabine
,28224231,MTD,Both MTD and RD of NC-6004 were determined to be 90 mg/m2.,NC-6004 Phase I study in combination with gemcitabine for advanced solid tumors and population PK/PD analysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28224231/),[mg] / [m2],90,266425,DB00441,Gemcitabine
,22134116,vesi,"Mean vesicle size was 45-65 nm for liposome preparations downsized by homogenization, and 80-100 nm when downsized by extrusion, the latter displaying narrower polydispersity.",Therapeutic efficacy of a lipid-based prodrug of mitomycin C in pegylated liposomes: studies with human gastro-entero-pancreatic ectopic tumor models. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22134116/),nm,45-65,269030,DB00441,Gemcitabine
,22134116,vesi,"Mean vesicle size was 45-65 nm for liposome preparations downsized by homogenization, and 80-100 nm when downsized by extrusion, the latter displaying narrower polydispersity.",Therapeutic efficacy of a lipid-based prodrug of mitomycin C in pegylated liposomes: studies with human gastro-entero-pancreatic ectopic tumor models. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22134116/),,80-100,269031,DB00441,Gemcitabine
,22134116,to,MLP to phospholipid mole ratio was 5% (~20 μg MMC-equivalents/μmol).,Therapeutic efficacy of a lipid-based prodrug of mitomycin C in pegylated liposomes: studies with human gastro-entero-pancreatic ectopic tumor models. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22134116/),%,5,269032,DB00441,Gemcitabine
,22134116,mole ratio,MLP to phospholipid mole ratio was 5% (~20 μg MMC-equivalents/μmol).,Therapeutic efficacy of a lipid-based prodrug of mitomycin C in pegylated liposomes: studies with human gastro-entero-pancreatic ectopic tumor models. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22134116/),%,5,269033,DB00441,Gemcitabine
,22134116,mole ratio,MLP to phospholipid mole ratio was 5% (~20 μg MMC-equivalents/μmol).,Therapeutic efficacy of a lipid-based prodrug of mitomycin C in pegylated liposomes: studies with human gastro-entero-pancreatic ectopic tumor models. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22134116/),μg,20,269034,DB00441,Gemcitabine
,17851637,time to progression,"Four patients had stable disease and the median time to progression was 3 months (95% confidence interval, CI: 1.7 to 9.1 months).","A multicenter phase II trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) and gemcitabine in advanced non-small-cell lung cancer with pharmacokinetic evaluation using peripheral blood mononuclear cells. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17851637/),month,3,269432,DB00441,Gemcitabine
,17317834,peritoneal,"At 120 mg/m(2), the median peritoneal area under the concentration versus time curve (AUC) was 82,612 ng/mL x h (range, 53,296-199,830) and the plasma AUC was 231 ng/mL x h (range, 47.6-259.5).",Phase I trial of intraperitoneal gemcitabine in the treatment of advanced malignancies primarily confined to the peritoneal cavity. ,AUMC-Q20,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17317834/),[ng] / [h·ml],"82,612",269866,DB00441,Gemcitabine
,17317834,area under the concentration versus time curve (AUC),"At 120 mg/m(2), the median peritoneal area under the concentration versus time curve (AUC) was 82,612 ng/mL x h (range, 53,296-199,830) and the plasma AUC was 231 ng/mL x h (range, 47.6-259.5).",Phase I trial of intraperitoneal gemcitabine in the treatment of advanced malignancies primarily confined to the peritoneal cavity. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17317834/),[ng] / [h·ml],"82,612",269867,DB00441,Gemcitabine
,17317834,plasma AUC,"At 120 mg/m(2), the median peritoneal area under the concentration versus time curve (AUC) was 82,612 ng/mL x h (range, 53,296-199,830) and the plasma AUC was 231 ng/mL x h (range, 47.6-259.5).",Phase I trial of intraperitoneal gemcitabine in the treatment of advanced malignancies primarily confined to the peritoneal cavity. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17317834/),[ng] / [h·ml],231,269868,DB00441,Gemcitabine
,17317834,peritoneal advantage (AUC(peritoneal)/AUC(plasma)),"The mean peritoneal advantage (AUC(peritoneal)/AUC(plasma)) was 847 (range, 356-1,385).",Phase I trial of intraperitoneal gemcitabine in the treatment of advanced malignancies primarily confined to the peritoneal cavity. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17317834/),,847,269869,DB00441,Gemcitabine
,15822162,elimination half life (t(1/2)),"The obtained mean parameters, elimination half life (t(1/2)) (10.67+/-3.38 min), area under the curve (AUC) (7.55+/-1.53 (microg x h)/ml), and clearance (CL) (3940.05+/-672.08 ml/min), were consistent with those reported in literature.",Pharmacokinetics of gemcitabine in Chinese patients with non-small-cell lung cancer. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15822162/),min,10.67,271978,DB00441,Gemcitabine
,15822162,area under the curve (AUC),"The obtained mean parameters, elimination half life (t(1/2)) (10.67+/-3.38 min), area under the curve (AUC) (7.55+/-1.53 (microg x h)/ml), and clearance (CL) (3940.05+/-672.08 ml/min), were consistent with those reported in literature.",Pharmacokinetics of gemcitabine in Chinese patients with non-small-cell lung cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15822162/),[h·μg] / [ml],7.55,271979,DB00441,Gemcitabine
,15822162,clearance (CL),"The obtained mean parameters, elimination half life (t(1/2)) (10.67+/-3.38 min), area under the curve (AUC) (7.55+/-1.53 (microg x h)/ml), and clearance (CL) (3940.05+/-672.08 ml/min), were consistent with those reported in literature.",Pharmacokinetics of gemcitabine in Chinese patients with non-small-cell lung cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15822162/),[ml] / [min],3940.05,271980,DB00441,Gemcitabine
,34426438,sur,"Both patients showed remarkably long surivial of 326 and 555 days, respectively.",Phase 2 Trial of Oncolytic H-1 Parvovirus Therapy Shows Safety and Signs of Immune System Activation in Patients With Metastatic Pancreatic Ductal Adenocarcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34426438/),,32,273484,DB00441,Gemcitabine
,34426438,sur,"Both patients showed remarkably long surivial of 326 and 555 days, respectively.",Phase 2 Trial of Oncolytic H-1 Parvovirus Therapy Shows Safety and Signs of Immune System Activation in Patients With Metastatic Pancreatic Ductal Adenocarcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34426438/),,55,273485,DB00441,Gemcitabine
,10997809,overall response rate,"Objectives responses were seen at all dose levels, with an overall response rate of 43% (95% confidence interval (95% CI): 25.5%-62.6%) in 30 evaluable patients.",Phase I and pharmacologic study of weekly gemcitabine and paclitaxel in chemo-naïve patients with advanced non-small-cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10997809/),%,43,273906,DB00441,Gemcitabine
